Document:

Prepared by R.R. Donnelley Financial -- EX-10.6

 Exhibit 10.6 

CONFIDENTIAL 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
 COMMERCIAL LICENSE AGREEMENT 

ENTERED INTO WITH 

COHERUS BIOSCIENCES, INC. 

([***]) 

 CONFIDENTIAL 

 

 This Commercial License Agreement (the “Agreement”) is made effective
on as of June 25, 2012 (the “Effective Date”), by and between SELEXIS SA, 18 chemin des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland SA (“Selexis”) and COHERUS BIOSCIENCES, INC., 201 Redwood
Shores Parkway, Suite 200, Redwood City, CA 94065 (“COMPANY”). 
 BACKGROUND 

Whereas, COMPANY is a biopharmaceutical Company engaged in the research, development, manufacturing and sale of biopharmaceutical products;

 Whereas, Selexis is a biotechnology Company engaged in the development and sale of recombinant cell lines based on proprietary technology
(“Selexis Technology”, as defined further below); 
 Whereas, Selexis is the owner of certain proprietary and confidential
information and know-how (“Selexis Know-How”, as defined further below), and intellectual property (“Selexis Patent Rights”, as defined further below); 

Whereas, Pursuant to a Services Agreement dated October 20, 2011 Selexis has developed (or will develop) certain recombinant cell lines
for COMPANY based on Selexis Technology and COMPANY has evaluated (or will evaluate) such cell lines (the “Services Agreement”); and 

Whereas, Selexis is willing to grant COMPANY, and COMPANY is willing to receive from Selexis, Selexis Know-How and Selexis Patent Rights and
licenses thereto related to the Selexis Technology, on the terms and conditions set forth herein. 
 AGREEMENT 

Now, therefore, the Parties, intending to be legally bound hereby, do hereby agree as follows: 

 

	1.	DEFINITIONS 

 The following capitalized terms, whether used in the singular or the
plural, shall have the following meanings as used in this Agreement, unless otherwise specifically indicated: 
 “Affiliate” shall mean any
Person that, at the date of this Agreement, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with the Party specified. For the purposes of this definition, “control” shall
mean the possession, direct or indirect, of the power to cause the direction of the management and policies of a Person, whether through ownership of fifty percent (50%) or more of the voting securities of such Person, by contract or otherwise.
A Person shall only be considered an Affiliate for so long as such control exists. 
 “Agreement” shall mean as defined on Page 2, 1st
paragraph. 

  
 1 

 CONFIDENTIAL 

 

 1.1 “BLA” shall mean a Biologics License Applications for the Product filed
with the FDA pursuant to 21 C.F.R. Part 601. 
 1.2 “Calendar Quarter” shall mean for each Calendar Year, each of the three
month periods ending March 31, June 30, September 30 and December 31. 
 1.3 “Calendar Year”
shall mean the period commencing on January 1 and ending twelve (12) consecutive calendar months later on December 31. 
 1.4
“Cell Line” shall mean a mammalian cell line that is developed using the Selexis Technology. 
 1.5 “Clinical
Trials” shall mean human studies designed to measure the safety and/or efficacy of the Product. Clinical Studies include Phase I Clinical Trials, Phase II Clinical Trials, and Phase III Clinical Trials. 

1.6 “Collaboration Partner” shall mean a Third Party with which COMPANY collaborates on the development of the production
process and/or commercialization of a Product or to which COMPANY has granted a license for the development of the production process and/or commercialization of a Product. 

1.7 “Combination Product” shall mean a Product that contains (a) the Company Protein and (b) one (1) or more
devices, components or therapeutically active pharmaceutical ingredients other than the Company Protein. 
 1.8 “Combination Product
Adjustment” shall mean the following: Net Sales for such combination product will be adjusted by multiplying actual Net Sales of such combination product by the fraction A/(A B) where A is the weighted (by sales volume) average invoice
price of the Product, if sold separately, and B is the weighted (by sales volume) average invoice price of any other active ingredient, device or component in the combination, if sold separately. If, on a country-by-country basis, the other active
ingredient, device or component in the combination is not sold separately, Net Sales shall be calculated by multiplying actual Net Sales of such combination product in such country by the fraction A/C where A is the invoice price of the Product, if
sold separately, in such country and C is the invoice price of the combination product in such country. if, on a country-by-country basis, neither the Product, nor the other active ingredient, device or component of the combination product, is sold
separately, Net Sales shall be [***]. 
 1.9 “Commercial License” shall mean as defined in Section 2.1. 

1.10 “COMPANY” shall mean as defined on Page 2, 1st paragraph. 

1.11 “Company Protein” means the monoclonal antibody identified by COMPANY as [***] (and identified as such in the
Proposal of the Services Agreement), the sequence of which is provided in Exhibit 2, and any progeny, derivative, part or fragment thereof. 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

  
 2 

 CONFIDENTIAL 

 

 1.12 “Confidential Information” shall mean and include but not be limited to
any technical and business information pertaining to materials and production techniques, products, processes and services, including without limitation relating to physical working models and samples of the products, research, development,
patentable and unpatentable inventions, manufacturing, purchasing and product development plans, forecasts, strategies and information, engineering, marketing, merchandising, selling, customer lists, customer prospects, software codes, algorithms,
names and expertise of employees and consultants, blueprints, technical information, trade secrets or know how or other related proprietary business information and data, in any case whether such information is provided in tangible or intangible
form, written, oral, graphic, pictorial or recorded form or stored on computer discs, hard drives, magnetic tape or digital or any other electronic medium if it is labelled or declared “Confidential” or if a Party may reasonably assume
that the information received must be treated confidential. Confidential Information shall also include any information or documents the Recipient received in confidence from a Third Party that are subject to similar covenants as those contained in
this Agreement. 
 1.13 “Contractor” shall mean a Third Party contractor who: (i) develops the production process for
Products or (ii) manufactures and supplies Products by using such production process. 
 1.14 “Default” shall mean as
defined in Section 7.2. 
 1.15 “Defaulting Party” shall mean as defined in Section 7.2. 

1.16 “Effective Date” shall have the meaning as given on Page 2, 1st paragraph. 

1.17 “FDA” shall mean the United States Food and Drug Administration, or any successor agency. 

1.18 “First Commercial Sale” shall mean, with respect to any Product in any country, the first sale of such Product for value
and for end-use or consumption by the general public in such country after Regulatory Approval as well as Pricing and Reimbursement Approval for such Product has been obtained in such country. For the avoidance of doubt, sales prior to receipt of
all Regulatory Approvals and Pricing and Reimbursement Approvals necessary to commence regular commercial sales, such as so-called “treatment IND sales”, “named patient sales” and “compassionate use sales”, and sales
for research or other non-commercial purposes shall not be construed as a First Commercial Sale. 
 1.19 “Force Majeure”
shall mean any occurrence beyond the reasonable control of a Party that prevents or substantially interferes with the performance by the Party of any of its obligations hereunder. 

1.20 “IND” shall mean an Investigational New Drug Application for the Product filed with the FDA pursuant to 21 C.F.R. Part
312, or any comparable filing made with a Regulatory Authority in another country (including the submission to a competent authority of a request for an authorisation concerning a clinical trial, as envisaged in Article 9, paragraph 2, of European
Directive 2001/20/EC). 

  
 3 

 CONFIDENTIAL 

 

 1.21 “Insolvent Party” shall mean as defined in Section 7.3. 

1.22 “Invention” shall mean any invention, idea, innovation, enhancement, improvement or feature, whether or not patentable
or registrable, together with any intellectual property rights relating thereto (including without limitation Patent Rights and rights in confidentiality and proprietary information). 

1.23 “Know-How” shall mean information in whatever form, including in any electronic, tangible or intangible medium, and
includes information and materials relating to Inventions and other know-how, trade secrets, data (including amongst other things all data from pre-clinical and clinical studies and other studies intended for regulatory submission), results,
formulae, DNA and amino acid sequence information and developments. 
 1.24 “Licensed Field of Use” shall mean the
treatment, prevention, diagnosis and palliation of all disease. 
 1.25 “Losses” shall mean as defined in Section 6.1.

 1.26 “Net Sales” shall mean the amount collected by COMPANY, its Affiliates and/or its sublicensees on account of sales
of Product to Third Parties in the Territory, less the following deductions: 
 1.26.1. sales and excise taxes and duties paid or allowed by
the selling party and any other governmental charges imposed upon the production, importation, use or sale of the Products; 
 1.26.2. bona
fide trade, quantity and cash discounts allowed on Products; 
 1.26.3. bona fide rebates, 

1.26.4. allowances or credits to customers on account of (i) rejection or return of Product, (ii) on account of retroactive price
reductions affecting the Product, and (iii) programs that provide low income, uninsured or other patients the opportunity to obtain discounted Products; and 

1.26.5. freight and insurance costs, if they are included in the selling price for the product invoiced to Third Parties or if they are billed
separately on an invoice, provided always that such deduction shall not be greater than the balance between the selling price actually invoiced to the Third Party and the standard selling price which would have been charged to such Third Party for
such Product exclusive of freight and insurance in the respective country or in a comparable country. 
 In the event that Products are sold
in any country in the form of a Combination Product, the Net Sales for any such Combination Product shall be computed pursuant to the Combination Product Adjustment in such country. 

  
 4 

 CONFIDENTIAL 

 

 In the event that Products are sold to a Third-Party distributor for purposes of resale by
the distributor, the distributor shall be considered a Third Party, and not a sublicensee, for purposes of determination of Net Sales, regardless of whether the distributor has entered into any sublicense with COMPANY. 

Sales of a Product between COMPANY and its Affiliates or sublicensees for resale shall be excluded from the computation of Net Sales, but the
subsequent resale of such Product to a Third Party shall be included within the computation of Net Sales. Any free-of-charge disposal or use of a Product for development, regulatory or marketing purposes, such as clinical trials, compassionate use
or indigent patient programs, shall not be deemed a sale or disposition for purposes of calculating Net Sales. 
 1.27
“Non-Defaulting Party” shall have the meaning as given in Section 7.2. 
 1.28 “Notice of Default”
shall have the meaning as given in Section 7.2. 
 1.29 “Party” shall mean Selexis or COMPANY, as the case may be; and
“Parties” shall mean Selexis and COMPANY, collectively. 
 1.30 “Patent Rights” shall mean any and all of
the following: (i) patent applications (including provisional patent applications) and patents (including the inventor’s certificates); (ii) any substitution, extension (including patent term extensions and supplementary protection
certificate), registration, confirmation, reissue, continuation, divisional, continuation-in-part, re-examination, renewal, patent of addition or the like thereof or thereto; (iii) any foreign counterparts of any of the foregoing; and
(iv) any utility model applications and utility models (whether or not corresponding to any of the foregoing). 
 1.31
“Person” shall mean an individual, a partnership, a joint venture, a corporation, a limited liability Company, a trust, an estate, an unincorporated organization, or any other entity, or a government or any department or agency
thereof, whether acting in an individual, fiduciary or other capacity. 
 1.32 “Phase I Clinical Trial” shall mean a
clinical trial conducted in humans which is principally intended to obtain data on the safety, tolerability, pharmacokinetic or pharmacodynamic properties of a product. Phase I shall be deemed to have commenced when the first patient in the study
has been treated. Phase I shall be deemed to have completed when the last patient has completed his or her treatment being investigated by that clinical trial as described in its protocol, the database is locked, and data from all patients,
according to protocol, has been analyzed for the primary endpoint. 
 1.33 “Phase II Clinical Trial” shall mean a clinical
trial conducted in humans in which the primary objective is a preliminary determination of therapeutic efficiency and/or to find an optimal dose range in patients with the disease target being studied. Phase II shall be deemed to have commenced when
the first patient in the study has been treated. Phase II shall be deemed to have completed when the last patient has completed his or her treatment being investigated by that clinical trial as described in its protocol, the database is locked, and
data from all patients, according to protocol, has been analyzed for the primary endpoint. 

  
 5 

 CONFIDENTIAL 

 

 1.34 “Phase III Clinical Trial” shall mean a clinical trial conducted in
humans in which the primary objective is a determination of therapeutic efficiency in patients with the disease target being studied. Phase III shall be deemed to have commenced when the first patient in the study has been treated. Phase III shall
be deemed to have completed when the last patient has completed his or her treatment being investigated by that clinical trial as described in its protocol, the database is locked, and data from all patients, according to protocol, has been analyzed
for the primary endpoint. 
 1.35 “Price and Reimbursement Approval” shall mean any approvals, licences, registrations or
authorisations of any supranational, national, regional, state or local Regulatory Authority or other regulatory agency, department, bureau or governmental entity, necessary to determine or set the pricing of a Product, and/or its reimbursement
level by the relevant health authorities, providers or other funding institutions, at supranational, national, regional, state or local level. 

1.36 “Product” shall mean any pharmaceutical preparation in final form containing the Company Protein as one of its active
ingredients, such Company Protein having been manufactured using a Cell Line. 
 1.37 “Regulatory Approval” shall mean any
approvals, licences, registrations or authorisations of any supranational, national, regional, state or local Regulatory Authority or other regulatory agency, department, bureau or governmental entity, necessary for the manufacture, marketing or
sale of the Product or conduct of clinical trials in a regulatory jurisdiction, excluding Price and Reimbursement Approval. 
 1.38
“Regulatory Authority” shall mean (i) the FDA or (ii) any and all governmental or supranational agencies, ministries, authorities or other bodies with similar regulatory authority with respect to approval or registration
of pharmaceutical or biologic products in any other jurisdiction anywhere in the world. 
 1.39 “Royalty Term” means with
respect to each Product sold in a particular country, the period beginning on the date of First Commercial Sale of such Product in such country and terminating on the expiration of the last-to-expire or lapse of any Valid Claims covering such
Product in such country. 
 1.40 “Selexis” shall have the meaning as given on Page 2, 1st paragraph. 

1.41 “Selexis Know-How” shall mean Selexis’ Confidential Information and Know-How relating to the construction and
development of recombinant cell lines for the manufacture of biopharmaceutical products and existing as of the Effective Date or obtained thereafter during the term of this Agreement. 

1.42 “Selexis Materials” shall mean the materials provided by Selexis to COMPANY under this Agreement and all modifications
and improvements thereof made by Selexis during the Term hereof. 

  
 6 

 CONFIDENTIAL 

 

 1.43 “Selexis Patent Rights” shall mean Patent Rights that: (i) are
owned or controlled by Selexis, (ii) which are necessary or useful for the use of Selexis Materials or the construction and development of Cell Lines, or the use, manufacture and purification of the Company Protein and/or the Product, and
(iii) are existing as of the Effective Date or obtained thereafter during the term of this Agreement. Without limiting the definition set forth in this Section, the Selexis Patent Rights as of the Effective Date are listed in Exhibit 1 hereto.

 1.44 “Selexis Technology” shall mean the Selexis Patent Rights, Selexis Know-How and Selexis Materials. 

1.45 “Taxes” shall mean all excises, taxes and duties with the exception of VAT. 

1.46 “Term” shall mean as defined in Section 7.1. 

1.47 “Territory” shall mean the entire world. 

1.48 “Third Party” shall mean a Person other than Selexis, COMPANY or an Affiliate of Selexis or COMPANY. 

1.49 “Valid Claim” shall mean any issued or granted claim of the Selexis Patent Rights that has not been revoked or held
unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, that is unappealable or remains unappealed at the end of the time allowed for appeal, or that has not been disclaimed, denied or admitted to be
invalid or unenforceable through reissue, re-examination, disclaimer or otherwise. 
 1.50 “VAT” shall mean value added tax
and any other similar turnover, sales or purchase, tax or duty levied by any other jurisdiction whether central, regional or local. 
  

	2.	COMMERCIAL LICENSES 

 2.1 Commercial Licenses. Selexis hereby grants to COMPANY
and its Affiliates a non-exclusive license (“Commercial License”) in the Territory, with the right to sublicense as per Section 2.2 hereafter, under the Selexis Technology, subject to the terms and conditions of the Agreement,
to use Cell Lines for the manufacture of Products in the Licensed Field of Use, either at Company facilities or Contractors (subject to Sections 2.1 and 2.2), and to make, have made, use, offer for sale, sell, import, export and otherwise exploit
Products, including, without limitation, the use of Products in Clinical Trials. 
 2.2 Sublicenses. COMPANY may grant sublicenses
under the foregoing Commercial License and/or transfer the Cell Lines and Selexis Know-How to any Third Party. For the avoidance of doubt, COMPANY shall not transfer Cell Lines to a Third Party for any purpose other than to make, have made, use,
offer for sale, sell, import and otherwise exploit Products. Any agreement granting such sublicense shall be consistent with the terms, conditions and limitations of this Agreement. In any event, COMPANY is fully liable and responsible for any
breach of any of its obligations hereunder committed by an Affiliate, a Collaboration Partner or Contractor, a consultant or agent to whom the Cell Line and the Selexis Technology or parts thereof are made available under any such sublicense.
Selexis agrees that, to the extent (i)

  
 7 

 CONFIDENTIAL 

 

 
provided for in each sublicense granted under this Agreement and (ii) such sublicense does not impose any obligations on Selexis in excess of those imposed on Selexis herein, all sublicenses
granted with respect to the rights granted under this Agreement shall survive termination of this Agreement and will automatically be assigned to Selexis upon such termination, in order to provide for the applicable sublicensee’s continued
enjoyment of its rights thereunder. 
 2.3 Transfer of Selexis Materials. COMPANY shall [***]. If COMPANY makes any such
transfer it shall notify Selexis within thirty (30) days of any such transfer and report the name and address of any Transferees together with confirmation that the Transferee has agreed to adhere to the obligations of confidentiality set out
in this Agreement. 
  

	3.	CONSIDERATION 

 3.1 Payments. 

3.1.1. Commercial License Exercise Payment. Upon the execution of this Agreement, COMPANY shall pay Selexis the sum of [***].

 3.1.2. Commercial License Milestone Payments. As partial consideration for the rights and licenses granted by Selexis to COMPANY
under this Agreement, COMPANY shall make the following milestone payments to Selexis within thirty (30) days after the first occurrence of such milestone events: 

3.1.2.1.             [***]: [***]; 

3.1.2.2.             [***]: [***]; 

3.1.2.3.             [***]: [***]; 

3.1.2.4.             [***]: [***]. 

The payments set forth above in this Section 3.1.2 shall be payable only once for each milestone event, upon the first occurrence of such milestone
event, regardless of the number of times each event occurs. 
 3.1.3. Commercial License Royalty Payments: In addition to the
foregoing milestone payments, during the Royalty Term, COMPANY shall pay Selexis on a Product-by-Product and country-by-country basis a royalty of [***] of Net Sales of all Products sold worldwide. In the case where royalties are due in
respect of the sale of Product 
  
 [***] Certain information in this document has been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 8 

 CONFIDENTIAL 

 

 
directly by COMPANY such royalties shall be paid for each Calendar Quarter within forty-five (45) days of the end of that Calendar Quarter. Where royalties are due in respect of the sale of
Products by a sub-licensee of COMPANY, payment shall be made within ninety (90) days of the end of that Calendar Quarter. For the avoidance of doubt no royalty payments shall be due in any country after the Royalty Term has expired in such
country. Where royalties are no longer due in accordance with the foregoing in respect of any Product in any country, the Commercial Licenses granted to COMPANY under this Agreement shall become perpetual, irrevocable, fully paid up and royalty free
in respect of such Product in such country and notwithstanding Section 2.3, COMPANY shall have the right to transfer the Selexis Materials to any Third Party in connection with the manufacture, use and sell of such Product in such country. 

3.2 Mechanism of Payment. The payments due to Selexis under this Agreement shall be made by wire transfer or electronic fund transfer
(at COMPANY’s discretion) to the credit and account of Selexis as follows : 
  

			
	Bank Name:	  	[***]
		  	[***]
		  	[***]
		
	Account:	  	[***]
		  	[***]
		  	[***]
		  	[***]
		
	To:	  	Selexis S.A.
		  	18, chemin des Aulx
		  	1228 Plan-les-Ouates
		  	Geneva, Switzerland

 3.3 Payment Terms. Save as provided in Section 3.1.3, COMPANY shall make payments due to Selexis
under this Agreement at the latest [***] after receipt of invoice except where such fees are due from a COMPANY licensee, in which case COMPANY shall have [***] after receipt of invoice to make such payments. All such fees and payments
are exclusive of any applicable VAT, other taxes, duties and excises (collectively, “Taxes”). 
 3.4 Records.
COMPANY and its Affiliates shall keep (and COMPANY shall use its best endeavours to procure that its sublicensees shall keep and make available to COMPANY) true accounts of Net Sales of Products and COMPANY shall deliver to Selexis at the same time
as the payments due under Section 3.1.3 a written account, including quantities of Net Sales of each such Product, broken down on a country-by-country basis in respect of those payments. Upon not less than sixty (60) days’ prior
written notice, Selexis is entitled to have such accounts audited by an independent expert of its choice for a period of [***] after receiving any such written account, solely to verify the accuracy of payments reported and paid hereunder.
Such audits may be made no more than once each calendar year and during normal business hours, with reasonable efforts to minimize disruption of COMPANY’S normal business 

 
 [***] Certain information in this document has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 9 

 CONFIDENTIAL 

 

 
activities. Such independent expert shall be bound by confidentiality terms at least as restrictive as the terms of Clause 10 of this Agreement and shall be authorized to disclose to Selexis only
the amount and accuracy of payments reported and actually paid or otherwise payable under this Agreement. COMPANY shall provide access to all information reasonably requested by such expert. The cost of any audit shall be borne by Selexis unless the
audit shows that COMPANY underpaid Selexis by more than two percent (2%) of the amounts due in which case the cost of the audit shall be borne by COMPANY 

3.5 Taxes. [***] will pay [***] taxes levied on account of any payments made to Selexis under this Agreement (other than
taxes on income, gains or profits levied against [***]). if any taxes are required to be withheld by Company from any payment made to Selexis under this Agreement, Company will (a) deduct such taxes from the payment made to Selexis,
(b) timely pay the taxes to the proper taxing authority, and (c) send proof of payment to Selexis and certify its receipt by the taxing authority within thirty (30) days following such payment. 

3.6 Single Royalty. Nothing shall oblige COMPANY or its sublicensees to pay or cause to be paid to Selexis more than one royalty on any
unit of Product, irrespective of how many Selexis Patent Rights may cover such Product. 
  

	4.	INTELLECTUAL PROPERTY 

 4.1 Ownership. Each Party shall retain the entire right
and title in and to its Inventions and Know-How which exists on the Effective Date of this Agreement or which is thereafter developed independently of the performance of this Agreement. 

4.2 In the event Selexis possesses, acquires, creates or is licensed any improvements to the Selexis Technology, subject to any bona fide
obligations owed by Selexis to third parties (in respect of which Selexis has notified COMPANY), such improvements shall automatically be included in the Selexis Patent Rights and/or the Selexis Know-how and thereby disclosed and licensed at no
extra cost to COMPANY in accordance with this Agreement. 
 4.3 Third Party Patent Rights. Selexis covenants that if Selexis becomes
aware or reasonably determines that the practice of the Selexis Technology and/or use of the Cell Lines in order to make, have made, use, sell, offer for sale or import any Product in the Field in the Territory would, or would allegedly infringe or
misappropriate any Third Party’s Patent Rights, Know-How or other intellectual property rights, it shall notify COMPANY of the same within five (5) days (the “Infringement Notice”). Selexis shall use its best efforts to
promptly resolve such infringement at Selexis’ cost to ensure that COMPANY may exercise its rights under this Agreement without infringing or misappropriating such Patent Rights, Know-How or other intellectual property rights, including using
its best efforts to obtain a license from the Third Party owner of such Patent Rights, Know-How or other intellectual property which entitles Selexis to continue to grant the rights to COMPANY set forth herein. Should such efforts not be successful,
Selexis shall inform COMPANY in writing. Selexis shall be responsible for payment of any and all fees, milestones, royalties or other payments owed to any Third Party for any 

 
 [***] Certain information in this document has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 10 

 CONFIDENTIAL 

 

 
Patent Rights or Know-How or other intellectual property rights licensed or acquired by it after the Effective Date, which are necessary or useful for COMPANY to make, have made, use, sell, offer
for sale or import any Product in the Field in the Territory without infringing or misappropriating a Third Party’s Patent Rights, Know-How or other intellectual property right. 

4.4 Enforcement of Selexis Patent Rights. If during the Term, either Party becomes aware of any infringement or potential infringement
of the Selexis Technology it shall promptly notify the other Party in writing and the Parties shall consult with each other to decide the best way to respond to such infringement or misuse. Selexis covenants that if Selexis becomes aware of an
infringement of the Selexis Patent Rights by Third Parties in the Licensed Field of Use, Selexis shall use its reasonable commercial efforts to prevent or enjoin such infringement. 

4.5 COMPANY Intellectual Property. COMPANY shall retain all right, title and interest in (and the unrestricted right to use) any and
all information, data, results, Know-How, products and the like, whether patentable or not, arising out of the conduct of the licenses granted hereunder and all intellectual property appurtenant thereto, including without limitation the Product
composition or sequence and any related intellectual property. COMPANY shall have the unrestricted right to publish or otherwise disclose the results and data obtained by the practice of the Selexis Technology provided such disclosure does not
include the Confidential Information of Selexis. The name of Selexis shall be given proper recognition in such publication(s) as scientifically appropriate. 

4.6 Further Assurance. Each Party agrees to execute and do all things at the cost of the other Party (if not specifically agreed
otherwise) as the other Party may reasonably require to give that other Party the full benefit of the provisions of this Section 4. 
  

	5.	REPRESENTATIONS, WARRANTIES, AND COVENANTS 

 5.1 Corporate Power. Each Party
hereby represents and warrants that such Party is duly organized and validly existing under the laws of the state (or country or other jurisdiction, as the context requires) of its incorporation and has full corporate power and authority to enter
into this Agreement and to carry out the provisions hereof. 
 5.2 Due Authorization. Each Party hereby represents and warrants that
such Party is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder and the person executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate actions. 

5.3 Binding Agreement. Each Party hereby represents and warrants that this Agreement is a legal and valid obligation binding upon it
and is enforceable in accordance with its terms, except as enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors’ rights generally and by
general equitable principles and public policy. 
 5.4 No Conflicts. Each Party hereby represents and warrants that the execution,
delivery and performance of this Agreement by such Party does not conflict with any agreement, instrument or understanding, oral or written, to which it is a Party or by which it may be bound, 

  
 11 

 CONFIDENTIAL 

 

 
nor violate any law or regulation of any court, governmental body or administrative or other agency having authority over it. 

5.5 Additional Warranties by Selexis. Selexis hereby warrants, represents and covenants to COMPANY that, to the best of its knowledge:

 5.5.1. As of the Effective Date, there are no Third Party intellectual property rights that may be asserted against COMPANY claiming that
the use by COMPANY of the Selexis Technology under this Agreement constitutes an infringement thereof; 
 5.5.2. As of the Effective Date,
there is no pending litigation which alleges that the use of Selexis Technology has infringed or misappropriated any of the intellectual property rights of any Third Party, and Selexis has not received any written claim that the use of Selexis
Technology infringes on any intellectual property rights of a Third Party or a request or demand from any Third Party for the licensing of any intellectual property rights of such Third Party in connection with the practice of the Selexis
Technology; 
 5.5.3. Selexis is the owner of or controls the Selexis Technology, and has the right to grant COMPANY the rights and licenses
granted COMPANY under this Agreement, and will not, knowingly during the Term, grant any rights to any Third Party that would adversely affect COMPANY‘s rights or licenses granted under this Agreement. 

5.5.4. The Selexis Technology is free and clear of any encumbrance, lien, mortgage, charge, restriction or liability of any kind whatsoever,
whether equitable or legal, that would conflict with or impair the rights granted to COMPANY under this Agreement; 
 5.5.5. As of the
Effective Date, none of the Selexis Patent Rights are involved in any interference or opposition proceeding, and Selexis has not received any request, demand or notice from any Third Party threatening or disclosing such a proceeding with respect to
any of the Selexis Patent Rights; and 
 5.5.6. As of the Effective Date, Selexis has not received any statement or assertion that
(i) any claim in any of the Selexis Patent Rights is, or may be or become rendered, invalid or unenforceable, (ii) any Third Party is aware of any basis as to the future potential invalidity or unenforceability of any claim of any of the
Selexis Patent Rights, or (iii) the Selexis Patent Rights do not list all required inventors. 
 5.5.7. Any replacement Selexis
Materials shall satisfy the characteristics set forth in the Selexis Report and shall be free of mycoplasma or other pathogenic contamination. 

5.6 Additional Warranties by COMPANY. COMPANY hereby warrants, represents and covenants to Selexis that, to the best of its knowledge:

 5.6.1. As of the Effective Date, there is no pending litigation which alleges that the use of the DNA sequence replicated by the Cell
Line has infringed or misappropriated any of the intellectual property rights of any Third Party, and COMPANY has not received any claim that the use thereof infringes on any intellectual property rights of a Third Party or a request or

  
 12 

 CONFIDENTIAL 

 

 
demand from any Third Party for the licensing of any intellectual property rights of such Third Party in connection with the use of the DNA sequence replicated by the Cell Line; 

5.7 Notification. Selexis shall notify COMPANY promptly during the Term, if: 

5.7.1. Selexis Patent Rights become involved in any interference or opposition proceeding, or Selexis receives any request, demand or notice
from any Third Party threatening or disclosing such a proceeding with respect to any of the Selexis Patent Rights; or 
 5.7.2. Selexis
receives any written statement or assertion that (i) any claim in any of the Selexis Patent Rights is, or may be or become rendered, invalid or unenforceable, (ii) any Third Party is aware of any basis as to the future potential invalidity
or unenforceability of any claim of any of the Selexis Patent Rights, or (iii) the Selexis Patent Rights do not list all required inventors. 

5.8 Disclaimer of Warranties by Selexis. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, SELEXIS DOES NOT MAKE ANY REPRESENTATION OR
WARRANTY TO COMPANY OF ANY NATURE, EXPRESS OR IMPLIED, THAT THE SELEXIS TECHNOLOGY WILL BE USEFUL FOR, OR ACHIEVE ANY PARTICULAR RESULTS AS A RESULT OF ANY USE BY COMPANY OF THE SELEXIS TECHNOLOGY PURSUANT TO ANY LICENSE GRANTED TO COMPANY UNDER
THIS AGREEMENT. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, SELEXIS SPECIFICALLY DISCLAIMS ANY WARRANTY OF NONINFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE. 

 

	6.	INDEMNIFICATION; LIMITATION OF LIABILITY 

 6.1 Indemnification by Selexis. During
the Term and thereafter, Selexis hereby agrees to save, defend and hold COMPANY, its Affiliates, and their respective officers, directors, employees, consultants and agents harmless from and against any and all liability, damage, loss or expense
(collectively, “Losses”) claimed by a Third Party resulting from (i) any breach of Selexis’ representations, warranties, and covenants set forth in this Agreement or (ii) the practice of licensed rights by COMPANY in
accordance with this Agreement, except to the extent that such Losses result from the gross negligence or intentional misconduct of COMPANY, its Affiliates, and their respective officers, directors, employees, consultants and agents. In the event
COMPANY seeks indemnification under this Section 6.1, COMPANY shall inform Selexis of a claim as soon as reasonably practicable after it receives notice of the claim, shall permit Selexis to assume direction and control of the defense of the
claim (including the right to settle the claim solely for monetary consideration), and shall cooperate as requested (at Selexis’ expense) in the defense of the claim but provided always that Selexis may not settle any such claim or otherwise
consent to an adverse judgment or order in any relevant action or other proceeding or make any admission as to liability or fault without the express written permission of COMPANY. 

6.2 Indemnification by COMPANY. During the Term and thereafter, COMPANY hereby agrees to save, defend and hold Selexis and its
officers, directors, employees, consultants 

  
 13 

 CONFIDENTIAL 

 

 
and agents harmless from and against any and all Losses claimed by a Third Party (i) that the [***] or (ii) resulting from personal injury or damage to property caused by any Products
(including breach of the warranty pursuant to clause 5.6), except to the extent that COMPANY is indemnified by Selexis in respect of those Losses pursuant to Section 6.1 or that such Losses result from the gross negligence or intentional
misconduct of Selexis its Affiliates, and their respective officers, directors, employees, consultants and agents. In the event Selexis seeks indemnification under this Section 6.2, Selexis shall inform COMPANY of a claim as soon as reasonably
practicable after it receives notice of the claim, shall permit COMPANY to assume direction and control of the defense of the claim (including the right to settle the claim solely for monetary consideration), and shall cooperate as requested (at
COMPANY’s expense) in the defense of the claim. 
 6.3 Insurance. COMPANY shall maintain product liability insurance (or
self-insure) in an amount consistent with industry standards; with respect to COMPANY, such insurance being in place by the time human clinical trials are initiated and maintained while clinical trials are underway or Product is offered for sale.
COMPANY shall name Selexis as an additional insured with respect to such insurance. Company shall provide a certificate of insurance (or evidence of self-insurance) evidencing such coverage to Selexis upon request. 

6.4 EXCEPT FOR LIABILITY FOR BREACH OF SECTION 8, NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL,
CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER; provided however, that this Section 6.4 shall not be construed to limit either Party’s indemnification obligations under this
Section 6. 
 6.5 Limitation of Liability. Excluding breaches of Section 8, Selexis’ liability under Section 6.1
will in no event exceed [***] the aggregate amount paid to Selexis under this Agreement, and Selexis’ liability otherwise under this Agreement, whether in contract or tort or otherwise, will not exceed [***] the aggregate amount paid to Selexis
under this Agreement. 
  

	7.	TERM AND TERMINATION 

 7.1 Term. This Agreement shall enter into effect on the
Effective Date. Unless earlier terminated pursuant to Sections 7.2, 7.3 or 7.4 of this Agreement shall remain in full force and effect on a country-by-country and Product-by-Product basis until the expiration of the Royalty Term with respect to such
Product (such period, the “Term”). Upon expiration of the Term on a country-by-country and Product-by-Product basis, the Commercial Licenses granted to COMPANY under this Agreement shall become perpetual, irrevocable, fully paid up
and royalty free in respect of such Product and country, and this provision shall survive expiration or termination of this Agreement. 

7.2 Termination for Default. In addition to any other remedies which may be available at law or equity, in the event of any material
breach of this Agreement by a Party (“Default”), the Party not in default (“Non-Defaulting Party”) shall have the right to give the 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

  
 14 

 CONFIDENTIAL 

 

 
other Party (“Defaulting Party”) written notice thereof (“Notice of Default”), which notice must state the nature of the Default in reasonable detail and request
that the Defaulting Party cure such Default within [***] days. If such Default is not cured within the period set forth herein after receipt of a Notice of Default by the Defaulting Party or if such Default is not capable of being cured, then
the Non-Defaulting Party, at its option, may terminate this Agreement by written notice effective upon receipt. 
 7.3 Termination for
Bankruptcy. In the event that a Party files for protection under bankruptcy laws, files a petition under any bankruptcy or insolvency act or has such a petition filed against it which is not discharged in [***] days thereof , or makes any
arrangement with its creditors or has a receiver or administrator appointed to the whole or any part of its assets or if an order shall be made or a resolution passed for its winding up unless such order or resolution is part of a scheme for its
amalgamation or reconstruction (“Insolvent Party”), the other Party shall have the right to serve immediate notice of termination of this Agreement, effective upon receipt. 

7.4 Termination by COMPANY. COMPANY may terminate this Agreement at any time by giving sixty (60) days written notice to Selexis.

 7.5 Effects of Expiration or Termination. 

7.5.1. Termination of Licenses. In the event of a termination of this Agreement by COMPANY pursuant to Section 7,2, 7.3, or 7.4 or
by Selexis pursuant to Sections 7.2 or 7.3, the rights and licenses granted under this Agreement shall terminate other than those licenses which have become perpetual as described in Sections 3.1,3 and 7.1. 

7.5.2. Selexis Confidential Information. Upon termination of this Agreement under Section 7.2 or 7.3 wherein COMPANY is the
Insolvent Party, or Section 7.4, COMPANY shall dispose of all tangible embodiments, including Selexis Materials, and render inaccessible or useless all electronic embodiments, of Selexis Confidential Information provided to COMPANY by Selexis
hereunder, except that (i) COMPANY may retain one (1) copy thereof for legal archival purposes, (ii) Company may retain any such Selexis Confidential Information to the extent necessary to exercise rights under licenses that have
become perpetual as described in Sections 3.1.3 and 7.1 and (iii) sublicensees possessing sublicenses that survive such termination may possess such Selexis Confidential Information 

7.5.3. COMPANY Confidential Information. Upon any expiration or termination of this Agreement, Selexis shall dispose of all tangible
embodiments, and render inaccessible or useless all electronic embodiments, of COMPANY Confidential Information provided to Selexis by COMPANY hereunder, except that Selexis may retain one (1) copy thereof for legal archival purposes. 

7.5.4. Accrued Obligations. Expiration or termination of this Agreement shall not relieve the Parties of any obligation or liability
accruing prior to such expiration or termination and all ancillary provisions necessary for the implementation of this Section 7.5.5 shall survive termination. 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

  
 15 

 CONFIDENTIAL 

 

 7.5.5. Survival. Sections 1, 3 (as to payments accrued during the Term under this
Agreement), 4, 6, 7.1, 7.5, 8, 9, and the final sentence of Section 3.1.3 shall survive termination or expiration of this Agreement. 

7.5.6. Wind Down. COMPANY and its Affiliates may continue, to the extent that COMPANY and its Affiliates continue to have an inventory
of Products, to fulfill orders received from customers for Products until up to twelve (12) months after the effective date of termination. For the Products sold by COMPANY and its Affiliates after the effective date of termination, COMPANY
shall continue to make payments to Selexis in accordance with Section 3.1.3. 
  

	8.	CONFIDENTIALITY 

 8.1 Nondisclosure. During the Term, and for a period of five
(5) years thereafter, each Party will maintain all Confidential Information of the other Party as confidential and will not disclose any Confidential Information to any Third Party except to its Affiliates, sublicensees, collaborators,
employees, agents, consultants and other representatives, who have a need to know such Confidential Information and who are bound by obligations of confidentiality at least as restrictive as set forth herein. Each Party may use such Confidential
Information only to the extent required to accomplish the purposes of this Agreement. Each Party will use at least the same standard of care as it uses to protect proprietary or confidential information of its own to ensure that its Affiliates,
employees, agents, consultants and other representatives do not disclose or make any unauthorized use of the Confidential Information. 

8.2 Exceptions. Confidential Information shall not include any information that the receiving Party can prove by competent evidence is:

 8.2.1. now, or hereafter becomes, through no act or failure to act on the part of the receiving Party, generally known or available; 

8.2.2. known by the receiving Party at the time of receiving such information, as evidenced by its records; 

8.2.3. hereafter furnished to the receiving Party by a Third Party, as a matter of right and without restriction on disclosure; 

8.2.4. independently developed by the receiving Party without the aid, application or use of Confidential Information; or 

8.2.5. the subject of a written permission to disclose provided by the providing Party. 

8.3 Authorized Disclosures. Each Party shall be permitted to disclose Confidential Information of the other Party: 

8.3.1. to the extent that such Confidential Information is required to be disclosed to comply with applicable laws or regulations (such as
disclosure to the United States Securities 

  
 16 

 CONFIDENTIAL 

 

 
and Exchange Commission or to comply with the request or order of any applicable Regulatory Authority, whether or not having the force of law) or with a court or administrative order; provided
however, that such Party shall first have given written notice of such required disclosure to the other Party, shall make reasonable efforts to narrow the scope of Confidential Information of the other Party required to be disclosed, and shall take
reasonable steps to allow the other Party at its own expense to seek a protective order to protect the confidentiality of the Confidential information required to be disclosed; 

8.3.2. solely on a need-to-know basis to potential or actual acquirers, merger partners, or assignees permitted under Section 9.1,
investment bankers, investors, lenders, or other potential financial partners, and their and each of the Parties’ respective directors, employees, contractors and agents, each of whom prior to disclosure must be bound by written obligations of
confidentiality and non-use no less restrictive than the obligations set forth in this Article 8 and for their use solely in connection with evaluating the potential acquisition or investment; and 

8.3.3. to establish rights or enforce obligations under this Agreement, but only to the extent such disclosure is necessary and provided that
such Party seeks confidential treatment of the Confidential Information to be disclosed. 
  

	9.	MISCELLANEOUS 

 9.1 Assignment. Neither this Agreement nor any interest hereunder
shall be assignable by either Party without the prior written consent of the other Party; provided, that either Party may assign this Agreement and all of its rights and obligations hereunder, without such consent, to an entity which acquires all or
substantially all of the business or assets of such Party (or the business or assets to which this Agreement pertains) whether by merger, consolidation, reorganization, acquisition, sale, license or otherwise; and COMPANY may assign this Agreement
and all of its rights and obligations hereunder, without such consent, to an Affiliate if COMPANY remains liable and responsible for the performance and observance of all of the Affiliate’s duties and obligations hereunder. This Agreement shall
be binding upon the successors and permitted assigns of the Parties and the name of a Party appearing herein shall be deemed to include the names of such Party’s successors and permitted assigns to the extent necessary to carry out the intent
of this Agreement. Any assignment not in accordance with this Section 9.1 shall be null and void. 
 9.2 Compliance with
Governmental Obligations. Each Party shall comply, upon reasonable notice from the other Party, with all governmental requests directed to either Party and provide all information and assistance necessary to comply with the governmental
requests. 
 9.3 Counterparts. This Agreement may be executed in any number of counterparts, each of which need not contain the
signature of more than one Party but all such counterparts taken together shall constitute one and the same agreement, and may be executed through the use of facsimiles. 

  
 17 

 CONFIDENTIAL 

 

 9.4 Dispute Resolution. The Parties agree that in the event of a dispute between them
arising from, concerning or in any way relating to this Agreement, the Parties shall undertake good faith efforts to resolve any such dispute in good faith with the matter being referred at the request of either Party to the general counsel for each
Party and, if remaining unresolved after thirty (30) days, then to the chief executive officers of each Party (or their designees). If after ninety (90) days of the matter first being referred to the general counsel the Parties are unable
to resolve such dispute, either Party may seek any remedy available pursuant to Section 9.8 of this agreement. 
 9.5 Entire
Agreement. This Agreement (including the Exhibits attached hereto, which are incorporated herein by reference) sets forth all of the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties
hereto with respect to the subject matter hereof; constitutes and contains the complete, final, and exclusive understanding and agreement of the Parties with respect to the subject matter hereof; and cancels, supersedes and terminates all prior
agreements and understanding between the Parties with respect to the subject matter hereof. There are no covenants, promises, agreements, warranties, representations conditions or understandings, whether oral or written, between the Parties other
than as set forth herein. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties hereto unless reduced to writing and signed by the respective authorized officers of the Parties. 

9.6 Force Majeure. Neither Party shall be liable to the other for loss or damages for any default or delay attributable to any Force
Majeure, if the Party affected shall give prompt notice of any such cause to the other Party. The Party giving such notice shall thereupon be excused from such of its obligations hereunder as it is thereby disabled from performing for so long as it
is so disabled, provided, however, that such affected Party commences and continues to take reasonable and diligent actions to cure such cause; and provided further that if any Force Majeure delays or prevents the performance of the obligations of
either Party for a continuous period in excess of six (6) months, the Party not so affected shall then be entitled to give notice to the affected Party to terminate this Agreement, specifying the date (which shall not be less than thirty
(30) days after the date on which the notice is given) on which termination will take effect. Such a termination notice shall be irrevocable, except with the consent of both parties, and upon termination the provisions of Section 9.5 shall
apply. 
 9.7 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such
other acts, as may be necessary or appropriate in order to carry out the purposes and intent of the Agreement. 
 9.8 Governing Law and
Jurisdiction. This Agreement shall be governed by and interpreted in accordance with the substantive laws of the State of Massachusetts. In relation to any legal action or proceedings arising out of or in connection with this Agreement
(“Proceedings”), each of the Parties irrevocably submits to the exclusive jurisdiction of the state and federal courts located in Boston, Massachusetts, and waives any objection to Proceedings in such courts on the grounds of venue or on
the grounds that Proceedings have been brought in an inappropriate forum. 

  
 18 

 CONFIDENTIAL 

 

 9.9 Independent Contractors. The relationship between Selexis and COMPANY created by
this Agreement is one of independent contractors and neither Party shall have the power or authority to bind or obligate the other Party except as expressly set forth in this Agreement. 

9.10 Interpretation of Agreement. Article and other descriptive headings used in this Agreement are for reference purposes only and
shall not constitute a part hereof or affect the meaning or interpretation of this Agreement. Whenever the context so requires, the use of the singular shall be deemed to include the plural and vice versa. 

9.11 License Obligations; Rights in Bankruptcy. Nothing in this Agreement imposes any obligation upon a Party to enter into any other
license or agreement with the other Party. All rights and licenses granted under or pursuant to this Agreement by Selexis are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code (i.e., Title 11 of
the U.S. Code) or analogous provisions of applicable law outside the United States, licenses of rights to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code or analogous provisions of applicable laws
outside the United States. The Parties agree that (i) either Party shall be entitled, to the full extent permitted by applicable bankruptcy law, to elect to retain of its rights as a licensor or licensee respectively, in the event that the
other Party files for bankruptcy in any jurisdiction or has any petition for bankruptcy filed against it, and (ii) either Party may, to the fullest degree permitted by applicable bankruptcy law, exercise all of its rights and elections under
the relevant bankruptcy law, including but not limited to retention of its rights as a licensor or licensee respectively, regardless of whether either Party files for bankruptcy in the United States or any other jurisdiction or has any petition for
bankruptcy filed against it. 
 9.12 Non-Disclosure. Except as otherwise required by law or regulation, and only after compliance
with this Section 9.12, neither Party shall issue a press release or make any other disclosure of the existence of or the terms of this Agreement, or otherwise use the name or trademarks or products of the other Party or the names of any
employee thereof, without the prior approval of such press release or disclosure by the other Party. However if, in the reasonable opinion of such Party’s counsel, a public disclosure shall be required by law, regulation, or court order,
including without limitation in a filing with the United States or Europe Securities and Exchange Commission or the United States Food and Drug Administration or the European Medicines Agency, the disclosing Party shall provide copies of the
disclosure reasonably in advance of such filing or other disclosure for the non-disclosing Party’s prior review and comment, and the non-disclosing Party shall provide its comments as soon as practicable. Notwithstanding the foregoing, either
Party may disclose the existence of and the terms of this Agreement solely on a need-to-know basis to potential or actual acquirers, merger partners, or assignees permitted under Section 9.1, investment bankers, investors, lenders, or other
potential financial partners, and their and each of the Parties’ respective directors, employees, contractors and agents, each of whom prior to disclosure must be bound by written obligations of confidentiality and non-use no less restrictive
than the obligations set forth in Article 8 and for their use solely in connection with evaluating the potential acquisition or investment. No disclosure permitted by this Section 9.12 shall contain any Confidential Information of the other
Party unless otherwise permitted in accordance with Section 8 herein. 

  
 19 

 CONFIDENTIAL 

 

 9.13 Notices. All notices and other communications required by this Agreement shall be
in writing in the English language and shall be deemed given if delivered personally or by facsimile transmission (receipt verified), mailed by registered or certified mail (return receipt requested), postage prepaid, or sent by express courier
service, to the Parties at the following addresses (or at such other address for a Party as shall be specified by like notice, provided, however, that notices of a change of address shall be effective only upon receipt thereof): 

 

					
	 	  	 To Company
	  	 Selexis

			
	Address:	  	Coherus BioSciences, Inc.	  	Selexis S.A.
		  	201 Redwood Shores Parkway, Suite 200	  	18 Chemin des Aulx
		  	Redwood City, CA 94085	  	1228 Plan-les-Ouates
		  		  	Geneva, Switzerland
			
	Attention:	  	Chief Executive Officer	  	General Assistant
			
	With a copy to:	  	Chief Business Officer	  	Chief Executive Officer
		  	Facsimile: +1 650 521-5910	  	+41 22 308-9361

 or to such addresses or addresses as the Parties hereto may designate for such purposes during the Term. Notices shall be
deemed to have been sufficiently given or made: (i) if by facsimile with confirmed transmission, when performed, and (ii) if by air courier upon receipt by the Party. 

9.14 Parties in Interest. This Agreement shall be binding upon and inure solely to the benefit of COMPANY and Selexis (and their
permitted successors and assigns) and nothing in this Agreement (express or implied) is intended to or shall confer upon any Third Party any rights, benefits or remedies of any nature whatsoever under or by reason of this Agreement. 

9.15 Severability. If any term, covenant or condition of this Agreement or the application thereof to any Party or circumstance shall,
to any extent, be held to be invalid or unenforceable, then the remainder of this Agreement, or the application of such term, covenant or condition to parties or circumstances other than those as to which it is held invalid or unenforceable, shall
not be affected thereby and each term, covenant or condition of this Agreement shall be valid and be enforced to the fullest extent permitted by law. 

9.16 Use of Name. No right, express or implied, is granted to either Party by this Agreement to use in any manner any trademark or
trade name of the other Party including the names “Coherus” and “Selexis” without the prior written consent of the owning Party. 

9.17 Waiver. The failure on the part of a Party to exercise or enforce any rights conferred upon it hereunder shall not be deemed to be
a waiver of any such rights nor operate to bar the exercise or enforcement thereof at any time or times hereafter. 

  
 20 

 CONFIDENTIAL 

 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
 In Witness Whereof, the Parties,
having read the terms of this Agreement and intending to be legally bound hereby, do hereby execute this Agreement. 
  

			
	SELEXIS S.A.
		
	By:	 	 /s/ Regine Brokamp

	Name:	 	Regine Brokamp
	Title:	 	Chief Operating Officer
	Date:	 	July 18, 2012
		
	By:	 	 /s/ Pierre-Alain Girod

	Name:	 	Pierre-Alain Girod
	Title:	 	Chief Scientific Officer
	Date:	 	July 18, 2012
	
	COHERUS BIOSCIENCE., INC.
		
	By:	 	 /s/ Dennis M. Lanfear

	Name:	 	Dennis M. Lanfear
	Title:	 	President and CEO
	Date:	 	June 25, 2012

  
 21 

 EXHIBIT 1 
  

SELEXIS PATENT RIGHTS 
 Patent 1. 

 

			
		
	Title	  	[***]
		
	Priority date	  	[***]
		
	Priority ID	  	[***]
		
	Publication ID	  	[***]
		
	Geographies	  	[***]
		
	Status	  	[***]

 Patent 2. 
  

			
		
	Title	  	[***]
		
	Priority date	  	[***]
		
	Priority ID	  	[***]
		
	Publication ID	  	[***]
		
	Geographies	  	[***]

  
 [***] Certain information in this document has been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

 EXHIBIT 2 COMMERCIAL LICENSE FOR [***] 

 

			
	COMPANY Product Name:	  	[***]
		
	AA Sequence - Light Chain	  	[***]
		
	AA Sequence - Heavy Chain	  	[***]

  
 [***] Certain information in this document has been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.Prepared by R.R. Donnelley Financial -- EX-10.7

 Exhibit 10.7 

Execution Version 
 AGREEMENT
AND PLAN OF MERGER 
 BY AND AMONG 

COHERUS BIOSCIENCES, INC., 

COHERUS INTERMEDIATE CORP., 

COHERUS ACQUISITION CORP., 

INTEKRIN THERAPEUTICS INC., 

AND 
 FORTIS ADVISORS LLC

 Dated as of January 8, 2014 

 TABLE OF CONTENTS 

 

									
	 	 	 	 	 	  	Page	 
		
	 ARTICLE I THE MERGER; ADDITIONAL ACTIONS
	  	 	2	  
		 	Section 1.1.	 	The Merger	  	 	2	  
		 	Section 1.2.	 	Effective Time	  	 	2	  
		 	Section 1.3.	 	Closing	  	 	2	  
		 	Section 1.4.	 	Effects of the Merger	  	 	3	  
		 	Section 1.5.	 	Certificate of Incorporation, By-Laws and Officers and Directors of the Surviving Corporation	  	 	3	  
		 	Section 1.6.	 	Further Assurances	  	 	3	  
		
	 ARTICLE II CONVERSION OF SHARES
	  	 	3	  
		 	Section 2.1.	 	Conversion of Capital Stock	  	 	3	  
		 	Section 2.2.	 	Earn Out Event; Compound Transaction Agreement	  	 	5	  
		 	Section 2.3.	 	Deposits of Securities at Closing; Escrow Fund	  	 	7	  
		 	Section 2.4.	 	Exchange of Certificates and Options	  	 	8	  
		 	Section 2.5.	 	Stockholders’ Representative	  	 	10	  
		 	Section 2.6.	 	Accredited Investors	  	 	12	  
		 	Section 2.7.	 	Legend	  	 	13	  
		 	Section 2.8.	 	Fractional Shares	  	 	14	  
		 	Section 2.9.	 	Management Incentive Grants	  	 	14	  
		 	Section 2.10.	 	Conversion of Sofinnova Note	  	 	14	  
		 	Section 2.11.	 	Withholding	  	 	14	  
		
	 ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY
	  	 	15	  
		 	Section 3.1.	 	Organization	  	 	15	  
		 	Section 3.2.	 	Capitalization	  	 	15	  
		 	Section 3.3.	 	Authority	  	 	16	  
		 	Section 3.4.	 	No Conflicts; Governmental Requirements	  	 	16	  
		 	Section 3.5.	 	Books and Records	  	 	17	  
		 	Section 3.6.	 	Financial Statements	  	 	18	  
		 	Section 3.7.	 	Absence of Undisclosed Liabilities	  	 	18	  
		 	Section 3.8.	 	Absence of Certain Changes or Events	  	 	19	  
		 	Section 3.9.	 	Properties	  	 	19	  
		 	Section 3.10.	 	Accounts Payable; Clinical Materials	  	 	19	  
		 	Section 3.11.	 	Contracts	  	 	20	  
		 	Section 3.12.	 	Absence of Questionable Payments	  	 	21	  
		 	Section 3.13.	 	Litigation	  	 	21	  

									
		 	Section 3.14.	 	Compliance with Law; Authorizations	  	 	21	  
		 	Section 3.15.	 	Intellectual Property	  	 	22	  
		 	Section 3.16.	 	Tax Matters	  	 	23	  
		 	Section 3.17.	 	Employee Benefit Plans	  	 	25	  
		 	Section 3.18.	 	Employee Compensation	  	 	26	  
		 	Section 3.19.	 	Employees	  	 	26	  
		 	Section 3.20.	 	Bank Accounts	  	 	27	  
		 	Section 3.21.	 	Brokers	  	 	27	  
		 	Section 3.22.	 	Disclosures	  	 	28	  
		
	 ARTICLE IV REPRESENTATIONS AND WARRANTIES OF PARENT, ACQUISITION HOLDCO AND ACQUISITION CORP
	  	 	28	  
		 	Section 4.1.	 	Organization, Good Standing and Qualification	  	 	28	  
		 	Section 4.2.	 	Subsidiaries	  	 	28	  
		 	Section 4.3.	 	Authorization	  	 	29	  
		 	Section 4.4.	 	Governmental Consents	  	 	29	  
		 	Section 4.5.	 	Valid Issuance of Merger Shares and Underlying Parent Common Stock	  	 	30	  
		 	Section 4.6.	 	Capitalization	  	 	30	  
		 	Section 4.7.	 	Agreements; Action	  	 	31	  
		 	Section 4.8.	 	Compliance with Other Instruments	  	 	32	  
		 	Section 4.9.	 	Intellectual Property	  	 	32	  
		 	Section 4.10.	 	Employees	  	 	33	  
		 	Section 4.11.	 	Related Party Transactions	  	 	34	  
		 	Section 4.12.	 	Litigation	  	 	34	  
		 	Section 4.13.	 	Title to Property and Assets	  	 	35	  
		 	Section 4.14.	 	Permits	  	 	35	  
		 	Section 4.15.	 	Employee Benefit Plans	  	 	35	  
		 	Section 4.16.	 	Tax Returns, Payments, and Elections	  	 	35	  
		 	Section 4.17.	 	Environmental and Safety Laws	  	 	36	  
		 	Section 4.18.	 	Financial Statements	  	 	36	  
		 	Section 4.19.	 	Changes	  	 	36	  
		 	Section 4.20.	 	Registration Rights; Voting Rights	  	 	37	  
		 	Section 4.21.	 	Disclosure	  	 	37	  
		 	Section 4.22.	 	Brokers	  	 	38	  
		 	Section 4.23.	 	Financial Capability	  	 	38	  
		
	 ARTICLE V COVENANTS AND ADDITIONAL AGREEMENTS
	  	 	38	  
		 	Section 5.1.	 	Conduct of Business	  	 	38	  
		 	Section 5.2.	 	No Solicitations	  	 	40	  
		 	Section 5.3.	 	Access to Information; Support; Confidentiality	  	 	41	  
		 	Section 5.4.	 	Company Stockholder Approval	  	 	43	  
		 	Section 5.5.	 	Prior Knowledge	  	 	43	  
		 	Section 5.6.	 	Supplemental Disclosure	  	 	43	  

  
 ii 

									
		 	Section 5.7.	 	Company Stock Plan	  	 	43	  
		 	Section 5.8.	 	Fulfillment of Conditions	  	 	44	  
		 	Section 5.9.	 	Director and Officer Indemnity	  	 	44	  
		 	Section 5.10.	 	Management Incentive Grants	  	 	45	  
		
	 ARTICLE VI CONDITIONS TO CLOSING
	  	 	45	  
		 	Section 6.1.	 	Conditions to the Obligations of Parent, Acquisition HoldCo and Acquisition Corp	  	 	45	  
		 	Section 6.2.	 	Conditions to the Obligations of the Company	  	 	46	  
		
	 ARTICLE VII SURVIVAL; INDEMNIFICATION; TAX MATTERS
	  	 	48	  
		 	Section 7.1.	 	Survival	  	 	48	  
		 	Section 7.2.	 	Indemnification	  	 	48	  
		 	Section 7.3.	 	Limitation of Liability	  	 	49	  
		 	Section 7.4.	 	Additional Indemnification Limitations	  	 	49	  
		 	Section 7.5.	 	Notice of Claims	  	 	50	  
		 	Section 7.6.	 	Defense of Third Party Claims	  	 	50	  
		 	Section 7.7.	 	Dispute Resolution Negotiation	  	 	50	  
		 	Section 7.8.	 	Indemnity Escrow Funds and Indemnity Payments	  	 	51	  
		 	Section 7.9.	 	Exclusive Remedy	  	 	52	  
		 	Section 7.10.	 	Tax Matters	  	 	53	  
		
	 ARTICLE VIII TERMINATION; EFFECT OF TERMINATION
	  	 	54	  
		 	Section 8.1.	 	Termination	  	 	54	  
		 	Section 8.2.	 	Effect of Termination	  	 	54	  
		
	 ARTICLE IX FEES AND EXPENSES
	  	 	55	  
		 	Section 9.1.	 	Expenses	  	 	55	  
		 	Section 9.2.	 	Stockholders of the Company	  	 	55	  
		
	 ARTICLE X DEFINITIONS
	  	 	55	  
		 	Section 10.1.	 	Table of Definitions	  	 	55	  
		 	Section 10.2.	 	Other Terms	  	 	61	  
		 	Section 10.3.	 	Other Definitional Provisions	  	 	61	  
		
	 ARTICLE XI MISCELLANEOUS
	  	 	61	  
		 	Section 11.1.	 	Press Releases	  	 	61	  
		 	Section 11.2.	 	Integration	  	 	61	  
		 	Section 11.3.	 	Assignment	  	 	62	  
		 	Section 11.4.	 	Waiver	  	 	62	  
		 	Section 11.5.	 	Notices	  	 	62	  
		 	Section 11.6.	 	Amendment	  	 	63	  
		 	Section 11.7.	 	Governing Law; Jurisdiction	  	 	63	  
		 	Section 11.8.	 	Third Party Beneficiaries	  	 	64	  
		 	Section 11.9.	 	Performance	  	 	64	  

  
 iii 

									
		 	Section 11.10.	 	Severability	  	 	64	  
		 	Section 11.11.	 	Extensions	  	 	64	  
		 	Section 11.12.	 	Section Headings	  	 	64	  
		 	Section 11.13.	 	Exhibits; Disclosure Schedules	  	 	64	  
		 	Section 11.14.	 	Counterparts	  	 	65	  

  
 iv 

			
	Exhibits
		
	Exhibit A	  	Stockholders Entering into a Voting and Release Agreement
		
	Exhibit B	  	Form of Voting Agreement and Release
		
	Exhibit C	  	Form of Certificate of Incorporation of the Surviving Corporation
		
	Exhibit D	  	Form of Bylaws of the Surviving Corporation
		
	Exhibit E	  	Directors and Officers of the Surviving Corporation
		
	Exhibit F	  	Payments to Stockholders and Management Incentive Grant Recipients
		
	Exhibit G	  	Compound Transaction Revenue; Percentage Payable to Stockholders and Management Incentive Grant Recipients
		
	Exhibit H	  	Second Amended and Restated Investors’ Rights Agreement
		
	Exhibit I	  	Second Amended and Restated Voting Agreement, as amended
		
	Exhibit J	  	Restated Certificate of Parent
		
	Exhibit K	  	Management Rights Agreement
		
	Exhibit L	  	Secondary Share Purchase Agreement
	
	Schedules
	
	Company Disclosure Schedule
	
	Parent Disclosure Schedule
		
	Schedule 6.1(c)	  	Consents Required
		
	Schedule 6.1(g)	  	Persons Executing the Rights Agreement
		
	Schedule 6.1(h)	  	Persons Executing the Voting Agreement

 AGREEMENT AND PLAN OF MERGER 

AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of January 8, 2014, by and among COHERUS BIOSCIENCES, INC., a
Delaware corporation (“Parent”), COHERUS INTERMEDIATE CORP., a Delaware corporation (“Acquisition HoldCo”), COHERUS ACQUISITION CORP., a Delaware corporation (“Acquisition Corp.”), INTEKRIN
THERAPEUTICS INC., a Delaware corporation (the “Company”) and FORTIS ADVISORS LLC, a Delaware limited liability company, solely in its capacity as the Stockholders’ Representative. Certain capitalized terms used in this
Agreement have the meanings ascribed to them in Article X. 
 RECITALS 

A. The Company is a Delaware corporation with its principal executive offices located at 555 Bryant Street, Suite 266, Palo Alto, CA 94301.

 B. Parent is a Delaware corporation with its principal executive offices located at 201 Redwood Shores Parkway, Suite 200, Redwood City,
CA 94065. Acquisition HoldCo is a newly formed wholly-owned direct subsidiary of Parent. Acquisition Corp. is a wholly-owned direct subsidiary of Acquisition HoldCo and was formed to merge with and into the Company (the “Merger”) so
that, as a result of the Merger, the Company will survive and become a wholly-owned direct subsidiary of Acquisition HoldCo and a wholly-owned indirect subsidiary of Parent. 

C. The respective Boards of Directors of Parent, Acquisition HoldCo, Acquisition Corp. and the Company have determined that this Agreement and
the consummation of the Merger in accordance with the laws of the State of Delaware and subject to the terms and conditions of this Agreement, is advisable and in the best interests of Parent, Acquisition, HoldCo, Acquisition Corp. and the Company
and their respective stockholders. 
 D. Acquisition HoldCo, in its capacity as the sole stockholder of Acquisition Corp., has approved
Acquisition Corp.’s execution of this Agreement and consummation of the Merger. 
 E. As a condition and inducement to Parent’s
willingness to enter into this Agreement, concurrently with the execution of this Agreement, each of the Persons identified on Exhibit A have entered into a Voting and Release Agreement substantially in the form attached hereto as Exhibit
B (the “Voting and Release Agreement”), which Voting and Release Agreement shall provide for, among other things, such Person’s approval of the Merger and agreement to vote its shares of common stock, par value $0.0001 per
share, of the Company (“Company Common Stock”) and its shares of Series 1 Preferred Stock, par value $0.0001 per share, of the Company (the “Company Preferred Stock” and together with the Company Common Stock, the
“Company Capital Stock”) in a manner consistent with such approval and agreement to waive such Person’s rights to dissent from the Merger and the other transactions contemplated hereby under Section 262 of the Delaware
General Corporation Law (the “DGCL”). 

 F. Parent, Acquisition HoldCo, Acquisition Corp., and the Company desire to make certain
representations and warranties, covenants and agreements in connection with the Merger and also to set forth the terms and conditions of the Merger, all as set forth in this Agreement. 

NOW, THEREFORE, in consideration of the foregoing and the mutual representations, warranties, covenants and agreements contained herein and
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, do hereby agree as follows: 

ARTICLE I THE MERGER; ADDITIONAL ACTIONS. 

Section 1.1. The Merger. At the Effective Time, upon the terms and subject to the conditions of this Agreement, Acquisition Corp. shall
be merged with and into the Company in accordance with the provisions of the DGCL. The Company shall be the surviving corporation in the Merger (the “Surviving Corporation”). As a result of the Merger, all of the respective
outstanding shares of capital stock or any securities exchangeable or convertible into capital stock of the Company and Acquisition Corp. shall be converted or cancelled in the manner provided in Article II. 

Section 1.2. Effective Time. At the Closing, a certificate of merger (the “Certificate of Merger”) shall be duly
prepared and executed by the Company and Acquisition Corp. and thereafter delivered to the Secretary of State of the State of Delaware (the “Secretary of State”) for filing, as provided in Section 251 of the DGCL, on the
Closing Date. The parties shall make all other filings required under the DGCL, and the Merger shall become effective at the time of the filing of the Certificate of Merger with the Secretary of State, or at such later time as may be agreed by
Parent and the Company and stated in the Certificate of Merger (the date and time of such filing (or stated later time, if any) being referred to herein as the “Effective Time”). 

Section 1.3. Closing. The closing of the Merger (the “Closing”) shall take place at the offices of Latham &
Watkins LLP, 140 Scott Drive, Menlo Park, California 94025-1008, on a date and at a time to be specified by the parties, which shall in no event be later than 10:00 a.m., local time, on the second business day following satisfaction of the
conditions set forth in Article VI, other than those conditions that by their nature cannot be satisfied until the Closing, but subject to the fulfillment or waiver of those conditions, unless this Agreement has been theretofore terminated pursuant
to its terms, or on such other date, time and place as the parties may mutually agree (the “Closing Date”). At the Closing there shall be delivered to Parent, Acquisition Corp. and the Company the certificates and other documents
and instruments required to be delivered under Article VI. 

  
 2 

 Section 1.4. Effects of the Merger. At the Effective Time, the effects of the Merger shall
be as provided in the applicable provisions of the DGCL. 
 Section 1.5. Certificate of Incorporation, By-Laws and Officers and
Directors of the Surviving Corporation. 
 (a) The certificate of incorporation of the Company, as in effect immediately prior to the
Effective Time, shall be amended at and as of the Effective Time so as to read in its entirety as set forth in Exhibit C and, as so amended, shall be the certificate of incorporation of the Surviving Corporation until thereafter amended as
provided by law and such certificate of incorporation. 
 (b) The by-laws in the form set forth in Exhibit D shall be the by-laws of
the Surviving Corporation at and as of the Effective Time until thereafter amended as provided by law, the certificate of incorporation of the Surviving Corporation and such by-laws. 

(c) From and after the Effective Time, the directors and officers of the Surviving Corporation shall be as set forth on Exhibit E
hereto, until their respective successors are duly elected and qualified or until their earlier death, resignation or removal in accordance with the Surviving Corporation’s certificate of incorporation and by-laws. 

Section 1.6. Further Assurances. Each party hereto shall execute such further documents and instruments and take such further actions
as may reasonably be requested by one or more of the others to consummate the Merger, to vest the Surviving Corporation with full title to all assets, properties, rights, approvals, immunities and franchises of Acquisition Corp. and the Company or
to otherwise effect the purposes of this Agreement. 
 ARTICLE II CONVERSION OF SHARES. 

Section 2.1. Conversion of Capital Stock. Subject to the terms and conditions of this Agreement, at the Effective Time, by virtue of
the Merger and without any further action on the part of any holder of Company Capital Stock: 
 (a) Capital Stock of Acquisition
Corp. Each issued and outstanding share of the common stock, par value $0.0001 per share, of Acquisition Corp. (“Acquisition Common Stock”) shall be converted into and become one fully paid and nonassessable share of common
stock, par value $0.0001 per share, of the Surviving Corporation (“Surviving Corporation Common Stock”). Each certificate representing outstanding shares of Acquisition Common Stock shall at the Effective Time represent an equal
number of shares of Surviving Corporation Common Stock. 
 (b) Cancellation of Treasury Stock and Stock Owned by Parent and Acquisition
Corp. All shares of Company Capital Stock that are owned by the Company as treasury stock and any shares of Company Capital Stock owned by Parent, Acquisition HoldCo or Acquisition Corp. or by any direct or indirect wholly-owned subsidiary of
Parent, Acquisition HoldCo or Acquisition Corp. automatically shall be cancelled and shall cease to exist and no consideration shall be delivered in exchange therefor. 

  
 3 

 (c) Conversion of Company Capital Stock; Payment of Merger Consideration. All shares of
Company Capital Stock (but excluding shares to be cancelled in accordance with Section 2.1(b)) shall no longer be outstanding and shall be cancelled automatically and shall cease to exist, and each holder of a certificate representing any such
shares of Company Capital Stock shall cease to have any rights with respect thereto, except the right to receive, without interest, the portion of the Acquisition Price as reflected on Exhibit F (which shall account for the portion of the
Acquisition Price payable to the Management Incentive Grant Recipients pursuant to Section 2.9) plus the Earn Out Payment, if any, and Compound Transaction Payments, if any, to be paid to such Person pursuant to Section 2.2 (and which
shall be further subject to Sections 2.4 and 2.6 with respect to whether such Person shall receive such merger consideration in the form of cash or shares of Parent Series B Preferred or Parent Common Stock, as applicable), upon the surrender of
such certificate in accordance with Section 2.4; provided that in no event shall the Acquisition Price plus the Earn Out Payment and any Compound Transaction Payments exceed the Merger Consideration Cap. Exhibit F is attached
hereto and sets forth: (i) the name of each Stockholder and Management Incentive Grant Recipient, reflecting the Company’s good faith determination, based upon representations and warranties of the applicable Person to the extent
available, as to the “accredited investor” status of each Stockholder and Management Incentive Grant Recipient as of the date of this Agreement; (ii) the number of shares or the amount of cash constituting the portion of the
Acquisition Price payable pursuant to this Section 2.1(c) and Section 2.9 to each Stockholder and Management Incentive Grant Recipient, respectively, at Closing (which form of consideration shall be determined with respect to such Person
in accordance with Sections 2.4 and 2.6); (iii) the number of shares or the amount of cash constituting the portion of the Acquisition Price to be withheld from each Stockholder and Management Incentive Grant Recipient pursuant to
Section 2.3(b) as Indemnity Escrow Funds; (iv) the number of shares and amount of cash constituting the portion of the Earn Out Funds to be paid to each Stockholder and Management Incentive Grant Recipient upon the occurrence of the Earn
Out Event pursuant to Section 2.2 (which form of consideration shall be determined with respect to such Person in accordance with Sections 2.4 and 2.6); and (v) the maximum amount of Compound Transaction Payments, if any, payable to each
Stockholder and Management Incentive Grant Recipient, pursuant to Section 2.2(b). If necessary, an updated Exhibit F shall be delivered by the Company at least two (2) business days before the Closing setting forth the information
described in the immediately preceding sentence, updated, if necessary, to reflect the good faith joint determination of Parent and the Company as to the “accredited investor” status of the Stockholders and Management Incentive Grant
Recipients as reflected on the Accredited Investor List. 
 (d) Dissenting Shares. Notwithstanding any provision of this Agreement to
the contrary, each outstanding share of Company Capital Stock (the holder of which has not voted in favor of the Merger or consented thereto in writing and has perfected such holder’s right to an appraisal of such holder’s shares in
accordance with the applicable provisions of the DGCL and has not effectively withdrawn or lost such right to appraisal (in each case, a “Dissenting 

  
 4 

 
Share”)) shall not be converted into or represent a right to receive the applicable Acquisition Price, the Earn Out Payment, if any, or Compound Transaction Payments, if any,
otherwise payable on such share pursuant to Section 2.2 (which form of consideration shall be determined with respect to such Person in accordance with Sections 2.4 and 2.6), but rather the holder thereof shall be entitled only to such rights
as are granted by the applicable provisions of the DGCL; provided, however, that any Dissenting Share held by a Person at the Effective Time who shall, after the Effective Time, withdraw the demand for appraisal or lose the right of
appraisal, in either case pursuant to the DGCL, shall be deemed to be converted into, as of the Effective Time, the right to receive the Acquisition Price applicable to such shares pursuant to Section 2.1(c) plus the Earn Out Payment, if any,
and Compound Transaction Payments, if any, to be paid on such shares in accordance with Section 2.2 (which form of consideration shall be determined with respect to such Person in accordance with Sections 2.4 and 2.6). The Company shall give
Parent (x) prompt notice of any written demands for appraisal, withdrawals of demands for appraisal and any other instruments served pursuant to the applicable provisions of the DGCL relating to the appraisal process received by the Company and
(y) prompt notice of and the opportunity to participate in all negotiations and proceedings with respect to demands for appraisal under the DGCL. The Company will not, except with the prior written consent of Parent, voluntarily make any
payment with respect to any demands for appraisal or settle or offer to settle any such demands prior to the Effective Time. 
 (e)
Treatment of Options. Prior to the date hereof, the Board of Directors of the Company (or, if appropriate, any committee thereof) has adopted appropriate resolutions and taken all other actions necessary to provide that each outstanding stock
option (each an “Option”) heretofore granted under the Company’s Amended and Restated 2005 Equity Incentive Plan, as amended to date (the “Company Stock Plan”), whether or not currently vested or exercisable at
the Effective Time, and which remains outstanding immediately prior to the Effective Time, shall be cancelled, no longer be outstanding and cease to represent the right to acquire shares of Company Common Stock. The Company Stock Plan (or other
plan, program or arrangement) providing for the issuance or grant of any other interest in respect of the capital stock of the Company shall terminate upon the Effective Time. 

Section 2.2. Earn Out Event; Compound Transaction Agreement. 

(a) Earn Out Event; Earn Out Funds. Upon the occurrence of the Earn Out Event, Parent shall: (i) within five (5) days of such
occurrence provide the Stockholders’ Representative with written notice thereof in accordance with Section 11.5 of this Agreement; and (ii) cause the Exchange Agent to pay to each Stockholder (other than holders of Dissenting Shares)
and Management Incentive Grant Recipient (subject to Section 2.9), such Person’s applicable pro rata amount of the Earn Out Funds as set forth on Exhibit F hereof. For clarity, the Earn Out Event may only occur once. 

  
 5 

 (b) Compound Transaction Agreement; Compound Transaction Revenue; Compound Transaction
Payments. Upon the execution of (i) any license, sublicense, development, collaboration, joint venture, partnering or similar agreement between Parent (or its Affiliate) and a third party pursuant to which Parent (or its Affiliate) has
granted to such third party the right (whether or not exclusive) to make, have made, use, have used, sell, have sold, offer to sell, import or have imported, market or distribute the Compound; or (ii) any agreement between Parent (or its
Affiliate) and a third party to sell all or substantially all of the assets related to the Compound to such third party ((i) and (ii) shall individually be known as a “Compound Transaction Agreement”), Parent shall:
(A) within five (5) days of such execution provide the Stockholders’ Representative with written notice thereof in accordance with Section 11.5 of this Agreement, which notice shall include the applicable percentage to be used to
determine such Compound Transaction Payments payable to the Stockholders and Management Incentive Grant Recipients pursuant to such Compound Transaction Agreement (such percentage to be determined as set forth in Exhibit G), (B) on or
before twenty (20) days following the actual receipt of any Compound Transaction Revenue, deposit with the Exchange Agent, for the benefit of the Stockholders (other than holders of Dissenting Shares) and Management Incentive Grant Recipients,
the applicable Compound Transaction Payments (less any amount thereof, if any, which would otherwise have been payable to holders of Dissenting Shares) by wire transfer of immediately available funds if such Compound Transaction Revenue is in the
form of cash, or by transfer of property or other non-cash form of such Compound Transaction Revenue if such Compound Transaction Revenue is in the form of property or other non-cash form and (C) cause the Exchange Agent to pay to each
Stockholder (other than holders of Dissenting Shares) and Management Incentive Grant Recipients, a cash amount or a portion of property or other non-cash form of Compound Transaction Revenue, in each case equal to such Stockholder’s and
Management Incentive Grant Recipient’s applicable percentage as set forth on Exhibit F hereof. If Compound Transaction Revenue includes property or other non-cash consideration, Parent and Stockholders’ Representative shall discuss
in good faith the method and timing of distribution of such property or other non-cash consideration following the execution of the applicable Compound Transaction Agreement, including whether or not Stockholders and Management Incentive Grant
Recipients are eligible to receive any non-cash consideration pursuant to applicable securities Laws. 
 (c) Definitions. For the
purposes of this Agreement, 
 (i) “Earn Out Funds” shall mean an aggregate amount equal to two million five hundred
thousand dollars ($2,500,000), payable in a combination of (1) shares of Series B preferred stock, par value of $0.0001 per share, of Parent (“Parent Series B Preferred”) (less the number of shares of Parent Series B Preferred
thereof, if any, which would otherwise have been payable to holders of Dissenting Shares) based on a Parent Series B Preferred price of $4.1841 per share, as set forth on Exhibit F hereof; provided that if the outstanding shares of
Parent Series B Preferred have been converted into shares of common stock, par value of $0.0001 per share, of Parent (“Parent Common Stock “) pursuant to the terms of Parent’s then-current certificate of incorporation,
“Earn Out Funds” shall instead refer, as applicable, to shares of Parent Common Stock issuable in connection with such conversion; and (2) cash, which form of consideration shall be determined with respect to any Person in accordance
with Sections 2.4 and 2.6. 

  
 6 

 (ii) any distribution made by Parent pursuant to Section 2.2(a) shall hereinafter be
referred to as an “Earn Out Payment”; and 
 (iii) any distributions made by Parent pursuant to Section 2.2(b) shall
hereinafter be referred to individually as a “Compound Transaction Payment” and collectively, as the “Compound Transaction Payments”; and 

(iv) the occurrence of Surviving Corporation’s or Parent’s first dosing of a human subject in the first Phase 2 Clinical Trial for
the Compound shall hereinafter be referred to as the “Earn Out Event”; and 
 (v) “Compound Transaction
Revenue” as used in this Agreement shall have the meaning set forth in Exhibit G; and 
 (vi) “Diligent
Efforts” means the efforts and resources which would be used (including the promptness in which such efforts and resources would be applied) by Parent or the Surviving Corporation consistent with the level of efforts and resources standard
in the pharmaceutical industry with respect to a product or potential product at a similar stage in its development or product life taking into account efficacy, safety, commercial value, the competitiveness of alternative products of third parties
that are in the marketplace or under development, and the patent and other proprietary position of such product. 
 (d) Operation of the
Business. The Parties understand and agree that Parent shall have complete discretion with respect to all decisions related to the research, development, manufacture, marketing, pricing and distribution of the Compound and the business of the
Surviving Corporation and Parent; provided, however, that (i) Parent shall take and shall cause Surviving Corporation to take all steps necessary to achieve the Earn Out Event unless otherwise consented to in writing by the
Stockholders’ Representative; and (ii) Parent shall use and cause Surviving Corporation to use Diligent Efforts to achieve, negotiate and execute Compound Transaction Agreements and earn Compound Transaction Revenue. 

Section 2.3. Deposits of Securities at Closing; Escrow Fund. 

(a) On or before the Closing Date, Parent shall deposit with the Exchange Agent for the benefit of the Stockholders and Management Incentive
Grant Recipients, for exchange in accordance with this Article II, through the Exchange Agent, cash and certificates representing the shares of Parent Series B Preferred (such cash and certificates for shares of Parent Series B Preferred being
hereinafter referred to as the “Exchange Fund”) payable and issuable, as applicable, pursuant to Section 2.1 as (i) the Acquisition Price and (ii) the Earn Out Funds. The Exchange Agent shall, pursuant to irrevocable
instructions, deliver out of the Exchange Fund the appropriate amounts of cash and shares of Parent Series B Preferred contemplated to be paid and issued, as applicable, pursuant to Section 2.1 and the Earn Out Payment contemplated to be
distributed pursuant to Section 2.2(a), if any. The Exchange Fund shall not be used for any other purpose. 

  
 7 

 (b) A portion of the Exchange Fund equal to one million dollars ($1,000,000), which shall be
comprised of a combination of (1) shares of Parent Series B Preferred based on a Parent Series B Preferred price of $4.1841 per share and (2) cash, which form of consideration shall be determined with respect to any Person in accordance
with Sections 2.4 and 2.6 (collectively, the “Indemnity Escrow Funds”), shall be used to satisfy payment in respect of claims made by the Buyer Indemnified Parties in accordance with Section 7.8 hereof. At the Closing, the
Exchange Agent, Acquisition Corp., the Company and the Stockholders’ Representative shall enter into a mutually acceptable escrow agreement containing the terms and conditions under which the Indemnity Escrow Funds will be held and released
(the “Escrow Agreement”). 
 Section 2.4. Exchange of Certificates and Options. 

(a) Exchange Procedures. 

(i) As soon as reasonably practicable (and in any event not later than five (5) business days) after the Effective Time, the Surviving
Corporation shall cause to be mailed to each Management Incentive Grant Recipient, to each holder of record of a certificate or certificates which immediately prior to the Effective Time represented outstanding shares of Company Capital Stock (the
“Certificates”) whose shares are converted in accordance with Section 2.1(c) into the right to receive the Applicable Acquisition Price plus the Earn Out Payment, if any, and Compound Transaction Payments, if any, to be paid to
each Management Incentive Grant Recipient and such holder in accordance with Section 2.2 of this Agreement, (A) a letter of transmittal in a form customary for transactions of a similar nature and reasonably acceptable to the Company,
Parent and the Exchange Agent (the “Letter of Transmittal”) and (B) customary instructions for use in effecting the surrender of the Certificates, if and as the case may be, in exchange for (or in the case of a Management
Incentive Grant Recipient who does not hold any Company Capital Stock, instructions for the receipt of) the portions of the Acquisition Price and Earn Out Funds, if any, deposited with the Exchange Agent and Compound Transaction Payments, if any, in
accordance with Section 2.2 of this Agreement. 
 (ii) Upon surrender of a Certificate to the Exchange Agent, if and as applicable,
together with a Letter of Transmittal, duly executed and completed in accordance with its terms, each Management Incentive Grant Recipient and holder of such Certificate who: 

(1) has certified as to their “accredited investor” status pursuant to Section 2.6 shall be entitled to receive in exchange
therefor, (A) in the case of an Management Incentive Grant Recipient, such portion of the aggregate Acquisition Price which such Management Incentive Grant Recipient has the right to receive in accordance with Section 2.1(c) and in an
amount with respect to such Management Incentive Grant Recipient as set forth on Exhibit F payable in shares of Parent Series B Preferred, plus the right to receive the Earn Out Payment, if any, payable in shares of Parent Series B Preferred
(or Parent Common Stock, as applicable), and Compound Transaction Payments, if any, in accordance with Section 2.2 and Exhibit F of this Agreement, and (B) in the case of a Certificate, such portion of the aggregate Acquisition
Price per share of Company Capital Stock represented thereby which such holder 

  
 8 

 
has the right to receive in accordance with Section 2.1(c) and in an amount with respect to such holder as set forth on Exhibit F payable in shares of Parent Series B Preferred, plus
the right to receive the Earn Out Payment, if any, payable in shares of Parent Series B Preferred (or Parent Common Stock, as applicable), and Compound Transaction Payments, if any, in accordance with Section 2.2 and Exhibit F of this
Agreement, and the Certificate so surrendered shall forthwith be cancelled; or 
 (2) has not certified as to their “accredited
investor” status pursuant to Section 2.6 shall be entitled to receive in exchange therefor, (A) in the case of an Management Incentive Grant Recipient, such portion of the aggregate Acquisition Price which such Management Incentive
Grant Recipient has the right to receive in accordance with Section 2.1(c) and in an amount with respect to such Management Incentive Grant Recipient as set forth on Exhibit F payable in cash, plus the right to receive the Earn Out
Payment, if any, payable in cash, and Compound Transaction Payments, if any, in accordance with Section 2.2 and Exhibit F of this Agreement, and (B) in the case of a Certificate, such portion of the aggregate Acquisition Price per
share of Company Capital Stock represented thereby which such holder has the right to receive in accordance with Section 2.1(c) and in an amount with respect to such holder as set forth on Exhibit F payable in cash, plus the right to
receive the Earn Out Payment, if any, payable in cash, and Compound Transaction Payments, if any, in accordance with Section 2.2 and Exhibit F of this Agreement, and the Certificate so surrendered shall forthwith be cancelled. 

(iii) If any Acquisition Price is to be remitted to a person whose name is other than that in which the Certificate for shares of Company
Capital Stock surrendered for exchange is registered, it shall be a condition of such exchange that the Certificate so surrendered shall be properly endorsed, with signature guaranteed, or otherwise in proper form for transfer, and that the person
requesting such exchange shall have paid any transfer and/or other taxes required by reason of the remittance of Acquisition Price to a person whose name is other than that of the registered holder of the Certificate surrendered, or the person
requesting such exchange shall have established to the satisfaction of the Surviving Corporation that such tax either has been paid or is not applicable. Except as otherwise provided in this Agreement, in no event shall any Management Incentive
Grant Recipient or the holder of any Certificate be entitled to receive interest on any funds to be received in the Merger. Until surrendered as contemplated by this Section 2.4(a), each Certificate (other than Certificates representing
Dissenting Shares) shall be deemed at all times after the Effective Time to represent only the right to receive the Acquisition Price plus the right to receive the Earn Out Payment, if any, and Compound Transaction Payments, if any, in accordance
with Section 2.2 of this Agreement. 
 (iv) The good faith joint determination of Parent and the Company shall be conclusive and
binding as to whether or not any Management Incentive Grant Recipient or holder of a Certificate has certified as to their “accredited investor” status pursuant to Section 2.6 and as to whether or not such Person is entitled to
receive any payment pursuant to this Agreement in the form of cash or shares of Parent Series B Preferred (or Parent Common Stock, as applicable). 

  
 9 

 (b) No Further Ownership Rights in Company Capital Stock. From and after the Effective
Time, the stock transfer books of the Company shall be closed and there shall be no further registration of transfers on the stock transfer books of the Surviving Corporation of the shares of Company Capital Stock which were outstanding immediately
prior to the Effective Time. If, after the Effective Time, Certificates are presented to the Surviving Corporation for any reason, they shall be cancelled and exchanged as provided in this Article II. 

(c) Termination of Exchange Fund. Other than the Indemnity Escrow Funds, any portion of the Exchange Fund attributable to the
Acquisition Price which remains undistributed to the Stockholders for six (6) months after the Effective Time or with respect to the portion of the Exchange Fund attributable to the Earn Out Payment, six (6) months after the occurrence of
the Earn Out Event, or with respect to Compound Transaction Payments deposited by Parent with the Exchange Agent in accordance with this Article II which remains undistributed to the Stockholders for six (6) months after the receipt of the
Compound Transaction Revenue by the Exchange Agent, shall be delivered to Parent, upon demand, and any Stockholders and Management Incentive Grant Recipients who have not theretofore complied with this Article II shall thereafter look only to Parent
(subject to abandoned property, escheat and other similar laws) as general creditors for payment of their claim for the applicable Acquisition Price, the Earn Out Payment, if any, or Compound Transaction Payments, if any, to be received in
accordance with this Article II. Neither Parent nor the Surviving Corporation shall be liable to any Stockholder or Management Incentive Grant Recipient for cash or shares representing any portion of the Acquisition Price, the Earn Out Payment or
Compound Transaction Payments delivered to a public official pursuant to any applicable abandoned property, escheat or similar law. 

Section 2.5. Stockholders’ Representative. 

(a) The Stockholders and Management Incentive Grant Recipients, by adopting this Agreement and the transactions contemplated hereby,
irrevocably appoint the Stockholders’ Representative as their agent and attorney-in-fact for purposes of (i) the determination of the level of effort applied by Parent or the Surviving Corporation in the operation of the business pursuant
to Section 2.2(d), (ii) the determination of the occurrence of the Earn Out Event pursuant to Section 2.2, (iii) the determination of the execution of a Compound Transaction Agreement, (iv) the resolution of any disputes
related to the occurrence of the Earn Out Event or the execution of a Compound Transaction Agreement, including the timing thereof, (v) the resolution of any disputes for which a Buyer Indemnified Party or Stockholder Indemnified Party may seek
indemnification or offset pursuant to Article VII, (vi) the enforcement of any rights the Stockholders or Management Incentive Grant Recipients may have against Parent or the Surviving Corporation under this Agreement, (vii) amendments to
this Agreement pursuant to Section 11.6 and (viii) to do or refrain from doing any further act or deed on behalf of the Stockholders and Management Incentive Grant Recipients which the Stockholders’ Representative deems necessary or
appropriate in his, her or its sole discretion relating to the subject matter of this Agreement and the Escrow Agreement. By virtue of the approval of the Merger and this Agreement by the Stockholders, or with respect to the execution

  
 10 

 
and delivery of a Letter of Transmittal as to the Management Incentive Grant Recipients and without any further action of any of the Stockholders and Management Incentive Grant Recipients or the
Company, each Stockholder and Management Incentive Grant Recipient (i) agrees that all actions taken by the Stockholders’ Representative under this Agreement or the Escrow Agreement shall be binding upon such Stockholder and Management
Incentive Grant Recipient and such Stockholder’s and Management Incentive Grant Recipient’s successors as if expressly confirmed and ratified in writing by such Stockholder and Management Incentive Grant Recipient, and (ii) waives any
and all defenses which may be available to contest, negate or disaffirm the action of the Stockholders’ Representative taken in good faith under this Agreement or the Escrow Agreement. Fortis Advisors LLC hereby accepts its appointment as the
Stockholders’ Representative. Parent shall be entitled to deal exclusively with the Stockholders’ Representative on all matters relating to (A) the determination of the level of effort applied by Parent or the Surviving Corporation in
the operation of the business pursuant to Section 2.2(d), (B) the determination of the occurrence of an Earn Out Event pursuant to Section 2.2, (C) the determination of the execution of a Compound Transaction Agreement, including
the timing thereof, (D) the resolution of any disputes related to the occurrence of the Earn Out Event or the execution of a Compound Transaction Agreement, (E) the resolution of any disputes for which a Buyer Indemnified Party or
Stockholder Indemnified Party may seek indemnification or offset pursuant to Article VII, and (F) the enforcement of any rights the Stockholders or Management Incentive Grant Recipients may have against Parent or the Surviving Corporation under
this Agreement, and shall be entitled to rely conclusively (without further evidence of any kind whatsoever) on any document executed or purported to be executed on behalf of any Stockholder or Management Incentive Grant Recipient by the
Stockholders’ Representative, and on any other action taken or purported to be taken on behalf of any Stockholder or Management Incentive Grant Recipient by the Stockholders’ Representative, as fully binding upon such Stockholder and
Management Incentive Grant Recipient. 
 (b) Certain Stockholders have entered into a letter agreement with the Stockholders’
Representative to provide direction to the Stockholders’ Representative in connection with the performance of its services under this Agreement and the Escrow Agreement (such Stockholders, including their individual representatives, hereinafter
referred to as the “Advisory Group”). Neither the Stockholders’ Representative (and its members, managers, directors, officers, contractors, agents and employees) nor any member of the Advisory Group (collectively, the
“Representative Group”) shall be responsible for any act done or omitted thereunder while acting in good faith and without gross negligence or willful misconduct in connection with this Agreement and the underlying transactions.
Each Stockholder and Management Incentive Grant Recipient shall, only to the extent of and in proportion to the portion of the Acquisition Price, Earn Out Payment (if any) and Compound Transaction Payments (if any) actually received by such
Stockholder and Management Incentive Grant Recipient, indemnify the Representative Group and hold the Representative Group harmless against any loss, liability or expense incurred without gross negligence, bad faith or willful misconduct on the part
of the Representative Group and arising out of or in connection with the acceptance or administration of the Representative Group’s duties hereunder, including the reasonable fees and expenses of any legal counsel or other professional retained
by the 

  
 11 

 
Representative Group, in connection with the acceptance and administration of the Stockholders’ Representative’ duties hereunder (collectively, the “Agent Expenses”).
Such Agent Expenses may be recovered directly from each Stockholder and Management Incentive Grant Recipient only to the extent of and in proportion to the portion of the Acquisition Price, Earn Out Payment (if any) and Compound Transaction Payments
(if any) actually received by such Stockholder and Management Incentive Grant Recipient. The Stockholders’ Representative shall be entitled to: (i) rely upon any spreadsheet setting forth pro rata portions of the Stockholders and
Management Incentive Grant Recipients, (ii) rely upon any signature believed by it to be genuine, and (iii) reasonably assume that a signatory has proper authorization to sign on behalf of the applicable Stockholder and Management
Incentive Grant Recipient or other party. The Stockholders’ Representative shall not be required to expend or risk its own funds or otherwise incur any financial liability in the exercise or performance of any of its powers, rights, duties or
privileges or administration of the Stockholders’ Representative duties. The powers, immunities and rights to indemnification granted to the Stockholders’ Representative and the Advisory Group under this Agreement: (i) are coupled
with an interest and shall be irrevocable and survive the death, incompetence, bankruptcy or liquidation of the respective Stockholders and Management Incentive Grant Recipients and shall be binding on any successor thereto, and (ii) shall
survive the delivery of an assignment by any Stockholder and Management Incentive Grant Recipient of the whole or any fraction of his, her or its interest in the Earn Out Payment (if any) or Compound Transaction Payment (if any). In addition, the
immunities and rights to indemnification shall survive the resignation or removal of the Stockholders’ Representative or any member of the Advisory Group and the Closing and/or any termination of this Agreement and the Escrow Agreement. 

(c) In the event that the Stockholders’ Representative shall dispute the level of effort applied by Parent or the Surviving Corporation in
the operation of the business pursuant to Section 2.2(d), the occurrence of the Earn Out Event, the execution of a Compound Transaction Agreement, the timing of the execution of such Compound Transaction Agreement or a request for
indemnification or setoff under Article VII, then the Stockholders’ Representative shall provide written notice to Parent (the “Dispute Notice”) specifying the amount disputed and the basis for the dispute, together with
supporting documentation reflecting the analysis and justification thereof. Parent and the Stockholders’ Representative (with the Advisory Group) shall thereafter attempt to resolve the dispute set forth in the Dispute Notice in accordance with
Section 7.7 of this Agreement. 
 Section 2.6. Accredited Investors. 

(a) Each Stockholder or Management Incentive Grant Recipient will represent pursuant a duly executed Letter of Transmittal, to Parent, if such
Person is an “accredited investor” as defined in Rule 501 under the Securities Act of 1933, as amended (“Securities Act”), and as follows with respect to the Parent Series B Preferred (or Parent Common Stock, as
applicable): 
 (i) It is acquiring such Parent Series B Preferred (or Parent Common Stock, as applicable) for investment for his own
account and not with a view to, or for resale in connection with, the distribution or other disposition thereof, other than as contemplated hereby; 

  
 12 

 (ii) Its knowledge and experience in financial and business matters are such that it is capable
of evaluating the merits and risks of acquisition of such Parent Series B Preferred (or Parent Common Stock, as applicable; 
 (iii) Its
financial condition is such that it can afford to bear the economic risk of holding such Parent Series B Preferred (or Parent Common Stock, as applicable) for an indefinite period of time and has adequate means for providing for its current needs
and contingencies and to suffer a complete loss of its investment in such Parent Series B Preferred (or Parent Common Stock, as applicable); 

(iv) All information that it has provided to Parent concerning itself and its financial position is correct and complete; and 

(v) It is an “accredited investor” as defined in Rule 501 under the Securities Act. 

(b) At least two (2) business days before the Closing, the Company shall deliver to the Exchange Agent a schedule that sets forth a
complete and accurate list of (i) all Stockholders and Management Incentive Grant Recipients who have certified, pursuant to a duly executed Letter of Transmittal, their status as “accredited investors” within the meaning of Rule 501
of Regulation D under the Securities Act and the number of shares of Company Capital Stock, if any, held by each such Person as of the date hereof, and (ii) all Stockholders and Management Incentive Grant Recipients who have not certified,
pursuant to a duly executed Letter of Transmittal, as to being “accredited investors” within the meaning of such rule, and the number of shares of Company Capital Stock held by each such Person as of the date hereof (the
“Accredited Investor List”). Notwithstanding anything in this Agreement to the contrary, no Person shall be entitled to any issuance of shares of Parent Series B Preferred Stock (or Parent Common Stock, as applicable) pursuant to
this Agreement unless such Person has delivered to the Exchange Agent a duly executed Letter of Transmittal certifying as to such Person’s status as an “accredited investor,” or except as may otherwise be approved by Parent in its
sole discretion. Each Stockholder or Management Incentive Grant Recipient who fails to deliver a duly executed Letter of Transmittal certifying as to such Person’s status as an “accredited investor” shall be deemed not to be an
“accredited investor” pursuant to this Agreement except as may otherwise be approved by Parent in its sole discretion. 
 Section
2.7. Legend. All certificates for shares of Parent Series B Preferred (or Parent Common Stock, as applicable) issued pursuant to Article II, and any shares issued upon the conversion of such shares of Parent Series B Preferred shall bear the
following legend: “THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. THE SHARES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN
EXEMPTION THEREFROM UNDER SAID ACT.” 

  
 13 

 Section 2.8. Fractional Shares. No certificates, scrip or book-entries representing
fractional shares of Parent Series B Preferred (or Parent Common Stock, as applicable) shall be issued in connection with the Merger, no dividend or distribution with respect to Parent Series B Preferred (or Parent Common Stock, as applicable) shall
be payable on or with respect to any fractional share and such fractional share interests will not entitle the owner thereof to any rights of a stockholder of Parent. Any fractional shares of Parent Series B Preferred to which a holder would
otherwise be entitled (after aggregating all fractional shares of Parent Series B Preferred issuable to such holder) shall be rounded down to the nearest whole number of shares. 

Section 2.9. Management Incentive Grants. At the Effective Time, Parent shall grant Merger Shares to the individuals (the “Management
Incentive Grant Recipients”) at the times and in the amounts set forth on Exhibit F (the “Management Incentive Grants”), and such individuals will become eligible for any Earn Out Payment and Compound Transaction
Payments that may become payable pursuant to the terms hereof, subject to each such individual entering into a restricted stock agreement with Parent in a form reasonably acceptable to Parent and the Company (each, a “Restricted Stock
Agreement”). The Management Incentive Grants shall vest upon the occurrence of a Trade Sale or the six month anniversary of an IPO (as such terms are defined in the Restricted Stock Agreement) (each, a “Vesting Event”),
provided that such Vesting Event occurs prior to the later of the seventh anniversary of the Closing Date or the holder’s “separation from service” with Parent and its Subsidiaries within the meaning of Section 409A of the Code.

 Section 2.10. Conversion of Sofinnova Note. At the Closing, Parent shall assume all of the Company’s obligations under the
Company’s Unsecured Convertible Promissory Note, dated December 9, 2013 (the “Promissory Note”), pursuant to which, and concurrent with the Closing, Sofinnova shall receive Coherus Securities (as defined in the Promissory
Note) upon the terms and conditions set forth in the Promissory Note. 
 Section 2.11. Withholding. Each of Parent, Acquisition
HoldCo, Acquisition Corp., the Surviving Corporation and the Exchange Agent shall be entitled to deduct and withhold from the amounts, if any, otherwise payable under this Agreement to any Stockholder, Management Incentive Grant Recipient and any
other Person such amounts as it is required to deduct and withhold with respect to any such payments under the Code or any other provision of U.S. federal, state, local or non-U.S. Tax law. To the extent that amounts are so withheld, such withheld
amounts shall be treated for all purposes of this Agreement as having been delivered and paid to the Persons in respect of which such deduction and withholding was made. 

  
 14 

 ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY. 

Except as set forth in the corresponding sections or subsections of the disclosure schedule delivered by the Company to Parent on the date
hereof (the “Company Disclosure Schedule”), the Company represents and warrants to Acquisition Corp., to Parent and to Acquisition HoldCo as follows: 

Section 3.1. Organization. 

(a) The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. Each Subsidiary
of the Company (each a “Company Subsidiary” and, collectively, the “Company Subsidiaries”) has been duly organized, and is validly existing and in good standing under the laws of the jurisdiction of its
incorporation or organization, as the case may. Each of the Company and each Company Subsidiary has all requisite power and authority to carry on its business as it is now being conducted and to own, use and lease its assets and properties. Each of
the Company and each Company Subsidiary is duly qualified or licensed as a foreign corporation to do business and is in good standing in each jurisdiction where the nature of its business or the ownership, leasing or operation of its assets and
properties makes such qualification or licensing necessary, except where the failure to be so qualified or licensed and in good standing would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect.

 (b) Section 3.1(b) of the Company Disclosure Schedule sets forth a true and complete list of all of the Company Subsidiaries. Except
as set forth in Section 3.1 of the Company Disclosure Schedule, neither the Company nor any Company Subsidiary owns, or has any interest in any shares or has an ownership interest in any other Person. 

Section 3.2. Capitalization. 

(a) As of the date of this Agreement, the total authorized shares of capital stock of the Company consisted solely of (i) 789,425 shares
of Company Common Stock, of which 33,703 shares were issued and outstanding; and (ii) 750,000 shares of Company Preferred Stock, of which 403,949 shares were issued and outstanding. As of the date of this Agreement, 409,699 shares of Company
Common Stock were reserved for issuance of which (i) 4,728 shares were reserved for issuance of future awards under the Company Stock Plan, (ii) 1,022 shares were reserved for issuance upon exercise of outstanding Options under the Company
Stock Plan, and (iii) 403,949 shares of Company Common Stock were reserved for issuance upon the conversion of the outstanding shares of Company Preferred Stock. 

(b) Other than the Company Common Stock, the Company Preferred Stock or as set forth on Section 3.2(b) of the Company Disclosure Schedule,
there are no outstanding or authorized options, warrants, convertible securities or other rights, agreements, arrangements or commitments of any character relating to the Company Capital Stock or obligating the Company to issue or sell any Company
Capital Stock, or any other interest in the Company. The Company does not have outstanding or authorized any stock appreciation, phantom stock, profit participation or similar rights. Other than the Voting and Release Agreement or as set forth on
Section 3.2(b) of the Company Disclosure Schedule there are no voting trusts, stockholder agreements, proxies or other agreements or understandings in effect with respect to the voting of the shares of Company Capital Stock or any shares of any
Company Subsidiary to which the Company or any Company Subsidiary is a party or, to the Company’s Knowledge, to which any other Person is a party. 

  
 15 

 (c) All the outstanding shares of Company Common Stock and Company Preferred Stock have been duly
authorized and validly issued and are fully paid and nonassessable. No shares of Company Capital Stock have been issued by the Company at any time in violation of the preemptive rights of any stockholder of the Company. All shares of Company Capital
Stock previously issued by the Company were offered, issued and sold in compliance in all material respects with all applicable Federal and state securities laws and regulations. Exhibit F contains a true, complete and accurate list of every
holder of Company Capital Stock. 
 (d) Except as set forth on Section 3.2(d) of the Company Disclosure Schedule, each outstanding share
of capital stock of each Company Subsidiary is duly authorized, validly issued, fully paid, nonassessable and free of preemptive rights and is owned, beneficially and of record, by the Company or another Company Subsidiary free and clear of all
Liens. 
 Section 3.3. Authority. The Company has requisite corporate power and authority to execute and deliver this Agreement, to
perform its obligations hereunder and, subject to receipt of the Company Stockholder Approval, to consummate the transactions contemplated hereby. The execution, delivery and performance of this Agreement by the Company and the consummation by the
Company of the transactions contemplated hereby have been duly authorized and approved by the Company’s Board of Directors, and except for (a) the filing of the Certificate of Merger pursuant to the DGCL and (b) the receipt of the
Company Stockholder Approval, no other corporate proceedings on the part of the Company or its stockholders are necessary to authorize this Agreement or the consummation of the transactions contemplated hereby. This Agreement has been duly
authorized, executed and delivered by the Company. Assuming the due authorization, execution and delivery of this Agreement by Parent, Acquisition HoldCo and Acquisition Corp., this Agreement is the legal, valid and binding obligation of the
Company, enforceable against the Company in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium or similar laws affecting the enforcement of
creditors’ rights generally and by the effect of general principles of equity (regardless of whether enforcement is considered in a proceeding in equity or at law). 

Section 3.4. No Conflicts; Governmental Requirements. 

(a) The execution, delivery and performance by the Company of this Agreement and, assuming the receipt of Company Stockholder Approval, the
consummation of the Merger do not, and will not, (i) violate or conflict with any provision of the certificate of incorporation or by-laws of the Company or any equivalent organizational documents of any Company Subsidiary, (ii) subject to
the governmental filings and other matters referred to in Section 3.4(b), violate any law, rule, regulation, ordinance or applicable constitution or order, writ, injunction, judgment, award, restriction, ruling or decree of any Governmental
Entity 

  
 16 

 
applicable to the Company or any Company Subsidiary or the transactions contemplated hereby, or (iii) result in a violation or breach of, conflict with, or constitute a default (or an event
which, with the passage of time or the giving of notice, or both, would reasonably be expected to constitute a default) under, or result in or give rise to any right of termination, modification, cancellation or acceleration, or require any consent,
approval or notice under, any note, bond, indenture, license, Lien, franchise, mortgage, loan or credit agreement, contract, agreement, lease, permit, guaranty or other agreement, instrument or obligation to which the Company or any Company
Subsidiary is a party or by which any assets or properties of the Company or any Company Subsidiary may be bound, except, in the case of clauses (ii) or (iii) of this Section 3.4(a), for any violation, breach, conflict, default, right
or lack of consent, approval or notice that would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. 

(b) Except for (i) the filing of the Certificate of Merger pursuant to the DGCL and, assuming the receipt of Company Stockholder Approval,
(ii) any other consents, approvals, authorizations, permissions, notices or filings which if not obtained or made would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect or materially delay
or hinder or render unlawful the consummation of the Merger or the other transactions contemplated by this Agreement or (iii) consents, approvals, authorizations, permissions, notices or filings which have heretofore been obtained or made, as
the case may be, by the Company, are in full force and effect and copies of which have been provided to Parent, the execution and delivery of this Agreement by the Company do not, and the performance by the Company of this Agreement will not,
require any consent, approval, authorization or permission of, or filing with or notification to, any governmental or regulatory authority, domestic or foreign. 

Section 3.5. Books and Records. The minute books and other similar records of the Company and each Company Subsidiary as made available
to Parent and its Representatives prior to the execution of this Agreement contain a true and complete record, in all material respects as of the date of this Agreement, of all actions taken at all meetings and by all written consents in lieu of
meetings of the stockholders, the board of directors and all committees of the board of directors of the Company and each Company Subsidiary. The stock transfer ledger and other similar records of the Company and each Company Subsidiary as made
available to Parent prior to the execution of this Agreement contain true and complete records, in all material respects as of the date of this Agreement, of all stock transfers related to the Company’s and each Company Subsidiary’s
capital stock. The Company has previously furnished to Parent true, complete and correct copies of the certificate of incorporation and the by-laws of the Company and any equivalent organizational documents of any Company Subsidiary, as in effect on
the date hereof. 

  
 17 

 Section 3.6. Financial Statements. 

(a) The Company has made available to Parent its unaudited financial statements of the Company as of and for the year ended December 31,
2012 (the “FYE Company Financial Statements”) and the unaudited financial statements of the Company as of and for the period ended September 30, 2013 (the “Interim Company Financial Statements” and,
together with the FYE Company Financial Statements, the “Company Financial Statements”). The Company Financial Statements were prepared on an unconsolidated basis but otherwise in accordance with U.S. generally accepted accounting
principles (“GAAP”) applied on a consistent basis during the periods involved and fairly present in all material respects the financial position of the Company as of the dates thereof and the results of operations and cash flows for
the periods then ended (subject, in the case of the Interim Company Financial Statements, to normal year-end adjustments and the absence of footnotes). The Company Financial Statements have been prepared from and are in accordance with the books and
records of the Company. 
 (b) The Company has made available to Parent the unaudited financial statements of each Company Subsidiary as of
and for the year ended December 31, 2012 (the “FYE Subsidiary Financial Statements”) and the unaudited financial statements of each Company Subsidiary as of and for the period ended September 30, 2013 (the “Interim
Subsidiary Financial Statements” and, together with the FYE Subsidiary Financial Statements, the “Subsidiary Financial Statements”). The Subsidiary Financial Statements have been prepared from and are in accordance with the
books and records of the applicable Company Subsidiary. 
 Section 3.7. Absence of Undisclosed Liabilities. 

(a) Except as reflected in the Company Financial Statements, the Company has not incurred any liability or obligation of any nature (whether
direct or indirect, matured or unmatured, or absolute, accrued, contingent or otherwise) that would be required to be reflected on a balance sheet or in notes thereto prepared in accordance with GAAP, except for (a) liabilities or obligations
incurred after September 30, 2013 in the ordinary course of business in an amount not in excess of $50,000 individually or $250,000 in the aggregate, (b) liabilities and obligations incurred after September 30, 2013 pursuant to or in
connection with this Agreement or the transactions contemplated by this Agreement, (c) liabilities and obligations disclosed in this Agreement or Section 3.7 of the Company Disclosure Schedule, or (d) liabilities or obligations which,
individually or in the aggregate, would not reasonably be expected to be material to the Company and the Company Subsidiaries, taken as a whole. All amounts of outstanding indebtedness owed by the Company are repayable at any time without requiring
the payment of any premium on the part of the Company or resulting in any penalty to the Company. 
 (b) Except as reflected in the
Subsidiary Financial Statements, the Company Subsidiary has not incurred any liability or obligation of any nature (whether direct or indirect, matured or unmatured, or absolute, accrued, contingent or otherwise) that would be required to be
reflected on a balance sheet or in notes thereto prepared in accordance with GAAP, except for (a) liabilities or obligations incurred after September 30, 2013 in the ordinary course of business in an amount not in excess of $50,000
individually or $250,000 in the aggregate, (b) liabilities and obligations incurred after September 30, 2013 pursuant to or in connection with this Agreement or the transactions contemplated by this Agreement, (c) liabilities and
obligations disclosed in this Agreement or Section 3.7 of the Company Disclosure Schedule, or (d) liabilities or obligations which, individually or in the aggregate, would not reasonably be expected to be material to the Company and the
Company Subsidiaries, taken as a whole. 

  
 18 

 Section 3.8. Absence of Certain Changes or Events. Since September 30, 2013, except
as specifically contemplated by, or as disclosed in, this Agreement or Section 3.8 of the Company Disclosure Schedule, the Company and each Company Subsidiary has conducted its businesses in the ordinary course consistent with past practice
and, since such date, there has not been (A) any Company Material Adverse Effect, (B) any event or development that would, individually or in the aggregate, reasonably be expected to prevent or materially delay the transactions
contemplated by this Agreement or (C) any action taken by the Company or any Company Subsidiary during the period from September 30, 2013 through the date of this Agreement that, if taken during the period from the date of this Agreement
through the Effective Time, would constitute a material breach of Section 5.1(a) or a breach of Section 5.1(b). 

Section 3.9. Properties. 

(a) The Company owns outright or has good and marketable fee title to or a valid leasehold or license interest in all of its Leased Real
Property, material personal assets and properties (including those reflected as assets on the balance sheet included in the Interim Company Financial Statements), in each case free and clear of any Lien. The Company and collectively with each of the
Company’s Subsidiaries have all necessary personal assets, equipment and properties to engage in the business as currently conducted by the Company and each Company Subsidiary. 

(b) Neither the Company nor any Company Subsidiary own any real property. 

(c) Section 3.9(c) of the Company Disclosure Schedule sets forth a list of all of the written, or, to the Company’s Knowledge, oral
leases, subleases or rights of occupancy pursuant to which the Company or any Company Subsidiary leases or subleases any real property or interest therein (collectively, as heretofore modified, amended or extended, the “Leases”),
(collectively, the “Leased Real Property”). True and correct copies of each of the Leases, including all amendments, modifications and extensions thereof, and all subordination, non-disturbance and/or attornment agreements related
thereto, have been made available by the Company to Parent. To the Company’s Knowledge, neither the Company nor any Company Subsidiary has received any written notice of default under any Lease. Neither the Company nor any Company Subsidiary is
in material default under any Lease and no event has occurred that with the giving of notice, the passage of time or both would constitute such a default by the Company or any Company Subsidiary. 

Section 3.10. Accounts Payable; Clinical Materials. 

(a) Section 3.10(a) of the Company Disclosure Schedule sets forth a true and correct list of each account payable of the Company and each
Company Subsidiary (and the age of such payable), as of the fifth (5th) business day immediately preceding the date of this Agreement. 

  
 19 

 (b) The clinical trial supply material inventory of the Compound owned by the Company or any
Company Subsidiary as of the date of this Agreement is described in Section 3.10(b) of the Company Disclosure Schedule. All such clinical trial supply materials are of such quality as to be useable for the clinical trials for the Compound
contemplated as of the date of this Agreement. As of the date of this Agreement, the Company and the Company Subsidiaries will have sufficient clinical trial supply material inventory to conduct a 210-patient clinical trial for the Compound. 

 Section 3.11. Contracts. 

(a) Section 3.11 of the Company Disclosure Schedule sets forth a true, correct and complete list of the following Contracts to which the
Company or any Company Subsidiary is a party and is currently in effect: 
 (i) any Contract that individually involves payments to or from
the Company or any Company Subsidiary, collectively, in excess of $50,000 on an annual basis 
 (ii) any debt instrument, including any loan
agreement, line of credit, promissory note, security agreement or other evidence of indebtedness, where the Company or any Company Subsidiary is a lender, borrower or guarantor; 

(iii) any Contract restricting the Company or any Company Subsidiary or, to the Company’s Knowledge, any of their respective employees
from engaging in any activity or line of business or competing with any Person or limiting the ability of any Person to compete with the Company or any Company Subsidiary; 

(iv) any joint venture, partnership or similar agreement; 

(v) any Contract with respect to (A) Company Intellectual Property that grants to a third party any rights to such Company Intellectual
Property or (B) Company Intellectual Property by which the Company or any Company Subsidiary has licensed rights to such Company Intellectual Property from a third party; 

(vi) any employment, severance or consulting Contract which will require the payment of amounts by the Company or any Company Subsidiary after
the date of this Agreement in excess of $50,000 per annum; 
 (vii) any Contract which, if terminated, would reasonably be expected to
result in a Company Material Adverse Effect; and 

  
 20 

 (viii) any Contract pursuant to which the Company or any Company Subsidiary is required to, or
obtains rights to, undertake the development or commercialization of any pharmaceutical product. 
 (b) The Contracts listed in
Section 3.11(a) of the Company Disclosure Schedule are all the material agreements relating to the operation of the currently conducted business of the Company and each Company Subsidiary. Each Contract listed in Section 3.11(a) of the
Company Disclosure Schedule is valid, binding and enforceable in all material respects in accordance with its terms with respect to the Company and, to the Company’s Knowledge, the other party thereto (except to the extent enforceability may be
limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors rights generally and by the effect of general principles of equity, regardless of whether enforcement is considered in a
proceeding in equity or at law) and the Company and each Company Subsidiary is not or, to the Company’s Knowledge, is not alleged to be, and, to the Company’s Knowledge, no other party to any such agreement is, in default in any material
respect under any such Contract and, except as contemplated by this Agreement, after the Merger all of such Contracts will remain in full force and effect, except for agreements which, by their terms (without giving effect to the execution and
delivery of this Agreement or the consummation of the transactions contemplated hereby), terminate prior to the consummation of the Merger or such other Contracts the termination of which would not, individually or in the aggregate, be reasonably
expected to have a Company Material Adverse Effect. 
 Section 3.12. Absence of Questionable Payments. Neither the Company or any
Company Subsidiary nor, to the Company’s Knowledge, any of its directors, officers, agents, employees or any other Persons acting on their behalf has, in connection with the operation of the Company’s or any Company Subsidiary’s
business, (i) used any corporate or other funds for unlawful contributions, payments, gifts or entertainment, or made any unlawful expenditures relating to political activity to foreign or domestic government officials, candidates or members of
political parties or organizations or established or maintained any unlawful or unrecorded funds in violation of Section 104 of the Foreign Corrupt Practices Act of 1977, as amended, or any other similar applicable foreign, federal or state
law; or (ii) paid, accepted or received any unlawful contributions, payments, expenditures or gifts. 
 Section 3.13.
Litigation. There are no actions, suits, claims, investigations or other legal proceedings pending or, to Company’s Knowledge, threatened against or by the Company or any Company Subsidiary affecting any of its properties or assets which if
determined adversely to the Company would result in a Company Material Adverse Effect. 
 Section 3.14. Compliance with Law;
Authorizations. 
 (a) To the Company’s Knowledge, the Company and each Company Subsidiary has complied, and their respective assets
and properties are in compliance, in all material respects with, and is not in violation of, in any material respect, any law, ordinance, code or governmental rule or regulation (collectively, “Laws”) to which it or its business is
subject. 

  
 21 

 (b) The Company and each Company Subsidiary has obtained and currently holds all material
licenses, permits, certificates or other governmental authorizations (collectively “Authorizations”) necessary for the ownership or use of their respective assets and properties and the conduct of their respective businesses as
currently conducted. 
 (c) The Company and each Company Subsidiary has complied in all material respects with, and is not in violation in
any material respect of, any Authorization necessary for the ownership or use of their respective assets and properties or the conduct of their respective businesses as currently conducted, all Authorizations necessary for the ownership or use of
their respective assets and properties and the conduct of their respective businesses are in full force and effect, and there are no proceedings pending or, to the Company’s Knowledge, threatened that seek the revocation, cancellation,
suspension or any adverse modification of any such Authorizations presently possessed by the Company or any Company Subsidiary. 

Section 3.15. Intellectual Property. 

(a) The Company has made available to Parent complete and accurate lists or other identifying information related to (including, where
applicable, true and accurate copies of) all of the following items used or held for use by the Company or any Company Subsidiary in the conduct of their respective businesses (1) patents, patent applications and patent disclosures issued or
filed, together with all reissues, divisions, continuations, continuations-in-part, revisions, extensions and reexaminations thereof, (2) trade names, common law trademarks, common law service marks, registered trademarks, registered service
marks, and applications for trademark registration or service mark registration, (3) registered copyrights and (4) domain name registrations. 

(b) The Company has made available to Parent complete and accurate lists or other identifying information related to (including, where
applicable, true and accurate copies of) all material licenses, sublicenses and other agreements by which the Company or any Company Subsidiary licenses or otherwise authorizes a third party to use any Intellectual Property of the Company or any
Company Subsidiary. Neither the Company or any Company Subsidiary nor, to the Company’s Knowledge, any third party is in breach of or default under any such license or other agreement, and each such license or other agreement is now valid and
in full force and effect, in each case except where such breach, invalidity or ineffectiveness would not be expected to have a Company Material Adverse Effect. 

(c) To the Knowledge of the Company, the Company or a Company Subsidiary owns or is licensed or otherwise has the right to use all Intellectual
Property necessary for the operation of business of the Company and each such Company Subsidiary as it is currently conducted. The Company or a Company Subsidiary has the right to bring actions for the infringement or other violation of the Company
Intellectual Property, except where such Company Intellectual Property is licensed from a third party on a nonexclusive basis. 

  
 22 

 (d) No written claim has been made to, nor any written notice received by, the Company to the
effect that the business operations of the Company or any Company Subsidiary as it is currently conducted infringe, dilute, misappropriate or otherwise violate the Intellectual Property rights of any third party, in each case except as would not be
expected to result in a Company Material Adverse Effect. Neither the Company nor any Company Subsidiary has any pending or, to the Company’s Knowledge, threatened or anticipated claims that a third party has violated or infringed any
Intellectual Property of the Company or any Company Subsidiary, in each case except for violations or infringements that would not be expected to result in a Company Material Adverse Effect. To the Company’s Knowledge, there is no pending claim
that the Company or any Company Subsidiary has violated or infringed any of a third party’s Intellectual Property rights. 
 (e) All of
the items listed or made available to Parent pursuant to Section 3.15(a) are: (i) to the Knowledge of the Company, valid and in full force, (ii) held of record in the name of the Company or the applicable Company Subsidiary free and
clear of all Liens and other claims, except for domain names and except as would not be expected to have a Company Material Adverse Effect, and (iii) to the Knowledge of the Company, are not the subject of any cancellation or reexamination
proceeding or any other proceeding challenging their extent or validity, other than office actions in the ordinary course of prosecution. 

(f) To the Company’s Knowledge, none of the material trade secrets of the Company or any Company Subsidiary have been disclosed to any
third party unless such disclosure was made pursuant to a confidentiality agreement. 
 Section 3.16. Tax Matters. 

(a) (i) The Company and each Company Subsidiary has timely filed Tax Returns required to be filed by it; (ii) all such Tax Returns are
true, complete and accurate in all material respects and all Taxes shown as due on such Tax Returns and all Taxes otherwise due have been timely paid; (iii) neither the Company nor any Company Subsidiary has waived or has been requested in
writing to waive (or agreed to any extension of) any limitations period in respect of Taxes; (iv) no adjustment relating to such Tax Returns has been proposed in writing by any Tax authority; (v) there are no pending or, to the
Company’s Knowledge, threatened actions or proceedings for the assessment or collection of Taxes against the Company or any Company Subsidiary; (vi) neither the Company nor any Company Subsidiary is a party to any Tax sharing or Tax
allocation agreement, or has any obligation under any Tax indemnity arrangement; (vii) there are no liens for Taxes upon the assets of the Company or any Company Subsidiary (other than liens for property taxes not yet due and payable);
(viii) all Taxes which the Company or any Company Subsidiary is required by law to withhold or to collect for payment have been duly withheld and collected, and have been paid or accrued, or reserved against and entered on the books of the
Company and the applicable Company Subsidiary in accordance with GAAP; and (ix) neither the Company nor any Company Subsidiary has been a United States real property holding corporation within the meaning of Section 897(c)(2) of the Code
during the applicable period specified in Section 897(c)(1)(A)(ii) of the Code. 

  
 23 

 (b) The Company (i) has not agreed to and is not required to make any adjustment pursuant to
Section 481(a) of the Code, (ii) has no Knowledge that the Internal Revenue Service (“IRS”) has proposed any such adjustment or change in accounting method with respect to the Company, and (iii) does not have any
application pending with the IRS or any other tax authority requesting permission for any change in accounting method. 
 (c) (i) Neither the
Company nor any Company Subsidiary is currently the subject of any audit or examination with respect to Taxes, (ii) there are no written requests for information from any Tax authority currently outstanding that could affect the Taxes of the
Company or any Company Subsidiary, (iii) there are no proposed reassessments in writing of any property owned by the Company or any Company Subsidiary that could increase the amount of any Tax to which the Company or any Company Subsidiary
would be subject, and (iv) no power of attorney that is currently in force has been granted by the Company with respect to any matter relating to Taxes. 

(d) The Company has delivered or made available to Parent correct and complete copies of all income and other material Tax Returns for all
taxable years remaining open under the applicable statute of limitations and examination reports, and statements of deficiencies assessed against or agreed to by the Company or any Company Subsidiary. 

(e) Except in respect of any affiliated, consolidated, combined, unitary or similar group of which the Company currently is a member, the
Company (i) is not and has not been a member of an affiliated group (within the meaning of Section 1504(a)(1) of the Code) or (ii) has not filed or been required to file or been included on or required to be included on a consolidated
federal income tax return or a state Tax Return on a consolidated, combined or unitary basis. 
 (f) Neither the Company nor any Company
Subsidiary has engaged in any reportable transaction within the meaning of Treas. Reg. §1.6011-4(b). 
 (g) No written claim has been
received by the Company or any Company Subsidiary from an authority in a jurisdiction where it does not file Tax Returns claiming that it is or may be subject to taxation in that jurisdiction, which claim, if successfully asserted, could reasonably
be expected to result in any liability for Taxes. 
 (h) Neither the Company nor any Company Subsidiary has any liability for the Taxes of
any other Person (i) under Treasury Regulation Section 1.1502-6 (or any similar provision of state, local or foreign law), (ii) as a transferee or successor, (iii) by Contract or (iv) otherwise. 

(i) No entity classification election pursuant to Treasury Regulations Section 301.7701-3 has been filed with respect to any of the
Company Subsidiaries. 
 (j) Neither the Company nor any Company Subsidiary has engaged in a trade or business, had a permanent establishment
(within the meaning of an applicable Tax treaty), or otherwise become subject to Tax jurisdiction in a country other than the country of its formation. 

  
 24 

 (k) The prices and terms for the provision of any property or services by or to the Company and
the Company Subsidiaries are arm’s length for purposes of the relevant transfer pricing laws, and all related documentation required by such laws has been timely prepared or obtained and, if necessary, retained. 

(l) For the period commencing on the first day of any Straddle Period and ending at the close of business on the Closing Date, no Company
Subsidiary has any material item of income which could constitute subpart F income within the meaning of Section 952 of the Code. As of the Closing Date, no Company Subsidiary will hold assets that constitute U.S. property within the meaning of
Section 956 of the Code. 
 Section 3.17. Employee Benefit Plans. 

(a) Section 3.17(a) of the Company Disclosure Schedule sets forth a complete and accurate list of all employee benefit plans as defined in
Section 3(3) of the “Employee Retirement Income Security Act of 1974, as amended (“ERISA”) and all other employee benefit arrangements, obligations, customs, or practices, whether or not subject to ERISA, to provide
benefits, other than salary, in respect of services rendered, to current or former employees of the Company, including employment agreements, severance agreements, executive compensation arrangements, incentive programs or arrangements, sick leave,
vacation pay, severance pay policies, plant closing benefits, repatriation or expatriation benefits, work permits, visas, salary continuation, disability, consulting or other compensation arrangements, workers’ compensation, deferred
compensation, bonus, stock option, stock appreciation, stock purchase, phantom stock, or other equity right, hospitalization, medical, dental or vision benefits or insurance, life insurance, tuition reimbursement or scholarship programs, fringe
benefits, cafeteria plan benefits and any plans or arrangements providing benefits or payments in the event of a change of control, change in ownership, or sale of a substantial portion (including all or substantially all) of the assets of the
business of the Company maintained or contributed to by the Company or any person that is, together with the Company, treated as a single employer under Section 414 of the Code or Section 4001(b) of ERISA (each, an “ERISA
Affiliate”) or pursuant to which the Company or any ERISA Affiliate could have Liability (collectively, “Employee Benefit Plans”). 

(b) The Company has furnished or made available to Purchaser true and complete copies of all material documents embodying each of the Employee
Benefit Plan. No Employee Benefit Plan is subject to ERISA reporting requirements. 
 (c) Each Employee Benefit Plan has been administered
and operated in material compliance with the requirements prescribed by any and all statutes, rules and regulations (including ERISA and the Code), and none of the Employee Benefit Plans promises or provides retiree medical or other retiree welfare
benefits to any person. 

  
 25 

 (d) No action, claim or proceeding is pending or, to the Knowledge of the Company, threatened in
writing with respect to any Company Benefit Plan (other than claims for benefits in the ordinary course) and, to the Knowledge of the Company, no fact or event exists that could give rise to any such action, claim or proceeding. 

(e) Neither the Company or any ERISA Affiliate has ever maintained, established, sponsored, participated in, contributed to, or is obligated to
contribute to, or otherwise incurred any obligation or Liability under any “employee pension benefit plan” within the meaning of Section 3(2) of ERISA. 

(f) None of the execution, delivery or performance of this Agreement by the Company, the consummation by the Company of the Merger or any other
transaction contemplated by this Agreement, or the Company’s compliance with any of the provisions of this Agreement will (either alone or in conjunction with any other event, including any termination of employment on or following the
Effective Time) (i) accelerate the time of payment or vesting, increase the amount of payment, or trigger any payment or funding, of any compensation or benefit or trigger any other material obligation under any Employee Benefit Plan;
(ii) obligate the Company or any Subsidiary of the Company to make any payment or provide any benefit in connection with a “change in ownership or effective control,” within the meaning of such term under Section 280G of the
Code, or (iii) would be reasonably expected to result in the payment or series of payments by the Company or any of the Company Subsidiaries to any person of an “excess parachute payment” within the meaning of Section 280G of the
Code. 
 (g) Each Employee Benefit Plan that is subject to Section 409A of the Code has been maintained and operated in documentary and
operational compliance with Section 409A of the Code or an available exemption therefrom. 
 Section 3.18. Employee
Compensation. Section 3.18 of the Company Disclosure Schedule contains a complete and accurate list of the titles and current annual salary rates of and bonuses paid or payable to all present officers and employees, and independent
contractors and consultants who are used in the operations of the Company’s and any Company Subsidiary’s business and who are material to the operations of the Company’s or any Company Subsidiary’s business or who receive
compensation, including, without limitation, cash and equity compensation, in an amount equal to at least $100,000 per annum. 
 Section
3.19. Employees. 
 (a) The Company and each of its Subsidiaries are in compliance, in all material respects, with all currently
applicable laws and regulations respecting terms and conditions of employment. There are no proceedings pending, or, to the Company’s Knowledge, reasonably expected or threatened in writing, between the Company or any of its Subsidiaries, on
the one hand, and any or all of its current or former employees, on the other hand. Neither the Company nor any Company Subsidiary is a party to any collective bargaining agreement or other labor union contract applicable to persons employed by the
Company or any Company 

  
 26 

 
Subsidiary, nor, to the Company’s Knowledge, are there any activities or proceedings of any labor union to organize any such employees. There is no strike, slowdown, work stoppage or lockout
existing, or, to the Company’s Knowledge, threatened, by or with respect to any employees of the Company or any Company Subsidiary. 

(b) Except as set forth on Section 3.19(b) of the Company Disclosure Schedule, every officer and employee, and independent contractor and
consultant who is or has been used in the operations of the Company’s and any Company Subsidiary’s business has executed a proprietary information agreement in substantially the form previously provided to Parent which is currently in full
force and effect and enforceable against such individual. 
 (c) The Company and each Company Subsidiary has complied in all material
respects with all applicable laws related to employment, including those related to wages, hours, worker classification, and collective bargaining, and the payment and withholding of taxes and other sums as required by Law. 

(d) Each person providing services to the Company or any Company Subsidiary that has been characterized as a consultant or independent
contractor and not an employee has been properly characterized as such and neither the Company or any Company Subsidiary has any liability or obligations, including under or on account of any Employee Benefit Plan, arising out of the hiring or
retention of persons to provide services to the Company or any Company Subsidiary and treating such persons as consultants or independent contractors and not as employees. 

(e) To the Company’s Knowledge, no employee of the Company or any Company Subsidiary is obligated under any contract (including licenses,
covenants or commitments of any nature) or other agreement, or subject to any judgment, decree or order of any court or administrative agency, that would materially interfere with such employee’s ability to promote the interest of the Company
or any Company Subsidiary or that would conflict with business of the Company or any Company Subsidiary or the execution delivery or performance of the Agreement and any documents contemplated hereunder. 

Section 3.20. Bank Accounts. Section 3.20 of the Company Disclosure Schedule contains a complete and accurate list of all bank
accounts, lock boxes and safe deposit boxes relating to the business and operations of the Company and each Company Subsidiary (including the name of the bank or other institution where such account or box is located and the name of each authorized
signatory thereto). 
 Section 3.21. Brokers. Neither Parent nor the Surviving Corporation shall directly or indirectly be obligated
to pay or bear (e.g., by virtue of any payment by or obligation of any of the Company or any Company Subsidiary at or at any time after the Closing) any brokerage, finder’s or other fee or commission to any broker, finder or investment banker
in connection with the transactions contemplated by this Agreement based on arrangements made by or on behalf of the Company or any Company Subsidiary. 

  
 27 

 Section 3.22. Disclosures. The Company has made available to Parent all the information
reasonably available to the Company that Parent has requested for deciding whether to enter into this Agreement and the Collateral Documents. No representation or warranty of the Company contained in this Agreement, as qualified by the Company
Disclosure Schedule, or any Collateral Document, and no certificate furnished or to be furnished to Parent at the Closing contains any untrue statement of a material fact or, to the Company’s Knowledge, omits to state a material fact necessary
in order to make the statements contained herein or therein not misleading in light of the circumstances under which they were made. It is understood that this representation is qualified by the fact that the Company has not delivered to Parent, and
has not been requested to deliver, a private placement or similar memorandum or any written disclosure of the types of information customarily furnished to purchasers of securities. 

ARTICLE IV REPRESENTATIONS AND WARRANTIES OF PARENT, ACQUISITION 

HOLDCO AND ACQUISITION CORP. 

Except as set forth in the corresponding sections or subsections of the disclosure schedule delivered by Parent to the Company on the date
hereof (the “Parent Disclosure Schedule” and with the Company Disclosure Schedule, the “Disclosure Schedules”), Parent, Acquisition HoldCo and Acquisition Corp. represent and warrant to the Company as follows.
Defined terms used without definition in this Article IV shall have the meaning given them in the Coherus Biosciences, Inc. Amended and Restated Series B Preferred Stock Purchase Agreement dated as of the Closing Date. 

Section 4.1. Organization, Good Standing and Qualification. Each of Parent, Acquisition HoldCo and Acquisition Corp. is a corporation
duly incorporated, validly existing, and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to enter into and carry out the provisions of this Agreement and the Collateral Documents. Parent
has all requisite corporate power and authority to own and operate its properties and assets, to carry on its business as currently conducted and as it is currently planned to be conducted. Parent is duly qualified to transact business and is in
good standing in each jurisdiction in which the nature of the business conducted by it, or its ownership or leasing of property, or its employment of employees or consultants therein, makes such qualification necessary and where any statutory fines
or penalties, or any corporate disability imposed for this failure to qualify, would materially and adversely affect Parent’s business, properties, assets, prospects, or financial condition. True and accurate copies of Parent’s Certificate
of Incorporation and Bylaws, each as of the date hereof and to be amended and in effect at the Closing, have been made available to the Company. 

Section 4.2. Subsidiaries. Except as set forth in Section 4.2 of the Parent Disclosure Schedule, Parent does not presently own or
control, directly or indirectly, any interest in any other corporation or other business entity. Parent is not a participant in any joint venture, partnership, or similar arrangement. 

  
 28 

 Section 4.3. Authorization. All corporate action on the part of Parent, Acquisition HoldCo
and Acquisition Corp., their respective officers, directors, and stockholders necessary for the authorization, execution, and delivery of this Agreement and the Collateral Documents, the performance of all obligations of Parent, Acquisition HoldCo
and Acquisition Corp. hereunder and thereunder, and the authorization, issuance (or reservation for issuance), sale, and delivery of the shares of Parent Series B Preferred (or Parent Common Stock, as applicable) constituting the Acquisition Price
and the Earn Out Funds (collectively, the “Merger Shares”) being issued hereunder and the Parent Common Stock issuable upon conversion of the Merger Shares has been taken and, assuming the due authorization, execution and delivery
of this Agreement and any Collateral Document to which it is a party by the Company, this Agreement and the Collateral Documents, when executed and delivered, will constitute valid and legally binding obligations of each of Parent, Acquisition
HoldCo and Acquisition Corp., enforceable in accordance with their respective terms, subject to: (i) laws limiting the availability of specific performance, injunctive relief, and other equitable remedies; (ii) bankruptcy, insolvency,
reorganization, moratorium or other similar laws now or hereafter in effect generally relating to or affecting creditors’ rights generally; and (iii) limitations on the enforceability of any indemnification provisions contained in this
Agreement or any of the Collateral Documents. The issuance of the Merger Shares is not, and the subsequent conversion of the Merger Shares into Parent Common Stock will not be, subject to any preemptive rights or rights of first refusal that have
not been properly waived or complied with. 
 Section 4.4. Governmental Consents. No consent, approval, order, or authorization of,
or registration, qualification, designation, declaration, or filing with, any federal, state, or local governmental authority on the part of Parent, Acquisition HoldCo or Acquisition Corp. is required in connection with the execution and delivery of
this Agreement or any Collateral Document or the consummation of any other transaction contemplated hereby or thereby, except for the following: (i) the filing of the Restated Certificate in the office of the Secretary of State of the State of
Delaware, which has been filed by Parent prior to the Closing; (ii) the filing of a notice of exemption pursuant to Section 25102(f) California Securities Law, which shall be filed by Parent promptly following the Closing; (iii) the
compliance with other applicable state securities laws, which compliance will have occurred within the appropriate time periods therefor; (iv) the filing of the Certificate of Merger pursuant to the DGCL; (v) any other consents, approvals,
authorizations, permissions, notices or filings which if not obtained or made would not (individually or in the aggregate), reasonably be expected to have a material adverse effect on the Surviving Corporation or materially delay or hinder or render
unlawful the consummation of the Merger or other transactions contemplated by this Agreement; and (vi) consents, approvals, authorizations, permissions, notices or filings which have heretofore been obtained or made, as the case may be, by
Parent, Acquisition HoldCo or Acquisition Corp., are in full force and effect and copies of which have been provided to the Company. Assuming that the representations of the Stockholders and Management Incentive Grant Recipients set forth in their
respective Letters of Transmittal are true and correct, the issuance of the Merger Shares in conformity with the terms of this Agreement are (and the Parent Common Stock issuable upon conversion of the Merger Shares will be) exempt from the
registration requirements of Section 5 of the Securities Act, and from the qualification requirements of Section 25110 of the California Securities Law, and neither Parent nor any authorized agent acting on its behalf will take any action
hereafter that would cause the loss of such exemptions. 

  
 29 

 Section 4.5. Valid Issuance of Merger Shares and Underlying Parent Common Stock. The
Merger Shares, when issued and delivered in accordance with the terms of this Agreement for the consideration expressed herein, will be duly and validly issued, fully paid, and nonassessable, and will be free of liens, encumbrances and restrictions
on transfer, other than restrictions on transfer under this Agreement and the Collateral Documents and under applicable state and federal securities laws and liens or encumbrances created by or imposed by a Stockholder or Management Incentive Grant
Recipient. The Parent Common Stock issuable upon conversion of the Merger Shares has been duly and validly reserved for issuance and, upon issuance in accordance with the terms of the Restated Certificate, will be duly and validly issued, fully
paid, and nonassessable and will be free of restrictions on transfer other than restrictions on transfer under this Agreement and the Collateral Documents and under applicable state and federal securities laws. 

Section 4.6. Capitalization. 

(a) The authorized capital stock of Parent consists, immediately prior to the Closing, of 48,391,200 shares of Parent Common Stock, 8,064,479
of which are issued and outstanding, and 29,883,497 shares of preferred stock, of which (a) 1,800,000 shares are designated Series A Preferred Stock (the “Parent Series A Preferred” and together with the Parent Series B
Preferred, the “Parent Preferred Stock”), 1,620,888 of which are issued and outstanding and (b) 28,083,497 shares are designated Series B Preferred Stock, 13,638,707 of which are issued and outstanding. Each share of Parent
Preferred Stock is initially convertible into one share of Parent Common Stock. Parent has also reserved an aggregate of 6,830,041 shares of Parent Common Stock for issuance to employees and consultants pursuant to the Plan, under which
(i) 42,604 shares have been issued and are reflected in the currently outstanding Parent Common Stock, (ii) options to purchase 3,837,041 shares are presently outstanding and (iii) 2,950,391 shares remain available for future grant.
All issued and outstanding shares of capital stock of Parent have been duly authorized and validly issued and are fully paid and nonassessable. True and accurate copies of the Plan and the signed agreements used thereunder have been made available
to the Company. Immediately prior to the Closing, (i) warrants to purchase 491,943 shares of Parent Series B Preferred and 106,560 shares of Parent Series A Preferred have been issued and are outstanding and (ii) convertible promissory
notes having an aggregate principal amount of $9,950,000.00 (the “2013 Convertible Notes”) have been issued and are outstanding pursuant to that certain Convertible Note and Warrant Purchase Agreement, dated as of July 15,
2013, by and among Parent and the parties named therein (as amended, the “2013 Bridge Financing Agreement”). True and accurate copies of the 2013 Bridge Financing Agreement, and the signed warrants and Convertible Notes used
thereunder have been made available to the Company. Other than as described above or provided in the Ancillary Agreements, there are no other outstanding rights, options, warrants, preemptive rights, rights of first refusal, or similar rights for
the purchase or acquisition from Parent of any securities of Parent nor are there any commitments to issue or execute any such rights, options, warrants, preemptive rights or rights of first refusal. Except as otherwise provided in the Restated
Certificate or the Ancillary Agreements, there are no outstanding rights or obligations of Parent to repurchase or redeem any of its securities. The respective rights, preferences, privileges, and restrictions of the Parent Preferred Stock and the
Parent Common Stock are as stated in the Restated Certificate. All outstanding securities of Parent have been issued in compliance with state and federal securities laws. 

  
 30 

 (b) Section 4.6 of the Parent Disclosure f sets forth the summary capitalization of Parent
immediately following the Closing, including the following (in each case, in the aggregate): (i) issued and outstanding Parent Common Stock; (ii) shares of Parent Common Stock exercisable under granted stock options; (iii) shares of
Parent Common Stock reserved and available for future award grants under the Plan; and (iv) issued and outstanding Parent Preferred Stock. All outstanding shares of the Parent Common Stock and all shares of Parent Common Stock underlying
outstanding options and warrants are subject to (i) a right of first refusal in favor of Parent upon any proposed transfer (other than transfers for estate planning purposes); and (ii) a lock-up or market standoff agreement of not less
than 180 days following Parent’s initial public offering pursuant to a registration statement filed with the Securities and Exchange Commission under the Securities Act. 

Section 4.7. Agreements; Action. 

(a) Except as set forth in Section 4.7 of the Parent Disclosure Schedule, there are no agreements, understandings, instruments, contracts,
proposed transactions, judgments, orders, writs, or decrees to which Parent is a party or by which it is bound that involves (i) obligations (contingent or otherwise) of, or payments to, Parent in excess of $50,000 other than obligations of, or
payments to, Parent arising from license, purchase, or sale agreements entered into in the ordinary course of business, (ii) the transfer or license of any Proprietary Right (as defined in Section 4.9 below) to or from Parent, other than
licenses arising from the purchase of “off the shelf” or other standard products and other than agreements entered into in the ordinary course of business, each of which agreements are not, individually, material to Parent’s business,
(iii) provisions restricting the development, manufacture, or distribution of Parent’s products or services, or (iv) indemnification by Parent with respect to infringements of Proprietary Rights other than indemnification obligations
arising from license agreements entered into in the ordinary course of business. For the purposes of meeting the foregoing threshold of $50,000, all indebtedness, liabilities, agreements, understandings, instruments, contracts, and proposed
transactions involving the same person or entity (including persons or entities Parent has reason to believe are affiliated therewith) shall be aggregated. 

(b) Except as set forth in Section 4.7 of the Parent Disclosure Schedule, Parent has not (i) declared or paid any dividends or
authorized or made any distribution upon or with respect to any class or series of its capital stock, (ii) incurred any indebtedness for money borrowed or any other liabilities individually in excess of $25,000 or, in the case of indebtedness
and/or liabilities individually less than $25,000, in excess of $50,000 in the aggregate (other than the Convertible Notes), (iii) made any loans or advances to any person, other than ordinary advances for travel expenses, or (iv) sold,
exchanged, or otherwise disposed of any of its assets or rights, other than the sale of its inventory in the ordinary course of business. For the purposes of meeting the foregoing thresholds of $25,000 and $50,000, all indebtedness, liabilities,
agreements, understandings, instruments, contracts, and proposed transactions involving the same person or entity (including persons or entities Parent has reason to believe are affiliated therewith) shall be aggregated. 

  
 31 

 (c) Parent is not a party to and is not bound by any contract, agreement, or instrument, or
subject to any restriction under its Restated Certificate or Bylaws, that materially and adversely affects Parent’s business, properties, assets, prospects, or financial condition. 

Section 4.8. Compliance with Other Instruments. Except as set forth in Section 4.8 of the Parent Disclosure Schedule, Parent is
not in violation or default of any provision of its Restated Certificate or Bylaws, each as of the date hereof and to be amended and in effect as of the Closing. Parent is not in violation or default of any provision of any instrument, mortgage,
deed of trust, loan, contract, commitment, judgment, writ, decree, order, or obligation to which it is a party or by which it or any of its properties or assets are bound which would materially adversely affect Parent’s business, properties,
assets, prospects, or financial condition or, to the best of Parent’s Knowledge, of any provision of any federal, state, or local statute, rule, or governmental regulation applicable to Parent which, individually or in the aggregate, would
materially adversely affect Parent’s business, properties, assets, prospects, or financial condition, taken as a whole. The execution, delivery, and performance of and compliance with this Agreement and the Ancillary Agreements and the issuance
and sale of the Shares will not result in any such violation, be in conflict with or constitute, with or without the passage of time or giving of notice, a default under any such provision, require any consent or waiver under any such provision
(other than any consents or waivers that have been obtained and which are identified on Section 4.8 of the Parent Disclosure Schedule), or result in the creation of any mortgage, pledge, lien, encumbrance, or charge upon any of the properties
or assets of Parent pursuant to any such provision, or the suspension, revocation, impairment, forfeiture, or nonrenewal of any material permit, license, authorization, or approval applicable to Parent, its business or operations, or any of its
assets or properties pursuant to any such provision. 
 Section 4.9. Intellectual Property. All patents, patent applications,
registered trademarks, trademark applications and copyright registrations owned by or recorded in the name of Parent (the “Parent Registered Proprietary Rights”) are set forth on Section 4.9(a) of the Parent Disclosure
Schedule. Parent Registered Proprietary Rights is subsisting and unexpired. Except as set forth on Section 4.9(b) of the Parent Disclosure Schedule, Parent has exclusive ownership, free of material liens and material adverse rights and
interests of others, of all Parent Registered Proprietary Rights. To Parent’s Knowledge, Parent owns or has the right to use all intellectual property, including without limitation all patents, trademarks, service marks, trade names,
copyrights, trade secrets, information, proprietary rights, and processes, and all applications and registrations of the foregoing (collectively, “Proprietary Rights”) necessary to operate its business as now conducted and as
proposed to be conducted within the twelve (12) months following the date of this Agreement. Except as set forth on Section 4.9(c) of the Parent Disclosure Schedule, and other than agreements entered into in the ordinary course of
business, each of which agreements are not exclusive or, individually, material to Parent’s business, there are no outstanding options, licenses, or agreements of any kind relating to any Proprietary Rights 

  
 32 

 
owned by Parent, nor is Parent bound by or a party to any such options, licenses, or agreements of any kind with respect to the Proprietary Rights of any other person or entity. To Parent’s
Knowledge, no person or entity is violating any of Parent’s Proprietary Rights. To Parent’s Knowledge, Parent has not violated and, by conducting its business as proposed to be conducted within the twelve (12) months following the
date of this Agreement, will not violate any of the Proprietary Rights of any other person or entity. Parent has not received any written communications alleging that Parent has violated, or by conducting its business as proposed to be conducted
within the twelve (12) months following the date of this Agreement, would violate the Proprietary Rights of any other person or entity. To the best of Parent’s Knowledge, (i) none of Parent’s employees or consultants are
obligated under any contract (including licenses, covenants, or commitments of any nature) or other agreement, or subject to any judgment, decree, or order of any court or administrative agency, that would interfere with the use of his or her best
efforts to promote the interests of Parent or that would conflict with Parent’s business as proposed to be conducted within the twelve (12) months following the date of this Agreement, (ii) neither the carrying on of Parent’s
business by the employees of Parent, nor the conduct of Parent’s business as proposed to be conducted within the twelve (12) months following the date of this Agreement, will conflict with or result in a breach of the terms, conditions or
provisions of, or constitute a default under, any contract, covenant, or instrument under which any of such employees or consultants is now obligated, and (iii) none of Parent’s current employees or consultants is, by virtue of such
employee’s or consultant’s activities in connection with Parent’s business, violating, infringing, or misappropriating any Proprietary Rights of any former employer of such employee or consultant. To Parent’s Knowledge, the
execution and delivery of this Agreement and the Ancillary Agreements will not conflict with or result in a breach of the terms, conditions or provisions of, or constitute a default under, any contract, covenant, or instrument under which any of
Parent’s employees or consultants is now obligated. Parent does not believe it is or will be necessary to utilize any inventions of any of its employees (or people it currently intends to hire) made prior to or outside the scope of their
employment by Parent. Parent takes commercially reasonable actions to protect and maintain its Proprietary Rights, including the confidentiality of material trade secrets. 

Section 4.10. Employees. Except as set forth on Section 4.10 of the Parent Disclosure Schedule, each current and former employee
of Parent and each current and former consultant to Parent has executed a current proprietary information agreement assigning to Parent all of his or her rights in all inventions and Proprietary Rights, in the form made available to the Company in
all material respects. No current or former employee or consultant has excluded works or inventions made prior to his or her employment or consulting relationship with Parent from his or her assignment of inventions to Parent. To Parent’s
Knowledge, no officer or key employee is in violation of any prior employee contract, proprietary information agreement, or noncompetition agreement. No employees of Parent are represented by any labor union or covered by any collective bargaining
agreement, nor are there any union organization activities pending or, to Parent’s Knowledge, threatened by Parent’s employees. There is no pending or, to Parent’s Knowledge, threatened labor dispute involving Parent and any group of
its employees. Parent has complied in all material respects with all applicable state and federal equal opportunity, minimum wage, immigration, workforce reduction, and other laws related to 

employment and termination of employment. Parent is not aware that any officer, key employee, or key consultant, or that any group of key employees or
consultants, intends to terminate their employment with Parent, nor does Parent have a present intention to terminate the employment or consultancy of any of the foregoing. 

  
 33 

 Section 4.11. Related Party Transactions. Except as set forth on Section 4.11 of the
Parent Disclosure Schedule and for the agreements explicitly contemplated hereby and by the Ancillary Agreements, there are no agreements, understandings, or proposed transactions between Parent and any of its officers, directors, affiliates, or any
affiliate thereof. No employee, officer, director, or stockholder of Parent or member of his or her immediate family is indebted to Parent. Except as set forth on Section 4.11 of the Parent Disclosure Schedule, there are no obligations of
Parent to employees, officers, directors, or stockholders of Parent (or commitments to make loans or extend or guarantee credit) other than for payment of salary for services rendered, reimbursement for reasonable expenses incurred on behalf of
Parent, and for other standard employee benefits made generally available to all employees. Except as set forth on Section 4.11 of the Parent Disclosure Schedule, no employee, officer, director, or stockholder of Parent or member of his or her
immediate family is entitled to any bonus, acceleration of benefits, or payment as the result of any change of control of Parent, any termination of employment, or any other event or combination of events. To Parent’s Knowledge, no employee,
officer, director, or stockholder of Parent or member of his or her immediate family has any direct or indirect ownership interest in any firm or corporation with which Parent is affiliated or with which Parent has a business relationship, or any
firm or corporation that competes with Parent, except that employees, officers, directors, or stockholders of Parent and members of their immediate families may own stock in publicly traded companies (representing less than 1% of the outstanding
stock of such company) that may compete with Parent. No member of the immediate family of any officer or director of Parent is directly or indirectly interested in any material contract with Parent. 

Section 4.12. Litigation. There is no action, suit, proceeding, or investigation (including without limitation any suit, proceeding, or
investigation involving the prior employment of any of Parent’s employees, their use in connection with Parent’s business of any information or techniques allegedly proprietary to any of their former employers, or their obligations under
any agreements with prior employers) pending or, to Parent’s Knowledge, currently threatened (including cease and desist letters or invitations to take a patent license) before any court, administrative agency, arbitration body, or other
governmental body (nor, to Parent’s Knowledge, is there any basis for any such action, suit, proceeding or investigation). Neither Parent nor, to Parent’s Knowledge, any of its directors or officers as key employers, is a party or subject
to, and none of its assets, properties or rights is bound by, the provisions of any order, writ, injunction, judgment, or decree of any court or government agency or instrumentality. There is no action, suit, or proceeding by Parent currently
pending or that Parent intends to initiate. 

  
 34 

 Section 4.13. Title to Property and Assets. Except as set forth on Section 4.13 of
the Parent Disclosure Schedule, Parent has good and marketable title to all of its properties and assets (other than Proprietary Rights, the representations and warranties relating to which are set forth in Section 4.9) that it owns free and
clear of all mortgages, liens, loans, and encumbrances, except liens for current taxes and assessments not yet due and minor liens and encumbrances which arise in the ordinary course of business and which do not, in any case, in the aggregate,
materially detract from the value or use of the property subject thereto or materially impair the operations of Parent. With respect to the property and assets it leases, Parent is in compliance with such leases and holds a valid leasehold interest
free of all liens, claims, or encumbrances. 
 Section 4.14. Permits. Except with respect to Proprietary Rights (the representations
and warranties to which are set forth in Section 4.9), Parent has all franchises, permits, licenses, and any similar authority necessary for the conduct of its business as now being conducted by it, the lack of which would materially and
adversely affect Parent’s business, properties, assets, prospects, or financial condition, and Parent believes it can obtain, without undue burden or expense, any similar authority for the conduct of its business as planned to be conducted.
Parent is not in default in any material respect under any of such franchises, permits, licenses, or other similar authority. 
 Section
4.15. Employee Benefit Plans. Except as set forth on Section 4.15 of the Parent Disclosure Schedule, Parent does not have any Employee Benefit Plan as defined in the Employee Retirement Income Security Act of 1974. 

Section 4.16. Tax Returns, Payments, and Elections. Except as set forth on Section 4.16 of the Parent Disclosure Schedule, Parent
has filed all tax returns and reports (federal, state, and local) as required by law, and such returns and reports are true and correct in all material respects and Parent has paid all taxes and other assessments due and has made adequate provisions
for the payment of all other taxes and assessments as reflected on the Financial Statements (as defined in Section 4.18 below). Parent has not elected pursuant to the Code, to be treated as a Subchapter S corporation or a collapsible
corporation pursuant to Section 1362(a) or Section 341(f) of the Code, nor has it made any other elections pursuant to the Code (other than elections that relate solely to methods of accounting, depreciation, or amortization) that would
have a material effect on Parent’s business, properties, assets, prospects, or financial condition. Parent has never had any tax deficiency proposed or assessed against it and has not executed any waiver of any statute of limitations on the
assessment or collection of any tax or governmental charge. None of Parent’s federal income tax returns and none of its state income or franchise tax or sales or use tax returns has ever been audited by governmental authorities. Parent has
withheld or collected from each payment made to each of its employees, the amount of all taxes (including, but not limited to, federal income taxes, Federal Insurance Contribution Act taxes and Federal Unemployment Tax Act taxes) required to be
withheld or collected therefrom, and has paid the same to the proper tax-receiving officers or authorized depositories. Neither Parent nor Acquisition HoldCo has any plan or intention to liquidate Acquisition HoldCo, merge Acquisition HoldCo with
any other entity or convert Acquisition HoldCo into a limited liability company or other non-corporate entity following the Merger. 

  
 35 

 Section 4.17. Environmental and Safety Laws. To Parent’s Knowledge, Parent is not in
violation of any applicable statute, law, or regulation relating to the environment or occupational health and safety, and no material expenditures are required in order to comply with any such existing statute, law, or regulation. 

Section 4.18. Financial Statements. Parent has made available to the Company its (a) unaudited income statement, balance sheet,
and statement of cash flows as of September 30, 2013, and (b) unaudited income statement, balance sheet and statement of cash-flows for the year ended December 31, 2012 (collectively, the “2013 Parent Financial
Statements”). The 2013 Parent Financial Statements are complete and correct in all material respects, have been prepared in accordance with GAAP, and present fairly the financial condition and operating results of Parent as of the dates and
for the periods indicated, subject to normal immaterial year-end audit adjustments and except that the 2013 Parent Financial Statements may not contain footnotes as would be required by GAAP. Except as disclosed in the 2013 Parent Financial
Statements, Parent is not a guarantor or indemnitor of any indebtedness of any other person or entity. Parent maintains and will continue to maintain a standard system of accounting established and administered in accordance with generally accepted
accounting principles. 
 Section 4.19. Changes. Since September 30, 2013, there has not been: 

(a) any change in the assets, liabilities, financial condition, or operating results of Parent from that reflected in the 2013 Parent Financial
Statements, except changes in the ordinary course of business that have not been and are not expected to be, individually or in the aggregate, materially adverse; 

(b) any damage, destruction, or loss, whether or not covered by insurance, materially and adversely affecting Parent’s business,
properties, assets, prospects, or financial condition (as such business is presently conducted and as it is proposed to be conducted); 
 (c)
any waiver or compromise by Parent of a valuable right or of a material debt owed to it; 
 (d) any satisfaction or discharge of any lien,
claim, or encumbrance or payment of any obligation by Parent, except in the ordinary course of business and that is not material to Parent’s business, properties, assets, prospects, or financial condition (as such business is presently
conducted and as it is proposed to be conducted); 
 (e) any material change or amendment to a material contract or arrangement by which
Parent or any of its assets or properties is bound or subject; 
 (f) any material change in any compensation arrangement or agreement with
any employee, officer, director, or stockholder; 
 (g) any sale, assignment, or transfer of any Proprietary Assets; 

  
 36 

 (h) any resignation or termination of employment of any officer, key employee, or key consultant,
or any group of key employees or consultants, of Parent; 
 (i) receipt of notice that there has been a loss of, or material order
cancellation by, any important customer of Parent; 
 (j) any mortgage, pledge, transfer of a security interest in, or lien created by
Parent, with respect to any of its material properties or assets, except liens for taxes not yet due or payable; 
 (k) any material change
in the contingent obligations of Parent by way of guaranty, endorsement, indemnity, warranty, or otherwise, except as set forth on Section 4.19(k) of the Parent Disclosure Schedule; 

(l) any declaration, setting aside of payment, or other distribution in respect of any of Parent’s capital stock, or any direct or
indirect redemption, purchase, or other acquisition of any of such stock by Parent; 
 (m) any other event or condition of any character that
will materially and adversely affect Parent’s business, properties, assets, prospects, or financial condition (as such business is presently conducted and as it is proposed to be conducted); or 

(n) any agreement or commitment by Parent to do any of the things described in this Section 4.19. 

Section 4.20. Registration Rights; Voting Rights. Except as provided in the Ancillary Agreements, (i) Parent has not granted or
agreed to grant, and is not under any obligation to provide, any rights to register under the Securities Act any of its presently outstanding securities or any of its securities that may be issued subsequently, and (ii) to Parent’s
Knowledge, no stockholder of Parent has entered into any agreement with respect to the voting of equity securities of Parent. 
 Section
4.21. Disclosure. Parent has made available to the Company all the information reasonably available to Parent that the Company has requested for deciding whether to accept the Merger Shares, including certain of Parent’s projections
describing its proposed business plan (the “Business Plan”). No representation or warranty of Parent contained in this Agreement, as qualified by the Parent Disclosure Schedule, and no certificate furnished or to be furnished to the
Company at the Closing contains any untrue statement of a material fact or, to Parent’s Knowledge, omits to state a material fact necessary in order to make the statements contained herein or therein not misleading in light of the circumstances
under which they were made. The Business Plan was prepared in good faith; however, Parent does not warrant that it will achieve any results projected in the Business Plan. It is understood that this representation is qualified by the fact that
Parent has not delivered to the Company, and has not been requested to deliver, a private placement or similar memorandum or any written disclosure of the types of information customarily furnished to purchasers of securities. 

  
 37 

 Section 4.22. Brokers. Neither the Company nor any Company Subsidiary shall directly or
indirectly be obligated to pay or bear (e.g., by virtue of any payment by or obligation of any of the Parent, Acquisition HoldCo or Acquisition Corp. at or at any time after the Closing) any brokerage, finder’s or other fee or commission to any
broker, finder or investment banker in connection with the transactions contemplated by this Agreement based on arrangements made by or on behalf of the Parent, Acquisition HoldCo or Acquisition Corp. 

Section 4.23. Financial Capability. Parent has sufficient cash on hand or financing available under existing credit facilities to pay
all cash amounts to be paid by it hereunder on and after the Closing Date and to pay all related fees and expenses. Parent acknowledges and agrees that its obligations to consummate the transactions contemplated hereby are not contingent upon its
ability to obtain any third party financing. 
 ARTICLE V COVENANTS AND ADDITIONAL AGREEMENTS. 

Section 5.1. Conduct of Business. The Company covenants and agrees that at all times from and after the date of this Agreement until
the Effective Time (except as expressly contemplated or permitted by this Agreement, or to the extent that Parent otherwise shall consent in writing) (which consent shall not be unreasonably withheld): 

(a) The Company shall, and shall cause each Company Subsidiary to, conduct its business only in, and shall not take any action except in, the
ordinary course of business consistent with past practice in all material respects. 
 (b) Without limiting the generality of paragraph
(a) of this Section 5.1, (i) the Company shall use, and shall cause each Company Subsidiary to use, its commercially reasonable efforts, to preserve intact its present business organization, to maintain its assets and properties in
good working order and condition, ordinary wear and tear excepted, to maintain insurance on its tangible assets and businesses in such amounts and against such risks and losses as are currently in effect, to preserve its relationship with material
customers and suppliers and others having significant business dealings with them and to comply in all material respects with all Laws and orders of all governmental or regulatory authorities applicable to any of them, and (ii) the Company
shall not, and shall not permit any Company Subsidiary to: 
 (1) amend or propose to amend its certificate of incorporation or by-laws or
any equivalent organizational documents of any Company Subsidiary except for amendments required by this Agreement; 
 (2) (w) declare, set
aside or pay any dividends on or make other distributions in respect of any of its capital stock, (x) split, combine, reclassify or take similar action with respect to any of its capital stock or issue or authorize or propose the issuance of
any other securities in respect of, in lieu of or in substitution for shares of its capital stock, (y) adopt a plan of complete or partial liquidation or resolutions providing for or authorizing such liquidation or a merger, consolidation,
restructuring, recapitalization or other reorganization (other than the approvals of the Merger required by the DGCL and this Agreement) or (z) directly or indirectly redeem, repurchase or otherwise acquire any shares of its capital stock or
any option with respect thereto (except for repurchases pursuant to outstanding agreements); 

  
 38 

 (3) issue, deliver or sell, or authorize or propose the issuance, delivery or sale of, any
shares of its capital stock or any option, warrant or similar right with respect thereto other than upon exercise or conversion of an Option or Company Preferred Stock outstanding on the date of this Agreement; 

(4) acquire (by merging or consolidating with, or by purchasing a substantial equity interest in or a substantial portion of the assets of, or
by any other manner) any business or any corporation, partnership, association or other business organization or division thereof or otherwise acquire or agree to acquire any assets other than the acquisition of assets in the ordinary course of
business consistent with past practice; 
 (5) except to the extent required by applicable law, (x) permit any change in (A) any
pricing, marketing, purchasing, investment, accounting, financial reporting, inventory, credit, allowance or Tax practice or policy or (B) any method of calculating any bad debt, contingency or other reserve for accounting, financial reporting
or Tax purposes or (y) make any material Tax election or settle or compromise any Tax liability; 
 (6) except as otherwise provided in
this Agreement or as set forth in Section 5.1(b)(6) of the Company Disclosure Schedule, (x) except to the extent such incurrence would not be in violation of or require disclosure pursuant to the terms of this Agreement, incur (which shall
not be deemed to include entering into credit agreements, lines of credit or similar arrangements until borrowings are made under such arrangements) any indebtedness for borrowed money or guarantee any such indebtedness or (y) voluntarily
purchase, cancel, prepay or otherwise provide for a complete or partial discharge in advance of a scheduled repayment date with respect to, or waive any right under, any indebtedness for borrowed money; 

(7) except as set forth in Section 5.1(b)(7) of the Company Disclosure Schedule and except for the actions with respect to stock options
and the Company Stock Plan expressly provided for in this Agreement, and except as required by law, enter into, adopt, amend in any material respect or terminate (other than in accordance with its terms) any benefit plans or other agreement,
arrangement, plan or policy between the Company and one or more of its directors, officers, employees or consultants, or increase in any manner the compensation or fringe benefits of any director, officer, employee or consultant or pay any benefit
not required by any plan or arrangement in effect as of the date hereof; 
 (8) increase, or agree to increase, the compensation or benefits
payable, or to become payable, to its officers or employees or grant any severance or termination pay to any of its directors, officers or other employees, or establish, adopt, enter into or amend any collective bargaining, bonus, profit sharing,
thrift, compensation, stock option, restricted stock, pension, retirement, deferred compensation, employment, termination, severance or other plan, agreement, trust, fund, policy or arrangement for the benefit of any director, officer or employee;
provided, however, that the foregoing provisions of this subsection shall not apply to any amendments to employee benefit plans described in Section 3(3) of ERISA that is required by Law; 

  
 39 

 (9) except for the amendments to the Options and the Company Stock Plan expressly provided for
in this Agreement or as set forth in the Company Disclosure Schedule, enter into any contract or amend or modify any existing contract, or engage in any new transaction outside the ordinary course of business consistent with past practice or not on
an arm’s length basis, with any Affiliate of the Company; 
 (10) waive or agree to any extension of any limitations period in respect
of Taxes; 
 (11) take any action or omit to take any action which would result in a breach, violation or inaccuracy of any representation,
warranty, covenant or agreement of the Company or any Company Subsidiary made in this Agreement; 
 (12) enter into any contract or
agreement which would require the consent of the other party thereto to consummate the transactions contemplated hereby; 
 (13) enter into,
terminate or, other than in the ordinary course of business, amend, any lease or sublease of any real property or purchase or sell any real property or any interest therein; or 

(14) enter into any contract, agreement, commitment or arrangement to do or engage in any of the foregoing. 

(c) Subject to applicable law, until the Effective Time, the Company shall (i) confer on a regular and frequent basis with Parent and/or
its Affiliates with respect to its business and operations, the business and operations of each Company Subsidiary and other matters relevant to the Merger, provided that, in no event shall Parent direct or advise the Company with
respect to the business or the operations of the Company or any Company Subsidiary, and (ii) promptly advise Parent, in writing, of any change or event, including any communication with the FDA, any communication regarding a license or
sublicense, any complaint, investigation or hearing by any Governmental Entity (or communication indicating the same may be contemplated) or the institution or threat of litigation, except for any change or event that would not, individually or in
the aggregate, be reasonably expected to have a Material Adverse Effect or materially and adversely affect the ability of the Company to consummate the transactions contemplated hereby. 

Section 5.2. No Solicitations. Until the Effective Time and unless this Agreement shall have been terminated pursuant to
Section 8.1, the Company shall not authorize or permit any officer, director, stockholder, employee, investment banker, financial advisor, attorney, accountant or other agent or representative of the Company (each, a
“Representative”), directly or indirectly, to initiate, solicit, encourage, or, participate in any negotiations regarding, furnish 

  
 40 

 
any confidential information in connection with, endorse or otherwise cooperate with, assist, participate in or facilitate the making of any proposal or offer for, or which may reasonably be
expected to lead to, an Acquisition Transaction, by any Person, or group (a “Potential Acquiror”). The Company shall promptly inform Parent, orally and in writing, of the material terms and conditions of any proposal or offer for,
or which may reasonably be expected to lead to, an Acquisition Transaction that it receives and the identity of the Potential Acquiror. The Company will immediately cease and cause to be terminated any existing activities, discussions or
negotiations with any parties conducted on or prior to the date of this Agreement heretofore with respect to any Acquisition Transaction. As used in this Agreement, “Acquisition Transaction” means any merger, consolidation or other
business combination involving the Company or any Company Subsidiary, or any acquisition in any manner of all or a substantial portion of the equity of, or all or a substantial portion of the assets of, the Company and the Company Subsidiaries,
whether for cash, securities or any other consideration or combination thereof, other than pursuant to the transactions contemplated by this Agreement. 

Section 5.3. Access to Information; Support; Confidentiality. 

(a) The Company shall, and shall cause each Company Subsidiary to, throughout the period from the date hereof to the Effective Time,
(i) provide Parent and its Affiliates and their respective Representatives with full access, upon reasonable prior notice, during normal business hours to all officers, employees, agents, accountants and customers of the Company or any Company
Subsidiary, and their respective assets, properties, books and records and (ii) furnish promptly to such persons (x) a copy of each report, statement, schedule and other document filed or received by the Company or any Company Subsidiary
pursuant to the requirements of federal or state securities laws or filed with any other governmental or regulatory authority, and (y) all other information and data (including copies of contracts, benefit plans and other books and records)
concerning the business, employees and operations of the Company and any Company Subsidiary (including product development) as Parent or any of such other persons reasonably may request upon reasonable advance notice and at Parent’s sole cost.
No investigation pursuant to this paragraph or otherwise shall affect any representation or warranty contained in this Agreement or any condition to the obligations of the parties hereto. 

(b) Without limiting any covenant contained in this Article V, Parent and the Company shall each, and Company shall cause each Company
Subsidiary to (a) use commercially reasonable efforts to assemble, prepare and file any information (and, as needed, to supplement such information) as may be reasonably necessary to obtain as promptly as practicable all governmental and
regulatory consents required to be obtained in connection with the transactions contemplated hereby, (b) use commercially reasonable efforts to obtain all material consents and approvals of third parties that any of Parent, the Company, any
Company Subsidiary or their respective Affiliates are required to obtain in order to consummate the Merger, and (c) take such other actions as may reasonably be necessary or as either party may reasonably request to satisfy the conditions of
Article VI or otherwise to comply with this Agreement and to consummate the transactions contemplated hereby as soon as practicable. 

  
 41 

 (c) Until the fifth anniversary of the Closing Date, except as required by Law or stock exchange
rule, the Stockholders’ Representative will treat and hold as confidential all confidential information concerning the business and operations of the Company and each Company Subsidiary, in oral, written, graphic or electronic form, including
trade secrets concerning their business and affairs, that is not generally available to the public (the “Post-Closing Confidential Information”), refrain from disclosing any of such Post-Closing Confidential Information except in
connection with this Agreement or the transactions contemplated hereby, and destroy, at the request of Parent, all tangible embodiments (and all copies) of the Post-Closing Confidential Information that are in their possession; provided,
however, that (i) the Stockholders’ Representative may retain archival copies of the Post-Closing Confidential Information to enable the Stockholders and the Stockholders’ Representative to comply with their respective
obligations under this Agreement or any Collateral Document or as necessary to meet any other legal or regulatory requirements or internal audit or internal document retention or other compliance requirements, to prosecute, defend or settle any
Action or indemnification claim or to maintain a record of materials transferred or disclosed to Parent, and (ii) the foregoing shall not prohibit disclosure of any Post-Closing Confidential Information by the Stockholders’ Representative
to its Representatives or to the Stockholders and Management Incentive Grant Recipients who are bound by similar obligations of confidentiality. In the event that the Stockholders’ Representative or any of its Representatives is requested or
required by any regulatory authority or pursuant to written or oral question or request for information or documents or otherwise in any legal proceeding, interrogatory, subpoena, civil investigative demand or similar process to disclose any
Post-Closing Confidential Information, the Stockholders’ Representative shall as promptly as practicable and to the extent legally permitted notify Parent of the request or requirement so that Parent may seek (at its sole expense) an
appropriate protective order or waive compliance with the provisions of this Section 5.3(c). If, in the absence of a protective order or the receipt of a waiver hereunder, the Stockholders’ Representative or any of its Representatives is
required to disclose any Post-Closing Confidential Information, the Stockholders’ Representative or its Representative, as applicable, may disclose such Post-Closing Confidential Information without breaching this Section 5.3(c);
provided, however, that such Person shall cooperate (at the sole expense of Parent) with Parent’s efforts to obtain an order or other assurance that confidential treatment will be accorded to such portion of the Post-Closing
Confidential Information required to be disclosed as Parent may designate. The foregoing provisions shall not apply to any Post-Closing Confidential Information that is (a) generally available to the public unless such Post-Closing Confidential
Information is so available due to a breach of this Section 5.3(c) by the Stockholders’ Representative or its Representatives, (b) disclosed to any Governmental Entity, (c) available to the Stockholders’ Representative from
another source that is (to the knowledge of the Stockholders’ Representative) not disclosing such Post-Closing Confidential Information in violation of a fiduciary or contractual duty to the Company or any Company Subsidiary or
(d) independently developed by the Stockholders’ Representative without reference to any of the Post-Closing Confidential Information. Notwithstanding the foregoing, the Stockholders, the Management Incentive Grant Recipients and the
Stockholders’ Representative may retain copies of books and records relating to Taxes of the Company and each Company Subsidiary for any taxable period or portions thereof ending on or before the Closing Date. 

  
 42 

 Section 5.4. Company Stockholder Approval. On or before the date of this Agreement, each
of the Stockholders listed on Exhibit A have executed and delivered to the Parent a Voting Agreement and Release. The Company shall, promptly after the execution of this Agreement, obtain the approval and adoption of this Agreement, the
Merger, and the other transactions contemplated by this Agreement by the required vote of the Stockholders under the DGCL and the Company’s certificate of incorporation and by-laws and following such consent provide written notice of such
action to each of the Stockholders that has not executed the Voting and Release Agreement in accordance with the DGCL. 
 Section 5.5.
Prior Knowledge. If Parent shall have knowledge on or prior to the Closing Date of the existence or occurrence of any fact or event which has caused, or is reasonably expected to cause, any inaccuracy or breach by the Company of any
representation, warranty, covenant or other obligation hereunder, then Parent shall notify the Company and the Stockholders’ Representative promptly of such matter in writing. If Parent fails to inform the Company and the Stockholders’
Representative of such fact or event as provided herein, such failure to notify will constitute a waiver and release by Parent of any rights it may have hereunder, including any right to delay the Closing or terminate this Agreement as a result of
such representation warranty, covenant or agreement being untrue or inaccurate because of such fact or event. 
 Section 5.6.
Supplemental Disclosure. The Company may, from time to time prior to or at the Closing, by notice in accordance with the terms of this Agreement, supplement, amend or create any Company Disclosure Schedule in order to add information or
correct previously supplied information; provided, however, that the foregoing proviso shall not apply to any supplement, amendment or addition that relates to any event or set of circumstances that occurred or existed prior to the date hereof. It
is agreed that the Company Disclosure Schedule may be amended to add immaterial, as well as material, items thereto. No such supplemental, amended or additional Company Disclosure Schedule shall be deemed to cure any breach for purposes of Article
VII; provided, that if the Closing occurs, then any such supplement, amendment or addition will be effective to cure and correct for all other purposes any breach of any representation, warranty or covenant that would have existed if the Company had
not made such supplement, amendment or addition, and all references to any Company Disclosure Schedule hereto that is supplemented or amended as provided in this Section 5.6 shall for all purposes after the Closing be deemed to be a reference
to such Company Disclosure Schedule as so supplemented or amended. 
 Section 5.7. Company Stock Plan. The Company has taken all
steps necessary to ensure that the Company is not or will not be bound by any Options, other options, warrants, rights or agreements which would entitle any person, other than the current stockholders of Acquisition Corp. or its Affiliates, to
acquire any capital stock of the Surviving Corporation or its Affiliates. 

  
 43 

 Section 5.8. Fulfillment of Conditions. Subject to the terms and conditions of this
Agreement, each of Parent and the Company will take or cause to be taken all commercially reasonable steps necessary or desirable and proceed diligently and in good faith to satisfy each condition to the other’s obligations contained in this
Agreement and to consummate and make effective the transactions contemplated by this Agreement, and neither the Company nor Parent will, take or fail to take any action that could be reasonably expected to result in the nonfulfillment of any such
condition. 
 Section 5.9. Director and Officer Indemnity. 

(a) From and after the Effective Time, Parent and Surviving Corporation agree to indemnify and hold harmless, and provide advancement of
expenses to, all past and present officers, all past and present directors of the Company and any person who becomes an officer or director of the Company after the date hereof but prior to the Effective Time to the same extent as such persons are
indemnified as of the date of this Agreement pursuant to the Amended and Restated Certificate of Incorporation of the Company, as filed with the Secretary of State of the State of Delaware August 13, 2012, the by-laws of the Company as in
effect on the date hereof and any indemnification agreement between the Company and such officers and directors for acts or omissions occurring at or prior to the Effective Time (including claims for indemnification related to acts or omission taken
in connection with the consideration and approval of the transaction contemplated by this Agreement). 
 (b) At the Effective Time and for a
period of six (6) years from the Effective Time, the Surviving Corporation shall cause to be maintained in effect in the certificate of incorporation and bylaws (and other comparable charter documents) of it or any successor of it, provisions
with respect to exculpation, indemnification and advancement of expenses that are at least as favorable to the intended beneficiaries as those presently contained in the certificate of incorporation and by-laws of the Company in effect immediately
prior to the Effective Time to the extent permitted by law. 
 (c) The rights of each indemnified party hereunder shall be in addition to,
and not in limitation of, any other rights such indemnified party may have under the certificate of incorporation or by-laws of the Company, any employment agreement or indemnification agreement in effect as of the date of the date hereof, the DGCL
or otherwise. The provisions of this Section 5.9 shall survive the consummation of the Merger. 
 (d) If Parent or Surviving Corporation
or any of its successors or assigns consolidates with or merges into any other entity and is not the continuing or surviving entity of such consolidation or merger or transfers all or substantially all of its assets to any other entity, then and in
each case, Parent or Surviving Corporation, as applicable, will cause proper provision to be made so that the successors and assigns of Parent or Surviving Corporation, as applicable, shall assume the obligations set forth in this Section 5.9.

 (e) The provisions of this Section 5.9 are expressly intended to be for the benefit of, and shall be enforceable by, each indemnified
party and his or her heirs, estates and personal representatives. 

  
 44 

 Section 5.10. Management Incentive Grants. Parent shall take all steps necessary to obtain
the approval by its board of directors and stockholders, to the extent required by the Restated Certificate, the Ancillary Agreements and the DGCL, to issue the Management Incentive Grants to the Management Incentive Grant Recipients and to execute
and deliver the Restricted Stock Agreements as contemplated by Section 2.9. 
 ARTICLE VI CONDITIONS TO CLOSING. 

Section 6.1. Conditions to the Obligations of Parent, Acquisition HoldCo and Acquisition Corp. The obligation of Parent, Acquisition
HoldCo and Acquisition Corp. to effect the Merger, is subject to the fulfillment on or prior to the Closing Date of each of the following conditions (all or any of which, other than Section 6.1(d), may be waived by Parent in its sole
discretion): 
 (a) Performance of Obligations; Representations and Warranties. The Company shall have performed and complied in all
material respects with all covenants and agreements contained in this Agreement that are required to be performed or complied with by it prior to or at the Closing Date, and, each of the Company’s and any Company Subsidiary’s
representations and warranties contained in Article III of this Agreement shall be true and correct in all material respects (if not qualified by Company Material Adverse Effect or materiality) and in all respects (if qualified by Company Material
Adverse Effect or materiality) as of the date hereof and as of the Closing Date other than in the case of representations and warranties made as of a specified date earlier than the Closing Date, which shall have been true and correct in all
material respects (if not qualified by Company Material Adverse Effect or materiality) and in all respects (if qualified by Company Material Adverse Effect or materiality) as of such specified date, and the Company shall have delivered to Parent a
certificate, dated the Closing Date executed on behalf of the Company by its Chairman, President or a Vice President, to such effect. 
 (b)
Resignations. The Company shall have delivered to Parent a resignation letter from each of the directors and officers of the Company and from each of the directors and officers of any Company Subsidiary, as instructed in writing by Parent.
Such resignations are to be effective at the Effective Time. 
 (c) Consents. The Company and each Company Subsidiary shall have
received or made the consents, approvals, authorizations, permissions, notices and filings listed on Schedule 6.1(c) and all of them shall be in form and substance satisfactory to Parent, Acquisition HoldCo and Acquisition Corp. 

(d) Stockholder Approval. The Company shall have obtained the approval by its stockholders of this Agreement, to the extent required by
the Company’s certificate of incorporation and the DGCL and shall have provided to Parent evidence of such approval (“Company Stockholder Approval”). For the avoidance of doubt, the delivery to Parent of an executed Voting and
Release Agreement by the Stockholders listed on Exhibit A shall constituted evidence of the Company Stockholder Approval. 

  
 45 

 (e) Illegality. There shall not have been issued and be in effect any order, decree or
judgment of any court or tribunal of competent jurisdiction which makes the consummation of the Merger illegal. 
 (f) Secretary’s
Certificate. The Company shall have delivered to Parent a certificate executed by the Secretary of the Company attaching and certifying as to the Company’s current certificate of incorporation and by-laws and the resolutions of the
Company’s Board of Directors and stockholders approving this Agreement and the transactions relating thereto. 
 (g) Rights
Agreement. Each of the Persons identified on Schedule 6.1(g) shall have executed and delivered to Parent the Second Amended and Restated Investors’ Rights Agreement (the “Rights Agreement”) in substantially the form
attached as Exhibit H. 
 (h) Voting Agreement. Each of the Persons identified on Schedule 6.1(h) shall have
executed and delivered to Parent the Second Amended and Restated Voting Agreement, as amended as of the Closing (the “Voting Agreement”) in substantially the form attached as Exhibit I. 

(i) Escrow Agreement. Parent shall have received an executed counterpart of the Escrow Agreement signed by each party thereto other than
Parent. 
 (j) Accredited Investor List. The Company shall have delivered to Parent the Accredited Investor List. 

Section 6.2. Conditions to the Obligations of the Company. The obligation of the Company to effect the Merger is subject to the
fulfillment at or prior to the Closing Date of each of the following conditions (all of which may be waived by the Company in its sole discretion). 

(a) Performance of Obligations; Representations and Warranties. Parent, Acquisition HoldCo and Acquisition Corp. shall have performed
and complied in all material respects with all covenants and agreements contained in this Agreement that are required to be performed or complied with by them prior to or at the Closing Date and each of the representations and warranties of
Acquisition HoldCo, Acquisition Corp. and Parent contained in Article IV of this Agreement shall be true and correct in all material respects (if not qualified by materiality) and in all respects (if qualified by materiality) as of the date hereof
and as of the Closing Date other than in the case of representations and warranties made as of a specified date earlier than the Closing Date, which shall have been true and correct in all material respects (if not qualified by materiality) and in
all respects (if qualified by materiality) as of such specified date, and each of Parent, Acquisition HoldCo and Acquisition Corp. shall have delivered to the Company a certificate, dated the Closing Date executed on behalf of each of them by an
authorized officer, to such effect. 

  
 46 

 (b) Stockholder Approval. This Agreement shall have been adopted by the requisite vote of
the stockholders of the Company, to the extent required by the Company’s certificate of incorporation and the DGCL. 
 (c)
Illegality. There shall not have been issued and be in effect any order, decree or judgment of any court or tribunal of competent jurisdiction which makes the consummation of the Merger illegal. 

(d) Secretary’s Certificate. Parent shall have delivered to the Company a certificate executed by the Secretary of Parent attaching
and certifying as to Parent’s current certificate of incorporation and by-laws and the resolutions of Parent’s Board of Directors approving this Agreement and the transactions relating thereto. 

(e) Escrow Agreement. The Company shall have received an executed counterpart of the Escrow Agreement signed by each party thereto other
than the Company and the Stockholders’ Representative. 
 (f) Rights Agreement. Parent shall have executed and delivered to each
of the Persons identified on Schedule 6.1(g) the Rights Agreement. 
 (g) Voting Agreement. Parent shall have executed and
delivered to each of the Persons identified on Schedule 6.1(h) the Voting Agreement. 
 (h) Restated Certificate of Parent. The
board of directors of Parent and the stockholders of Parent shall have adopted Parent’s Restated Certificate (the “Restated Certificate”) in the form attached hereto as Exhibit L which reserves an appropriate number of
shares of Series B Preferred to permit the issuances contemplated by this Agreement and Parent shall have filed the Amendment with the Secretary of State of the State of Delaware on or prior to the Closing, which shall continue to be in full force
and effect as of the Closing. 
 (i) Board of Directors of Parent. James I. Healy, M.D., Ph.D. shall have been appointed to serve as a
member of the Board of Directors of Parent effective immediately following the Closing. 
 (j) Management Rights Agreement. Parent
shall have executed Sofinnova’s customary Management Rights Agreement in the form attached hereto as Exhibit K. 
 (k)
Secondary Purchase Agreement. Cook Pharmica LLC shall have agreed to sell 1,195,000 shares of Parent Series B Preferred to Sofinnova pursuant to the Secondary Share Purchase Agreement in the form attached hereto as Exhibit L (the
“Secondary Share Purchase Agreement”). 
 (l) Parent Stockholder Approval. Parent shall have obtained the approval by
its stockholders of this Agreement and the transactions contemplated by this Agreement, to the extent required by the Restated Certificate, the Ancillary Agreements and the DGCL, and shall have provided to Company evidence of such approval. 

  
 47 

 ARTICLE VII SURVIVAL; INDEMNIFICATION; TAX MATTERS. 

Section 7.1. Survival. Except as otherwise provided herein, all the representations and warranties of the Company, Parent, Acquisition
HoldCo and Acquisition Corp. contained in or made pursuant to this Agreement shall survive the Closing and shall remain operative and in full force and effect for a period of twelve (12) months after the Effective Time (such period being
referred to as the “Indemnity Period”), regardless of any investigation or statement as to the results thereof made by or on behalf of any Person before or after the Closing, provided, however, that (a) the
representations and warranties contained in Sections 3.1, 3.2, 3.3 and 3.21 (collectively, the “Company Fundamental Representations”), and Sections 4.1, 4.3, 4.5, 4.6 and 4.23 (collectively, the “Parent Fundamental
Representations”, shall survive after the Closing Date until thirty (30) days after the expiration of the applicable statute of limitations (including any expirations thereof); (b) the representations and warranties contained in
Section 3.16 shall survive after the Effective Time until thirty (30) days after the expiration of the applicable statutes of limitations (including any extensions thereof); and (c) claims based on fraud or intentional
misrepresentations shall survive after the Effective Time until thirty (30) days after the expiration of the applicable statutes of limitations (including any extensions thereof). Notwithstanding anything herein to the contrary, any
representation, warranty, covenant and agreement which is the subject of a properly asserted Claim Notice prior to the expiration of the Indemnity Period shall survive solely with respect to such claim or any dispute underlying such Claim Notice
until the final resolution thereof in accordance with this Article VII. 
 Section 7.2. Indemnification. 

(a) Subject to the provisions of this Article VII, the Stockholders and Management Incentive Grant Recipients shall severally, and not jointly,
indemnify Parent, its employees, agents, directors, officers, subsidiaries and its Affiliates, including Acquisition HoldCo, Acquisition Corp. and the Surviving Corporation, and the employees, agents, directors, officers and subsidiaries of its
Affiliates (the “Buyer Indemnified Parties”) from and against any and all damages, claims, losses (including loss of value), expenses, costs, obligations and liabilities, including liabilities for all reasonable attorneys’,
accountants’, and experts’ fees and expenses including those incurred to enforce the terms of this Agreement or any Collateral Document (collectively, “Losses”) asserted against, or paid, suffered or incurred by any Buyer
Indemnified Party which, directly or indirectly, arise out of, result from, are based upon or relate to: (i) (x) the breach of any representation or warranty made by the Company in this Agreement or (y) the breach by the Company of
its covenants or agreements set forth in this Agreement; and (ii) Pre-Closing Tax Liabilities, except to the extent such Pre-Closing Tax Liabilities are attributable to a breach of any covenant contained in Section 7.10(f) or (g). 

(b) Subject to the provisions of this Article VII, Parent shall indemnify each of the Stockholders and Management Incentive Grant Recipients
and their respective employees, agents, directors, officers, subsidiaries and its Affiliates (the “Stockholder Indemnified Parties”) 

  
 48 

 
from and against any and all Losses asserted against, or paid, suffered or incurred by any Stockholder Indemnified Party which, directly or indirectly, arise out of, result from, are based upon
or relate to: (i) the breach of any representation or warranty made by Parent, Acquisition HoldCo or Acquisition Corp. in this Agreement or (ii) the breach by Parent, Acquisition HoldCo or Acquisition Corp. of any of their respective
covenants or agreements set forth in this Agreement. 
 Section 7.3. Limitation of Liability. After the Closing, the Indemnified
Parties’ rights to indemnification under Section 7.2 shall be subject to the following: 
 (a) (i) in no event shall the aggregate
amount to be paid to the Buyer Indemnified Parties under Article VII exceed One Million Dollars ($1,000,000) (the “Overall Indemnity Cap”), which amount shall be calculated with respect any payment from the Indemnity Escrow Funds in
the manner set forth in Section 7.8; (ii) in no event shall the aggregate amount to be paid to Stockholder Indemnified Parties under Section 7.2 exceed One Million Dollars ($1,000,000); and (iii) the Indemnified Parties shall be
entitled to recover any Loss otherwise recoverable pursuant to Section 7.2(a)(i)(x) or Section 7.2(b)(i), as appropriate, (other than indemnification for breaches of the Company Fundamental Representations or Parent Fundamental
Representations, as appropriate, to which the Indemnity Threshold Amount shall not apply) only to the extent the aggregate of Losses otherwise recoverable pursuant to Section 7.2(a)(i)(x) or Section 7.2(b)(i), as appropriate, exceeds
Twenty Five Thousand ($25,000) (the “Indemnity Threshold Amount”) in the aggregate; provided, that, if all such Losses exceed the Indemnity Threshold Amount, the Indemnified Parties shall be entitled to recover for all
such indemnifiable Losses including the Indemnity Threshold Amount; 
 (b) in no event shall any Stockholder or Management Incentive Grant
Recipient be required to provide indemnification under Article VII for any amount exceeding the pro rata amount of the Acquisition Price withheld from such Stockholder or Management Incentive Grant Recipient pursuant to Section 2.3 as Indemnity
Escrow Funds; and 
 (c) the limitations set forth in this Section 7.3 shall not apply with respect to any claim arising out of or
resulting from fraud or intentional misrepresentation. 
 Section 7.4. Additional Indemnification Limitations. The Buyer Indemnified
Parties’ sole recourse for indemnification due to any Loss under Section 7.2 shall be by way of release to Parent of Indemnity Escrow Funds, subject to the Overall Indemnity Cap, as set forth in Section 7.8; provided,
however, the Buyer Indemnified Parties shall have the right to seek recovery of any Losses at any time directly from the Stockholders and Management Incentive Grant Recipients with respect to Losses based upon fraud or intentional
misrepresentation committed by any Stockholder or Management Incentive Grant Recipient, severally and not jointly with any other Stockholder or Management Incentive Grant Recipient, as set forth in Section 7.9(i). For the avoidance of doubt,
the Stockholder Indemnified Parties shall have the right to seek recovery of any Losses at any time from Parent with respect to Losses based upon fraud or intentional misrepresentation, as set forth in Section 7.9(i). 

  
 49 

 Section 7.5. Notice of Claims. If any Buyer Indemnified Party or Stockholder Indemnified
Party, as applicable (each, an “Indemnified Party”) reasonably believes in good faith that it has suffered or incurred any Loss for which such Indemnified Party is entitled to indemnification pursuant to this Article VII from the
Stockholders/Management Incentive Grant Recipients or Parent, respectively (the “Indemnifying Party”), it shall notify the Indemnifying Party promptly in writing (at its address set forth in Section 11.5), and in any event
within the applicable time period specified in Section 7.1, describing such Loss, all with reasonable particularity and containing a reference to the provisions of this Agreement in respect of which such Loss shall have occurred (a
“Claim Notice”); provided, however, that the Stockholders’ Representative shall be deemed to be the Stockholder Indemnified Party (whether it is the Indemnified Party or the Indemnifying Party) for purposes of this Article VII.
If any legal action is instituted by a third party with respect to which any of the Indemnified Parties intend to claim indemnity under this Section 7.5, such Indemnified Party shall promptly give a Claim Notice to notify the Indemnifying Party
with respect to such legal action. In any event, a failure or delay in notifying the Indemnifying Party shall not affect the Indemnified Party’s right to indemnity, except only to the extent such failure or delay materially and adversely
prejudices the ability to defend against any legal action. 
 Section 7.6. Defense of Third Party Claims. Because the right to
indemnity is limited as provided herein, the Indemnified Parties shall have the right to conduct and control, through counsel of their own choosing, reasonably acceptable to the Indemnifying Party, any third party legal action or other claim, but
the Indemnifying Party may, at its election, participate in the defense thereof at its sole cost and expense; provided, however, that if the Indemnified Parties shall fail to defend any such legal action or other claim, then the
Indemnifying Party may defend, through counsel of their own choosing, such legal action or other claim, and so long as it gives the Indemnified Party at least fifteen (15) days’ notice of the terms of the proposed settlement thereof and
permit the Indemnified Party to then undertake the defense thereof, except as set forth below, settle such legal action or other claim and recover the amount of such settlement or of any judgment and the costs and expenses of such defense. Neither
the Indemnifying Party nor the Indemnified Party shall compromise or settle any such legal action or other claim without the prior written consent of the other, which consent shall not be unreasonably withheld, except that under no circumstances
shall Parent, the Stockholders’ Representative or the Stockholders/Management Incentive Grant Recipients be required to consent to the entry of an order for injunctive or other non-monetary relief. All costs and expenses reasonably incurred in
defending any such third party legal action or other claim, including the amount of any settlement or of any judgment, shall be paid out as provided herein. 

Section 7.7. Dispute Resolution Negotiation. 

(a) The Stockholders and Management Incentive Grant Recipients, on the one hand, and Parent, on the other hand, shall attempt to resolve any
dispute arising out of or relating to this Agreement promptly by negotiation in good faith between an agent chosen by the Stockholders’ Representative and an executive officer of Parent who has authority to settle the dispute. Each party shall
give the other party involved written notice of any dispute not resolved 

  
 50 

 
in the ordinary course of business. Within seven (7) days after delivery of such notice, the party receiving notice shall submit to the other a written response thereto. The notice and the
response shall include: (i) a statement of each party’s position(s) regarding the matter(s) in dispute and a summary of arguments in support thereof, and (ii) the name and title of the executive officer who will represent Parent and
any other Person who will accompany that executive officer, in the case of Parent, or the name of the agent who will represent the Stockholders and Management Incentive Grant Recipients and any other Person who will accompany that agent, in the case
of the Stockholders and Management Incentive Grant Recipients. 
 (b) Within fourteen (14) days after delivery of the notice, the
designated agent of the Stockholders and Management Incentive Grant Recipients and the designated executive officer of Parent shall meet at a mutually acceptable time and place, and thereafter, as often as they reasonably deem necessary, to attempt
to resolve the dispute. All reasonable requests for information made by one party to the other shall be honored in a timely fashion. All negotiations conducted pursuant to this Section 7.7 (and any of the parties’ submissions in
contemplation hereof) shall be kept confidential by the parties and shall be treated by the parties and their representatives as compromise and settlement negotiations under the Federal Rules of Evidence and any similar state rules. 

Section 7.8. Indemnity Escrow Funds and Indemnity Payments. 

(a) Any payment to the Buyer Indemnified Parties in respect of any claim for indemnification under this Article VII shall be made, subject to
the Overall Indemnity Cap, by release of Indemnity Escrow Funds consisting of ratable portions of shares of Parent Series B Preferred (or Parent Common Stock, as applicable) and cash (based on the allocation of shares of Parent Series B Preferred
and cash issued or paid by Parent in connection with payment of the Acquisition Price) to the Buyer Indemnified Parties by the Exchange Agent within five (5) business days after the date of the final determination of any amounts due and owing
to the Buyer Indemnified Parties under this Article VII and pursuant to the instructions contained in the Escrow Agreement. Subject to the Overall Indemnity Cap, the portion of the Indemnity Escrow Funds released to the Buyer Indemnified Parties
hereunder in the form of shares of Parent capital stock shall be valued at the higher of (i) the fair market value of such shares at the time they are released (provided that this clause (i) shall only apply in the event that shares of
Parent Common Stock are publicly-traded at the time such indemnification claim is satisfied), and (ii) $4.1841 per share of Parent Series B Preferred, as adjusted to reflect any stock split, reclassification, recapitalization or similar event
after the date hereof. 
 (b) On the expiration of the Indemnity Period, the Exchange Agent shall be instructed by Parent and the
Stockholders’ Representative to release all or a portion of the Indemnity Escrow Funds to the Stockholders entitled thereto in accordance with Section 7.8(f) and the instructions contained in the Escrow Agreement, such that, following such
release, the value of the amount remaining of the Indemnity Escrow Funds, if any, equals the aggregate amount of claims for indemnification under this Article VII properly asserted in a Claim Notice in accordance with this Article VII prior to the
expiration of the Indemnity Period but not yet resolved (such unresolved claims, the “Unresolved Indemnification Claims”). 

  
 51 

 (c) To the extent applicable, the Indemnity Escrow Funds retained for the Unresolved
Indemnification Claims shall be released by the Exchange Agent (to the extent not utilized to pay the Buyer Indemnified Parties for any such claims resolved in favor of the Buyer Indemnified Parties) upon their resolution in accordance with this
Article VII and pursuant to the instructions contained in the Escrow Agreement. 
 (d) Upon the final determination of any amounts to be paid
from the Indemnity Escrow Funds pursuant to this Section 7.8, each of Parent and the Stockholders’ Representative shall execute joint written instructions to the Exchange Agent instructing the Exchange Agent to disburse the Indemnity
Escrow Funds in accordance with this Section 7.8. 
 (e) Notwithstanding the foregoing or any other provision in this Agreement, to the
extent any portion of the Indemnity Escrow Funds is payable pursuant to this Section 7.8 to a Stockholder who is not at such time entitled to receive the Acquisition Price pursuant to Section 2.4, such portion of the Indemnity Escrow Funds
shall remain in escrow with the Exchange Agent until such time as such Stockholder is entitled to receive the Acquisition Price pursuant to Section 2.4. 

(f) Release of the Indemnity Escrow Funds pursuant to this Section 7.8 to the Stockholders and Management Incentive Grant Recipients on or
following the expiration of the Indemnity Period shall be allocated among the Stockholders and Management Incentive Grant Recipients as set forth on Schedule F (and which shall be further subject to Sections 2.4 and 2.6 with respect to
whether such Person shall receive such payment in the form of cash or shares of Parent Series B Preferred). 
 (g) Any payment to the
Stockholder Indemnified Parties in respect of any claim for indemnification under this Article VII shall be made by Parent by wire transfer of immediately available funds to such Stockholder Indemnified Party within ten (10) business days after
the date of the final determination of any amounts due and owing to the Stockholder Indemnified Party under this Article VII. 
 (h) The
indemnification amount to which an Indemnified Party may become entitled under this Article VII shall be net of (i) any actual recovery received by the Indemnified Party from a third party with respect to the facts giving rise to the claim for
indemnification less any costs reasonably incurred by the Indemnified Party in connection with obtaining such recovery in respect of such claim and (ii) any Tax benefit actually realized by the Indemnified Party with respect to the Losses
giving rise to the claim for indemnification. 
 Section 7.9. Exclusive Remedy. Except for (i) claims based upon fraud or
intentional misrepresentation, and (ii) the remedies set forth in Section 11.9, the remedies set forth in Article VII hereof, including Section 7.2, constitute the sole and exclusive remedy for breaches of the representations,
warranties, covenants and agreements contained in this Agreement. 

  
 52 

 Section 7.10. Tax Matters. 

(a) The Company shall cause to be prepared and filed prior to the Closing all Tax Returns of the Company and the Company Subsidiaries that are
required to be filed on or before the Closing and shall pay, prior to the Closing, all Taxes required to be paid with respect to such Tax Returns. Such Tax Returns shall be prepared in accordance with all applicable laws and consistent with past
practice. The Company shall deliver to Parent, at least fifteen (15) days prior to the Effective Time, draft copies of all such Tax Returns that are required to be prepared and filed pursuant to this Section 7.10(a) for Parent’s
review and consent, which consent shall not be unreasonably withheld. The Company shall provide Parent with reasonable cooperation with respect to its review of the Tax Returns. 

(b) Parent makes no representations or warranties to the Company or to any Stockholder or Management Incentive Grant Recipient regarding the
Tax treatment of the Merger, or any of the Tax consequences to the Company, the Company Subsidiaries, any Stockholder or Management Incentive Grant Recipient or any other Person of this Agreement, the Merger or any of the other transactions or
agreements contemplated hereby. The Company acknowledges that the Company and the Stockholders are relying solely on their own Tax advisors in connection with this Agreement, the Merger and the other transactions and agreements contemplated hereby.

 (c) Any transfer, documentary, stamp, registration and other similar Taxes and fees (including any penalties and interest) imposed in
connection with the transactions contemplated herein shall be borne 50% by the Stockholders and 50% by Parent. 
 (d) Parent shall prepare
and file all Tax Returns of the Company and any Company Subsidiary for all Straddle Periods. For purposes of determining Pre-Closing Tax Liabilities, the portion of any Tax of the Company or the Company Subsidiaries that relates to the portion of
any Straddle Period ending on the Closing Date will be: (i) in the case of real and personal property taxes and similar ad valorem taxes, deemed to be the amount of such Taxes for the entire Straddle Period multiplied by a fraction, the
numerator of which is the number of calendar days of such Straddle Period in the Pre-Closing Tax Period and the denominator of which is the number of calendar days in the entire Straddle Period; and (ii) in the case of all other Taxes,
determined as though the taxable year of the Company or the Company Subsidiary terminated at the close of business on the Closing Date, provided, that exemptions, allowances and deductions that are calculated on an annual basis shall be allocated
between the Pre-Closing Tax Period and the period after the Closing Date in proportion to the number of days in each such period. Any Tax Returns for Straddle Periods shall be prepared in accordance with past practice unless otherwise required by
Laws. 
 (e) [Intentionally omitted.] 

(f) Following the Closing, unless required by Laws or a Governmental Entity, Parent shall not file or permit to be filed any Tax Return,
including any amended Tax Return, for the Company or any Company Subsidiary for any Pre-Closing Tax Period that would increase the liability of the Stockholders and the Management Incentive Grant Recipients under Section 7.2(a)(ii) (taking into
account all limitations under Article VII) without the prior written consent of the Stockholders’ Representative, which shall not be unreasonably withheld. 

  
 53 

 (g) The Stockholders and Management Incentive Grant Recipients shall not have liability under
Section 7.2(a)(ii) for Taxes to the extent such Taxes would not have arisen but for (i) other than transactions specifically contemplated by this Agreement, any transactions effected by Parent on the Closing Date outside of the ordinary
course of business with respect to the Company or any Company Subsidiary, or (ii) any election filed under Section 338 of the Code (or comparable provision of state, local or non-U.S. law) with respect to the transactions contemplated by
this Agreement. 
 (h) Parent and the Stockholders’ Representative agree to cooperate, as and to the extent reasonably requested by the
other party, in connection with (i) the preparation and filing of any Tax Return relating to the Company or any Company Subsidiary, and (ii) any examination, audit or other proceeding by a Governmental Entity with respect to any such Tax
Return or otherwise with respect to Taxes of the Company or any Company Subsidiary. 
 ARTICLE VIII TERMINATION; EFFECT OF TERMINATION. 

Section 8.1. Termination. This Agreement may be terminated at any time prior to the Closing Date, and the transactions contemplated
hereby may be abandoned: 
 (a) by mutual written agreement of the parties hereto; 

(b) by either the Company or Parent upon notification to the non-terminating party by the terminating party: 

(i) at any time ninety (90) days following the date of this Agreement if the Merger shall not have been consummated on or prior to such
date and such failure to consummate the Merger is not caused by a breach of this Agreement by the terminating party; 
 (ii) there has been
a material breach of this Agreement on the part of the non-terminating party and either (x) the non-terminating party fails to cure such breach within ten (15) days following notification thereof by the terminating party or (y) the
breach is not reasonably capable of being cured within ten (15) days after notice thereof. 
 Section 8.2. Effect of
Termination. 
 Except for any willful breach of this Agreement by any party hereto (which breach and liability therefor shall not be
affected by the terminations of this Agreement), if this Agreement is terminated pursuant to Section 8.1 hereof, then this Agreement shall become void and of no effect with no liability on the part of any party hereto (or any of their
respective Representatives or Affiliates), except that (1) no party hereto shall be relieved of any obligation or liability arising from any prior breach by such party of any provision of this Agreement; and (2) the provisions of
Section 5.3(c) and Article XI will continue to apply following any such termination. 

  
 54 

 ARTICLE IX FEES AND EXPENSES. 

Section 9.1. Expenses. Subject to Section 9.2, each party hereto shall pay its own expenses incidental to the preparation of this
Agreement, the carrying out of the provisions of this Agreement and the consummation of the transactions contemplated hereby. 
 Section
9.2. Stockholders of the Company. In no event shall Parent, Acquisition HoldCo, Acquisition Corp. or the Company be liable (before or after the Closing) for any fees and expenses of the Stockholders of the Company relating to the transactions
contemplated by this Agreement, including legal, accounting and financial advisory fees. 
 ARTICLE X DEFINITIONS. 

Section 10.1. Table of Definitions. As used in this Agreement the terms set forth below shall have the following meanings: 

“Acquisition Price” shall mean an aggregate of five million dollars ($5,000,000), payable in a combination of (a) shares
of Parent Series B Preferred, based on a Parent Series B Preferred price of $4.1841 per share as of the Effective Time and (b) cash. 

“Affiliate” of a Person shall mean any other Person who directly or indirectly through one or more intermediaries controls,
is controlled by or is under common control with, such first Person. 
 “Code” shall mean the Internal Revenue Code of
1986, as amended. 
 “Collateral Document” shall mean any Exhibit to this Agreement and certificate or schedule delivered
by a Person or any of its respective directors, officers, employees or trustees pursuant to this Agreement. 
 “Company Intellectual
Property” shall mean the Company’s Intellectual Property which would necessarily be infringed by the making, having made, using, selling, offering for sale, or importing of the Compound. 

“Company Material Adverse Effect” means any change, circumstance, development, effect or occurrence that has or would
reasonably be expected to have a material adverse effect on (a) the business, assets, financial condition or results of operations of the Company and the Company Subsidiaries, taken as a whole, or (b) the Company’s ability to
consummate the Merger pursuant to the terms hereof; provided, however, that the term “Company Material Adverse Effect” will not include any change, circumstance, development, effect or occurrence caused by (i) changes in applicable
Laws or decisions by courts or any Governmental Entity, (ii) changes in GAAP or any interpretation thereof, (iii) actions or 

  
 55 

 
omissions of the Company or any Company Subsidiary taken with the consent of Buyer in contemplation of the transactions contemplated under this Agreement, (iv) actions or omissions of the
Company or any Company Subsidiary expressly permitted by this Agreement or any Collateral Documents, (v) general economic conditions, including changes in the credit, debt, financial, capital or reinsurance markets (including changes in
interest or exchange rates, prices of any security or market index or any disruption of such markets), in each case, in the United States or anywhere else in the world, (vi) events or conditions generally affecting the industries in which the
Company and the Company Subsidiaries operate, (vii) global, national or regional political conditions, including national or international hostilities, acts of terror or acts of war, sabotage or terrorism or military actions or any escalation
or worsening of any hostilities, acts of war, sabotage or terrorism or military actions, (viii) pandemics, earthquakes, hurricanes, tornados or other natural disasters, (ix) entry into, or announcement, the pendency or consummation of this
Agreement, or (x) any failure to meet any projections, forecasts, guidance, estimates, milestones, budgets or financial or operating predictions of revenue, earnings, cash flow or cash position (provided, that (A) the matters described in
clauses (i), (ii), (v), (vi), (vii) and (viii) shall be included in the term “Company Material Adverse Effect” to the extent any such matter has a disproportionate, materially adverse impact on the business, assets, financial
condition or results of operations of the Company and the Company Subsidiaries, taken as a whole, relative to other participants in the business of the Company and (B) clause (x) will not prevent a determination that any change or effect
underlying any such change or failure, as applicable, has resulted in a Company Material Adverse Effect, to the extent such change or effect is not otherwise excluded from this definition of Company Material Adverse Effect). 

“Compound” shall mean the compound known as InteKrin 131 and any salts, solvates and crystalline forms of such compound or
other formulations thereof. 
 “Contract” shall mean any lease, contract, commitment and agreement, written or, to the
Company’s Knowledge, oral other than purchase orders or purchase order commitments issued in the ordinary course of business consistent with past practices. 

“Exchange Agent” shall mean a bank or trust company designated as the exchange and paying agent by Parent and reasonably
satisfactory to the Company, or such other Person as Parent and the Company may otherwise mutually agree. 
 “Governmental
Entity” shall mean any: (i) federal, state, local, foreign or international government; (ii) court, arbitral or other tribunal or governmental or quasi-governmental authority of any nature (including any governmental agency,
political subdivisions, instrumentalities, branch, department, official, or entity); or (iii) body exercising, or entitled to exercise, any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of
any nature pertaining to government. 
 “Intellectual Property” means patents and patent applications, trademarks, service
marks, trade names, copyrights, trade secrets, inventions, disclosures, technology, know-how, designs, formulae, confidential and proprietary information, and registrations and applications for registration of copyrights, trademarks, service marks,
trade names, trade dress, domain names, and invention disclosures. 

  
 56 

 “Knowledge” means (a) when used to qualify a representation, warranty or
other statement of the Company or any Company Subsidiary in this Agreement, the actual knowledge of any of Evgeny Zaytsev, M.D., Ph.D., and Dennis M. Lanfear and; (b) when used to qualify a representation, warranty or other statement of Parent
or any Parent Subsidiary in this Agreement, the actual knowledge of any of Dennis M. Lanfear and Matthew R. Hooper. 

“Lien” shall mean any mortgage, pledge, lien, security interest, conditional or installment sale agreement, encumbrance,
charge or other claims of third parties of any kind, except for (a) liens for Taxes or governmental charges or claims (i) not yet due and payable or (ii) being contested in good faith and by appropriate proceedings, if a reserve or
other appropriate provision, if any, in accordance with GAAP shall have been made therefor; (b) statutory liens of landlords and liens of carriers, warehousemen’s, mechanics and materialmen’s and other incurred in the ordinary course
of business for sums not yet due and payable if a reserve or other appropriate provision, if any, in accordance with GAAP shall have been made therefor; (c) liens incurred or deposits made in connection with workers’ compensation,
unemployment insurance and other similar types of social security programs in each case in the ordinary course of business; (d) with respect to personal property only, purchase money security interests incurred in the ordinary course of
business; (e) easements, rights-of-way, restrictions and other similar non-monetary charges or encumbrances, in each case, which do not interfere with the ordinary conduct of the Company’s or any Company Subsidiary’s operations and do
not or would not materially detract from the value of the property to which such encumbrance relates; and (g) with respect to the Leased Property only and in addition to the items above, liens, security interests or encumbrances and other minor
irregularities in title, more of which, independently or in the aggregate interfere in any material aspect with the present use of or occupancy by the Company or any Company Subsidiary. 

“Merger Consideration Cap” shall mean Eighty Million Eight Hundred Forty Two Thousand Nine Hundred Nine Dollars
($80,842,909). For purposes of calculating whether the Merger Consideration Cap has been reached or exceeded, (a) the issuance of shares of Parent Series B Preferred as the Acquisition Price and the Earn Out Payment, if any, shall be deemed to
have an aggregate value of Five Million Dollars ($5,000,000) and Two Million Five Hundred Thousand Dollars ($2,500,000), respectively, as and when issued; and (b) any property or other form of non-cash consideration distributed to the
Stockholders and the Management Incentive Grant Recipients as Compound Transaction Payments shall have the fair market value as determined in good faith by the Board of Directors of Parent, at the time of distribution; provided, however, that to the
extent such property or other form of non-cash consideration consists of publicly traded securities, then the value attributed to such securities shall be the average of the high and low selling prices on the date immediately prior to the date such
securities are distributed. 

  
 57 

 “Party” shall mean Parent, Acquisition HoldCo, Acquisition Corp., the Company
and the Stockholders’ Representative. 
 “Person” shall mean any individual, corporation, partnership, limited
partnership, limited liability company, other business organization, trust, association or entity or government agency or authority. 

“Pre-Closing Tax Liabilities” shall mean all obligations for Taxes owed by the Company (or the Surviving Corporation as its
successor in the Merger) or any Company Subsidiary for any period or portion thereof ending on or prior to the Closing. 

“Pre-Closing Tax Period” shall mean any Tax period (or portion thereof) ending on or before the Closing Date. 

“SEC” shall mean the Securities and Exchange Commission. 

“Sofinnova” shall mean Sofinnova Venture Partners VII, L.P. 

“Stockholder” shall mean the holders of shares of Company Capital Stock as set forth on Exhibit F. 

“Stockholders’ Representative” shall mean Fortis Advisors LLC, or its successor chosen in accordance with
Section 2.5. 
 “Straddle Period” shall mean any Tax period beginning on or before the Closing Date and ending after
the Closing Date. 
 “Subsidiary” shall mean any Person of which a specified Person owns directly or indirectly through a
subsidiary, a nominee arrangement or otherwise at least a majority of the outstanding capital stock (or other shares of beneficial interest) entitled to vote generally or otherwise have the power to elect a majority of the board of directors or
similar governing body or the legal power to direct the business or policies of such Person. 
 “Tax” (and, with
correlative meaning, “Taxes” and “Taxable”) shall mean any and all taxes, fees, levies, duties, tariffs, imposts, and other charges in the nature thereof (together with any and all interest, penalties, additions to
tax and additional amounts imposed with respect thereto, whether disputed or not) imposed by any government or taxing authority, including: taxes or other charges on or with respect to income, franchises, windfall or other profits, gross receipts,
property, sales, use, capital stock, payroll, employment, social security, workers’ compensation, unemployment compensation, or net worth; taxes or other charges in the nature of excise, withholding, ad valorem, stamp, transfer, value added, or
gains taxes; license, registration and documentation fees; and customs duties, tariffs, and similar charges. 
 “Tax
Return” shall mean any return, report or similar statement filed or required to be filed with respect to any Tax (including any attached schedules), including any information return, claim for refund, amended return or declaration of
estimated Tax and all federal, state, local and foreign returns, reports and similar statements. 

  
 58 

 Each term listed in the table below has the meaning ascribed to such term in the section of this
Agreement listed opposite such term. 
  

			
	 Accredited Investor List
	  	Section 2.6(b)
	 Acquisition Common Stock
	  	Section 2.1(a)
	 Acquisition Corp.
	  	Preamble
	 Acquisition HoldCo.
	  	Preamble
	 Acquisition Transaction
	  	Section 5.2
	 Advisory Group
	  	Section 2.5(b)
	 Agent Expenses
	  	Section 2.5(b)
	 Agreement
	  	Preamble
	 Authorizations
	  	Section 3.14(b)
	 Business Plan
	  	Section 4.21
	 Buyer Indemnified Parties
	  	Section 7.2
	 Certificate of Merger
	  	Section 1.2
	 Certificates
	  	Section 2.4(a)(i)
	 Claim Notice
	  	Section 7.5
	 Closing
	  	Section 1.3
	 Closing Date
	  	Section 1.3
	 Company
	  	Preamble
	 Company Capital Stock
	  	Recitals
	 Company Common Stock
	  	Recitals
	 Company Disclosure Schedule
	  	Article III
	 Company Financial Statements
	  	Section 3.6(a)
	 Company Fundamental Representations
	  	Section 7.1
	 Company Preferred Stock
	  	Recitals
	 Company Stock Plan
	  	Section 2.1(e)
	 Company Stockholder Approval
	  	Section 6.1(d)
	 Company Subsidiary/Company Subsidiaries
	  	Section 3.1(a)
	 Compound Transaction Agreement
	  	Section 2.2(b)
	 Compound Transaction Payment
	  	Section 2.2(c)(iii)
	 Compound Transaction Revenue
	  	Section 2.2(c)(v)
	 Delaware Courts
	  	Section 11.7
	 DGCL
	  	Recitals
	 Diligent Efforts
	  	Section 2.2(c)(vi)
	 Disclosure Schedules
	  	Article IV
	 Dispute Notice
	  	Section 2.5(c)
	 Dissenting Share
	  	Section 2.1(d)
	 Earn Out Event
	  	Section 2.2(c)(iv)
	 Earn Out Funds
	  	Section 2.2(c)(i)

  
 59 

			
	 Earn Out Payment
	  	Section 2.2(c)(ii)
	 Effective Time
	  	Section 1.2
	 Employee Benefit Plans
	  	Section 3.17(a)
	 ERISA
	  	Section 3.17(a)
	 ERISA Affiliate
	  	Section 3.17(a)
	 Escrow Agreement
	  	Section 2.3(b)
	 Exchange Fund
	  	Section 2.3(a)
	 FYE Company Financial Statements
	  	Section 3.6(a)
	 FYE Subsidiary Financial Statements
	  	Section 3.6(b)
	 GAAP
	  	Section 3.6(a)
	 Indemnified Party
	  	Section 7.5
	 Indemnity Escrow Funds
	  	Section 2.3(b)
	 Indemnity Period
	  	Section 7.1
	 Indemnity Threshold Amount
	  	Section 7.3(a)
	 Interim Company Financial Statements
	  	Section 3.6(a)
	 Interim Subsidiary Financial Statements
	  	Section 3.6(b)
	 IRS
	  	Section 3.16(b)
	 Laws
	  	Section 3.14(a)
	 Leased Real Property
	  	Section 3.9(d)
	 Leases
	  	Section 3.9(d)
	 Letter of Transmittal
	  	Section 2.4(a)(i)
	 Losses
	  	Section 7.2
	 Management Incentive Grants
	  	Section 2.9
	 Management Incentive Grant Recipients
	  	Section 2.9
	 Merger
	  	Recitals
	 Merger Shares
	  	Section 4.3
	 Option
	  	Section 2.1(e)
	 Overall Indemnity Cap
	  	Section 7.3(a)
	 Parent
	  	Preamble
	 Parent Common Stock
	  	Section 2.2(c)(i)
	 Parent Disclosure Schedule
	  	Article IV
	 Parent Fundamental Represenations
	  	Section 7.1
	 Parent Preferred Stock
	  	Section 4.6(a)
	 Parent Registered Proprietary Rights
	  	Section 4.9
	 Parent Series A Preferred
	  	Section 4.6(a)
	 Parent Series B Preferred
	  	Section 2.2(c)(i)
	 Post-Closing Confidential Information
	  	Section 5.3(c)
	 Potential Acquiror
	  	Section 5.2
	 Promissory Note
	  	Section 2.10
	 Proprietary Rights
	  	Section 4.9
	 Representative
	  	Section 5.2
	 Representative Group
	  	Section 2.5(b)
	 Restated Certificate
	  	Section 6.2(h)
	 Restricted Stock Agreement
	  	Section 2.9

  
 60 

			
	 Rights Agreement
	  	Section 6.1(g)
	 Secretary of State
	  	Section 1.2
	 Secondary Share Purchase Agreement
	  	Section 6.2(k)
	 Securities Act
	  	Section 2.6(a)
	 Stockholder Indemnified Parties
	  	Section 7.2(b)
	 Subsidiary Financial Statements
	  	Section 3.6(b)
	 Surviving Corporation
	  	Section 1.1
	 Surviving Corporation Common Stock
	  	Section 2.1(a)
	 Unresolved Indemnification Claims
	  	Section 7.8(b)
	 Vesting Event
	  	Section 2.9
	 Voting Agreement
	  	Section 6.1(h)
	 Voting and Release Agreement
	  	Recitals
	 2013 Bridge Financing Agreement
	  	Section 4.5
	 2013 Convertible Notes
	  	Section 4.5
	 2013 Parent Financial Statements
	  	Section 4.18

 Section 10.2. Other Terms. Other terms may be defined elsewhere in the text of this Agreement and,
unless otherwise indicated, shall have such meaning throughout this Agreement. 
 Section 10.3. Other Definitional Provisions. 

(a) The words “hereof,” “herein,” and “hereunder” and words of similar import, when used in this Agreement, shall
refer to this Agreement as a whole and not to any particular provision of this Agreement. Whenever the words “include,” “includes” or “including” (or any variation thereof) are used in this Agreement, they shall be
deemed to be followed by the words “without limitation.” 
 (b) The terms defined in the singular shall have a comparable meaning
when used in the plural, and vice versa. 
 ARTICLE XI MISCELLANEOUS. 

Section 11.1. Press Releases. Except as required by law, none of Parent, Acquisition HoldCo, Acquisition Corp. or the Company shall
issue any press release or otherwise make public any information with respect to the subject matter of this Agreement nor the transactions contemplated hereby, without the prior written consent of each of the other parties to this Agreement. 

Section 11.2. Integration. This Agreement (together with the Exhibits and the Disclosure Schedules), the Collateral Documents and the
confidentiality agreement set forth the entire understanding of the parties hereto with respect to the transactions contemplated hereby, and, except as set forth in this Agreement, there are no representations or warranties, express or implied, made
by any party to this Agreement (or any of their Affiliates) with respect to the subject matter of this Agreement. Any and all previous agreements and understandings between or among the parties regarding the subject matter hereof, whether written or
oral, are superseded 

  
 61 

 
by this Agreement and the agreements referred to or contemplated herein. The parties acknowledge that all parties participated in the drafting of this Agreement and agree that any rule of law or
any legal decision that may or would require interpretation of any alleged ambiguities in this Agreement against the party that drafted it has no application and is expressly waived. In the event of a conflict or inconsistency between the terms of
this Agreement (including the representations, warranties, covenants and indemnification provisions hereof) and the terms of any other documents delivered or required to be delivered in connection with the consummation of the transactions
contemplated by this Agreement, the parties acknowledge and agree that the terms of this Agreement shall supersede such conflicting or inconsistent terms in such other documents and the terms of this Agreement shall define the rights and obligations
of the parties and their respective officers, directors, employees, stockholders and Affiliates with respect to the subject matter of such conflict or inconsistency. 

Section 11.3. Assignment. This Agreement may not be assigned by operation of law or otherwise. 

Section 11.4. Waiver. Any term or provision of this Agreement may be waived at any time by the party entitled to the benefit thereof
only by a written instrument duly executed by such party. 
 Section 11.5. Notices. Any notice, request, demand, waiver, consent,
approval, or other communication which is required or permitted to be given to any party hereunder shall be in writing and shall be deemed given only if delivered to the party personally or sent to the party by facsimile transmission (promptly
followed by a hard-copy delivered in accordance with this Section 11.5), or by reputable overnight courier service, addressed to the party at its address set forth below; provided, however, that all such notices, requests, demands, waivers,
consents, approvals, or other communications given or delivered to the Stockholders’ Representative shall also require delivery of a copy of such writing to the electronic mail address of the Stockholders’ Representative as set forth
below: 
 If to Parent, Acquisition HoldCo or Acquisition Corp.: 

Coherus Biosciences, Inc. 

201 Redwood Shores Parkway 

Suite 200 

Redwood City, California 94065 

Facsimile: 

Attention: 

with a copy to: 

Latham & Watkins LLP 

140 Scott Drive 

Menlo Park, California 94025-1008 

Facsimile: (650) 463-2600 

  
 62 

 Attention: Alan Mendelson, Esq. 

If to the Company: 

Intekrin Therapeutics Inc. 

555 Bryant Street 

Suite 266 

Palo Alto, California 94301 

Facsimile: (866) 286-2242 

Attention: Chief Executive Officer 

with a copy to: 

King & Spalding LLP 

601 South California Avenue 

Palo Alto, California 94304-1050 

Facsimile: (650) 422-6800 

Attention: Laura I. Bushnell, Esq. 

If to the Stockholders or the Stockholders’ Representative: 

Fortis Advisors LLC 

Attention: Notice Department 

4225 Executive Square, Suite 1040 

La Jolla, California 92037 

Fax: (858) 408-1843 

Email: notices@fortisrep.com 

or to such other address or Person as any party may have specified in a notice duly given to the other party as provided herein. Such notice, request, demand,
waiver, consent, approval or other communication will be deemed to have been given as of the date so delivered. 
 Section 11.6.
Amendment. This Agreement shall not be amended, modified, revised, supplemented or terminated orally and no waiver of compliance with any provision hereof and no consent provided for herein shall be effective other than by a written
instrument executed and delivered (a) prior to the Closing Date, by all of the parties hereto; and (b) after the Closing Date, by Parent and the Stockholders’ Representative (acting exclusively for and on behalf of the Stockholders
and Management Incentive Grant Recipients). 
 Section 11.7. Governing Law; Jurisdiction. This Agreement shall be governed by and
construed in accordance with the laws of the State of Delaware (regardless of the laws that might otherwise govern under applicable principles of conflicts of laws thereof) as to all matters, including, but not limited to, matters of validity,
construction, effect, performance and remedies. Notwithstanding anything herein to the contrary, Parent, the Company, Acquisition HoldCo, 

  
 63 

 
Acquisition Corp. and the Stockholders hereby irrevocably and unconditionally consent to submit to the exclusive jurisdiction of the courts of the State of Delaware and of the United States of
America located in the Delaware (the “Delaware Courts”) for any litigation arising out of or relating to this Agreement or the transactions contemplated hereby (and agrees not to commence counterclaims except in such courts), waives
any objection to the laying of venue of any such litigation in the Delaware Courts and agrees not to plead or claim in any Delaware Court that such litigation brought therein has been brought in any inconvenient forum. 

Section 11.8. Third Party Beneficiaries. Except for the provisions of Article II (Conversion of Shares), Section 5.9 (Director and
Officer Indemnity) and Article VII, the representations, warranties, covenants and agreements contained in this Agreement are for the sole benefit of the parties hereto, and their respective successors and assigns, and they shall not be construed as
conferring, and are not intended to confer, any rights on any other Person. 
 Section 11.9. Performance. In the event that any Party
shall fail or refuse to consummate the transactions contemplated by this Agreement or any default under, or breach of, any representation, warranty or covenant of this Agreement on the part of any Party shall have occurred that results in the
failure to consummate the transactions contemplated hereby, the Parties acknowledge and agree that any breach of the terms of this Agreement would give rise to irreparable harm for which money damages would not be an adequate remedy and accordingly
the Parties agree that, in addition to any other remedies, each shall be entitled to enforce the terms of this Agreement by a decree of specific performance. 

Section 11.10. Severability. If any term or other provision of this Agreement is determined to be invalid, illegal or incapable of
being enforced by any rule of law or public policy, all other terms and provisions of the Agreement shall remain in full force and effect. Upon such determination, the parties hereto shall negotiate in good faith to modify this Agreement so as to
give effect to the original intent of the parties to the fullest extent permitted by applicable law. 
 Section 11.11. Extensions. At
any time prior to the Closing Date, either party may by appropriate action, extend the time for compliance by or waive performance of any representation, warranty, agreement, condition or obligation of the other party. 

Section 11.12. Section Headings. All section headings are for convenience only and shall in no way modify or restrict any of the terms
or provisions hereof. 
 Section 11.13. Exhibits; Disclosure Schedules. All Exhibits referred to herein and the Disclosure Schedules
are intended to be and hereby are specifically made a part of this Agreement. Disclosure of any fact or item in any section of the Disclosure Schedules referenced by a particular section in this Agreement shall be deemed to have been disclosed with
respect to every other section in this Agreement. The specification of any dollar amount in the representations or warranties contained in this Agreement or the inclusion of any specific item in any section of the Disclosure Schedules is not
intended to imply that such amounts, or higher or lower amounts or the items so included or other items, are or are not material, and no party shall use the fact of the setting of such amounts or the inclusion of any such item in any dispute or
controversy as to whether any obligation, items or matter not described herein or included in the Disclosure Schedules is or is not material for purposes of this Agreement. 

  
 64 

 Section 11.14. Counterparts. This Agreement may be executed in two or more counterparts,
each of which shall be deemed an original, and the Company, Stockholders’ Representative, Parent, Acquisition HoldCo and Acquisition Corp. may become a party hereto by executing a counterpart thereof. This Agreement and any counterpart so
executed shall be deemed to be one and the same instrument. Delivery of an executed counterpart of a signature page to this Agreement or any Collateral Document by facsimile or as a pdf or similar attachment to an electronic communication shall have
the same effect as delivery of a manually executed counterpart to this Agreement or Collateral Document. 

  
 65 

 IN WITNESS WHEREOF, the parties hereto, intending to be legally bound, have duly executed this
Agreement on the date first above written. 
  

			
	COHERUS BIOSCIENCES, INC.
		
	By:	 	/s/ Dennis M. Lanfear
		 	Name: Dennis M. Lanfear
		 	Title: President and Chief Executive Officer
	
	COHERUS INTERMEDIATE CORP.
		
	By:	 	/s/ Dennis M. Lanfear
		 	Name: Dennis M. Lanfear
		 	Title: President and Chief Executive Officer
	
	COHERUS ACQUISITION CORP.
		
	By:	 	/s/ Dennis M. Lanfear
		 	Name: Dennis M. Lanfear
		 	Title: President and Chief Executive Officer
	
	INTEKRIN THERAPEUTICS INC.
		
	By:	 	/s/ Dennis M. Lanfear
		 	Name: Dennis M. Lanfear
		 	Title: Acting President and Chairman
	
	FORTIS ADVISORS LLC
		
	By:	 	/s/ Ryan Simkin
		 	Name: Ryan Simkin
		 	Title: Managing Director

  
 66

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}]]